COVID-19 Infection in Transplant Patients: Difference between revisions

	WikiDoc Resources for COVID-19 Infection in Transplant Patients
Articles
Most recent articles on COVID-19 Infection in Transplant Patients Most cited articles on COVID-19 Infection in Transplant Patients Review articles on COVID-19 Infection in Transplant Patients Articles on COVID-19 Infection in Transplant Patients in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on COVID-19 Infection in Transplant Patients Images of COVID-19 Infection in Transplant Patients Photos of COVID-19 Infection in Transplant Patients Podcasts & MP3s on COVID-19 Infection in Transplant Patients Videos on COVID-19 Infection in Transplant Patients
Evidence Based Medicine
Cochrane Collaboration on COVID-19 Infection in Transplant Patients Bandolier on COVID-19 Infection in Transplant Patients TRIP on COVID-19 Infection in Transplant Patients
Clinical Trials
Ongoing Trials on COVID-19 Infection in Transplant Patients at Clinical Trials.gov Trial results on COVID-19 Infection in Transplant Patients Clinical Trials on COVID-19 Infection in Transplant Patients at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on COVID-19 Infection in Transplant Patients NICE Guidance on COVID-19 Infection in Transplant Patients NHS PRODIGY Guidance FDA on COVID-19 Infection in Transplant Patients CDC on COVID-19 Infection in Transplant Patients
Books
Books on COVID-19 Infection in Transplant Patients
News
COVID-19 Infection in Transplant Patients in the news Be alerted to news on COVID-19 Infection in Transplant Patients News trends on COVID-19 Infection in Transplant Patients
Commentary
Blogs on COVID-19 Infection in Transplant Patients
Definitions
Definitions of COVID-19 Infection in Transplant Patients
Patient Resources / Community
Patient resources on COVID-19 Infection in Transplant Patients Discussion groups on COVID-19 Infection in Transplant Patients Patient Handouts on COVID-19 Infection in Transplant Patients Directions to Hospitals Treating COVID-19 Infection in Transplant Patients Risk calculators and risk factors for COVID-19 Infection in Transplant Patients
Healthcare Provider Resources
Symptoms of COVID-19 Infection in Transplant Patients Causes & Risk Factors for COVID-19 Infection in Transplant Patients Diagnostic studies for COVID-19 Infection in Transplant Patients Treatment of COVID-19 Infection in Transplant Patients
Continuing Medical Education (CME)
CME Programs on COVID-19 Infection in Transplant Patients
International
COVID-19 Infection in Transplant Patients en Espanol COVID-19 Infection in Transplant Patients en Francais
Business
COVID-19 Infection in Transplant Patients in the Marketplace Patents on COVID-19 Infection in Transplant Patients
Experimental / Informatics
List of terms related to COVID-19 Infection in Transplant Patients

VisualWikitext

Latest revision as of 14:39, 21 July 2020

For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gurmandeep Singh Sandhu,M.B.B.S.[2]

Overview

Renal transplant patients are under immunosuppression to modulate the immune response to graft. Moreover these patients have various underlying chronic kidney diseases and other co-morbidities such as diabetes and hypertension, which can impact the results in COVID-19 infection. Hence these patients are at a higher risk of developing COVID-19 associated complications. The clinical manifestations, treatment, and prognosis of COVID-19 infection may be different from the general population. It is believed that any transplant recipient presented to the infection would result in a high level of cases; however, the risk of the donor to recipient transmission is unknown.

Historical Perspectives

In 1965, Tyrrell and Bynoe used cultures of human ciliated embryonal trachea to propagate the first human coronavirus (HCoV) in vitro.^[1]^[2]
The etiological agent involved is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), first detected in Wuhan, China. On March 12, 2020 the World Health Organization declared the COVID-19 outbreak a pandemic.^[3]
The earlier SARS epidemic of Hong Kong is known to affect both pediatric and adult renal transplant patients where the severity of disease in adult patients was more than that in pediatric patients^[4]
The first reported case of COVID-19 infection in renal transplant patient, was a 52‐year‐old man who received living‐related kidney transplantation 12 years for chronic glomerulonephritis, in Wuhan, China. He made a successful recovery and was discharged on day 13.^[5]

Classification

COVID-19 infection may be classified according to WHO into four subtypes based on severity. Classification of COVID-19 infection in renal transplant patients depends on the severity of COVID-19 manifestations is following:^[6]

Mild Disease		Symptomatic patients meeting the case definition for COVID-19 No pneumonia No hypoxia
Moderate Disease		Adolescent or adult Pneumonia with fever, dyspnea, cough, and fast breathing SpO₂ > or = 90% Child Signs of non-severe pneumonia (cough, difficulty breathing, fast breathing or chest indrawing) Fast breathing(breaths/min) <2 months: > or = 60 2-11 months: > or = 50 1-5 years: > or = 40 Diagnosis can be made clinically, Chest Imaging (radiograph, CT scan, Ultrasound) may assist in diagnosis.
Severe Disease	Severe Pneumonia	Adolescent or adult Signs of Pneumonia plus one of following: Respiratory rate > 30 breaths/min Severe Respiratory Distress SpO₂ < 90% Child Pneumonia plus at least one of following Central cyanosis or SpO₂ < 90% Severe respiratory distress (fast breathing, grunting, severe chest indrawing) General danger signs such as inability to breastfeed or drink, lethargy, or unconsciousness or convulsions Fast breathing(breaths/min) <2 months: > or = 60 2-11 months: > or = 50 1-5 years: > or = 40 Diagnosis can be made clinically, Chest Imaging (radiograph, CT scan, Ultrasound) may assist in diagnosis.
Critical Disease	Acute Respiratory Distress Syndrome (ARDS)	Onset: within 1 week of pneumonia or new worsening respiratory symptoms. Chest imaging: (radiograph, CT scan, or lung ultrasound): bilateral opacities, not related to volume overload, lobar or lung collapse, or nodules Origin of pulmonary infiltrates: Respiratory failure not explained by cardiac failure or fluid overload. Oxygenation impairment in adults: -Mild ARDS: 200 mmHg < PaO₂/FiO₂^a ≤ 300 mmHg (with PEEP or CPAP ≥ 5 cmH₂O) -Moderate ARDS: 100 mmHg < PaO₂/FiO₂ ≤ 200 mmHg (with PEEP ≥ 5 cmH₂O) -Severe ARDS: PaO₂/FiO₂ ≤ 100 mmHg (with PEEP ≥ 5 cmH₂O) Oxygenation impairment in children: note OI and OSI. Use OI when available. If PaO₂ not available, wean FiO₂ to maintain SpO₂ ≤ 97% to calculate OSI or SpO₂/FiO₂ ratio: • Bilevel (NIV or CPAP) ≥ 5 cmH₂O via full face mask: PaO₂/FiO₂ ≤ 300 mmHg or SpO₂/FiO₂ ≤ 264. • Mild ARDS (invasively ventilated): 4 ≤ OI < 8 or 5 ≤ OSI < 7.5. • Moderate ARDS (invasively ventilated): 8 ≤ OI < 16 or 7.5 ≤ OSI < 12.3. • Severe ARDS (invasively ventilated): OI ≥ 16 or OSI ≥ 12.3.
	Sepsis	Adults: Acute life-threatening organ dysfunction caused by a dysregulated host response to suspected or proven infection. Signs of organ dysfunction: altered mental status, difficult or fast breathing, low oxygen saturation, reduced urine output, fast heart rate, weak pulse, cold extremities or low blood pressure, skin mottling, laboratory evidence of coagulopathy, thrombocytopenia, acidosis, high lactate, or hyperbilirubinemia. Children Suspected or proven infection and ≥ 2 age-based systemic inflammatory response syndrome (SIRS) criteria, of which one must be abnormal temperature or white blood cell count.
	Septic shock	Adults: Persistent hypotension despite volume resuscitation, requiring vasopressors to maintain MAP ≥ 65 mmHg and serum lactate level > 2 mmol/L Children: Any hypotension (SBP < 5th centile or > 2 SD below normal for age) or two or three of the following: altered mental status; bradycardia or tachycardia (HR < 90 bpm or > 160 bpm in infants and heart rate < 70 bpm or > 150 bpm in children); prolonged capillary refill (> 2 sec) or weak pulse; fast breathing; mottled or cool skin or petechial or purpuric rash; high lactate; reduced urine output; hyperthermia or hypothermia

Pathophysiology

The normal physiology of in renal transplant patients can be understood as follows to that in general population^[7]. However, the renal transplant recipients are at remain at higher risk to catch COVID-19^[8]and develop severe complications due to chronic immunosuppressed state which is implicated in various viral infections such as cytomegalovirus, herpes zoster, norovirus infections.^[8]^[9]^[10]

Genetics

The Angiotensin-converting enzyme 2 and Dipeptidyl peptidase has been associated with the development of SARS-Cov and MERS-CoV^[11]^[12]
Angiotensin-converting enzyme 2 and Dipeptidyl peptidase have been implicated in the uptake of SARS-Cov and MERS-CoV^[11]^[12]
Several studies have indicated that viral S-protein RBD interacts with host ACE2 receptor. S protein changes thus make the human cells permissive to SARS-CoV and SARS-CoV-2 infection^[13] ^[14] ^[15] ^[16] ^[17]ACE2: ACE ratio is higher in the kidneys compared to the respiratory system. (1:1 in the kidneys VS 1:20 in the respiratory system).^[18]These receptors are found in the proximal tubules of kidney^[11]^[12]SARS-CoV2 spike(S) protein is cleaved and activated by transmembrane serine protease family (TMPRSS) after attaching to angiotensin-converting enzyme 2 (ACE2) receptors. This allows the virus to release fusion peptide that aides in membrane fusion..^[19]
There is a possibility of association between MHC class I(HLA A, B & C) with incidence of COVID-19 infection as well as severity of complications^[20]
HLA-B*46:01 gene product is believed to show lowest binding to SARS-CoV-2 indicating decreased viral presentation to immune system. Whereas HLA-B*15:03 shows increased affinity to SARS-CoV-2^[20]leading to higher likelihood in developing immunity.

Associated Conditions

Acute Kidney Injury has been reported in patients with COVID-19 infection along with presence of proteinuria, hematuria. In a case observation, 4 out of 7 patients had AKI which may indicate that renal transplant patients are at higher risk AKI on being infected with COVID-19 whereas only 29% AKI was seen in critically ill patients of general population.^[21]
Acute Kidney Injury seen in COVID-19 infection can be from the cytotropic effect (Uptake of SARS-Cov-2 virus into proximal tubule cells is possible explanation for the AKI seen in COVID patients^[11]^[12]) of the viral particles as well as systemic inflammatory response induced by the cytokines. Patients admitted with severe disease, acute respiratory distress syndrome (ARDS) or in patients admitted to ICU have a higher incidence of AKI . ^[8]. Other possible reasons that can play a role in AKI development, are multi-organ failure resulting in acute tubular necrosis (ATN), volume reduction causing prerenal ATN, high fever, drug toxicity, hypotension, and contrast exposure. ^[22] ^[23]
Pro-inflammatory cytokine levels are elevated in the COVID-19 infection and there is activation of T-cell response. ^[24]
There is higher cytokine levels and there is occurrence of cytokine storm in severe cases. In cytokine storm the, the immune system damages the healthy tissue rather than virus.^[25] According to an autopsy report of six patients, the light microscopy indicated CD68+ macrophage infiltration of the tubulointerstitium and severe ATN. The tubules showed complement 5b-9 deposition in all six cases, but deposition in glomeruli and capillaries were seldom seen. Some CD8+ T lymphocyte cells and CD56+ (natural killer) cells were seen in kidney tissue^[26]

Causes

Life Threatening Causes

Even though the CT findings in COVID-19 pneumonia were similar in renal transplant recipients and general population, due to chronic immunosuppression, the clinical features of COVID-19 in renal transplant patients may be atypical.^[27]^[28]
In one of the study, nine of the 10 patients had fever, cough, shortness of breath, and fatigue; three had diarrhea; eight had lymphopenia; six had renal injury; and six had liver function damage.^[29]^[30]^[7]
It needs to be verified whether the severity of COVID-19 pneumonia differs in immunocompromised transplant patients than non-immunocompromised population. According to a report from China’s Infectious Disease Information system, out of 72,314 COVID-19 cases in general population, 81% were reported as mild, whereas 19% were either severe or critical. And, in report from study in renal transplant patients, the number of severe cases were 80% compared to only 10% in their infected family members and 19% in general population. Moreover, average duration of illness was nearly twice i.e. 35 days compared to 18 days in control group and 17-20 days reported in general population.^[31]^[7]

Differentiating from other Diseases

As the general presentation of COVID-19 is similar in general population and renal transplant patients, it should be differentiated from other diseases presenting with cough, fever, shortness of breath, and tachypnea.
- To review the differential diagnosis, click here

COVID-19 associated AKI in renal transplant patients must be differentiated from other causes of AKI , such as congestive heart failure, hemorrhage, dehydration, liver failure, urinary tract obstruction, Interstitial nephritis, glomerulonephritis and nephrotoxic medications.
- For the differential diagnosis of AKI, click here.

Epidemiology and Demographics

Incidence

Due to the lack of broad screening that includes the general population (including asymptomatic patients) and the lack of PCR and antibody tests with acceptable sensitivity and specificity, an accurate estimate of the incidence rate of coronavirus disease 2019 (COVID-19) cannot be accurately estimated.
Data indicates that the rate of severe complications of COVID-19 is almost 25%, and kidney is also one of the main organs affected in severe illness.^[32]. The risk is further increased in patients having chronic kidney disease(CKD), patients on chronic replacement therapies, and patients with kidney transplants.^[33]
AKI is seen in 5-15% of the SARS-CoV and MERS-CoV infection^[33]

Prevalence

For details on the real-time prevalence and spread of COVID-19, click here.
As it is prevalent in all the continents of the world, World Health Organization (WHO) has declared COVID-19 outbreak a pandemic.
Among patients with influenza-like-illness and without risk factors for COVID-19, 5% were positive for COVID-19.
In an analysis of 14 articles^[34]^[35]^[36]^[37]

^[38] ^[39] ^[40] ^[41]^[42],

- Median interval of transplantation - 4 years. (range .25-30.1)

Case-fatality rate

Due to limited testing of asymptomatic individuals, the potential inaccuracies of early PCR tests and antibody tests, the inconsistent reporting and lack of organized data, an accurate case-fatality rate of COVID-19 has yet to be established.
According to analysis of recent studies^[34]^[35]^[36]^[37]

^[38] ^[39] ^[40] ^[41]^[42], a fatality rate of 17.4% (4/23) in renal transplant patients was reported

Age

Renal transplant patients of all ages are at a higher risk of COVID-19 due to immunosuppression.
The youngest renal transplant patient who died of COVID-19 according to recent studies was 71 years old.^[34]^[35]^[36]

^[37] ^[38]^[40] ^[41]^[42]

In general population, COVID-19 associated AKI has higher incidence in elderly.

Gender

Male are more commonly affected by COVID-19 than female.^[43]
Female dying from COVID-19 are generally elder than men(median age: 82 vs. 79 years for women vs. men, respectively).^[43]

Race

According to study done in New York, 14 recipients affected by COVID-19, (39%) were black, and 15 recipients (42%) were Hispanic.^[44]

Risk Factors

Common risk factors in the development of transplant patients to COVID-19 are:

Immunosuppression^[8]
Chronic Renal Failure^[8]^[45]
Co-Morbidities^[8]
- Diabetes
- Hypertension
- Hyperlipidemia
- H/o Heart Disease
Male Sex^[44]^[46]
Old Age^[44]^[46]
Current or h/o smoking tobacco^[44]

Possible a/w donor COVID-19 infection^[46]

Screening

According to one of the COVID-19 Rapid Guidelines for renal transplant patients:^[47]

Patient presents with Sore throat,Dry cough or Fever

Dypsnea, RR>30/min, SpO2<93%

If Present Then refer for admission

Creatinine is raised but no Lymphopenia or No Abnormality on CT chest

If not, check Creatinine, C-RP, CXR & CT chest

Lymphopenia but Creatinine normal and Ct chest normal

Admit in usual ward and evaluate Lymphopenia

Evaluate the Causes of rise in creatinine

Is Xray positive for COVID-19?

If No, then Do CT Chest

If CT Chest is negative then refer a patient for Home Care, Medical Treatment, Diagnostic Test, and Daily Follow-ups

If Chest Xray or CT chest is indicative of COVID-19 infection: Admit the patient

Screening for AKI

Serial monitoring of kidney function tests should be considered in renal transplant patients^[48]

BUN
Creatinine
Urine analysis

Gut Ischemia, coagulopathies, and disseminated intravascular coagulopation have been seen later in the course of illness^[45]

The following should be measured in all patients with severe COVID-19 infection on admission to prevent and screen for coagulopathies.

Natural History, Complications and Prognosis

The majority of renal transplant recipients with COVID-19 present with same course of infection as in general population^[49]. The clinical features in renal transplant recipients may be atypical due to chronic state of suppressed immune system and other chronic co-morbidities in transplant patients^[8]^[50]^[5]. Early clinical features include cough, fever, fatigue, diarrhea, sore throat, and shortness of breath. If left untreated, COVID-19 in transplant recipients may progress to develop dypsnea, hypoxemia, oliguria, confusion, fluid retention and pro coagulative state^[49]. Common complications of COVID-19 in renal patients may include Pneumonia, Acute Respiratory Distress Syndrome, Acute Kidney Injury and Disseminated Intravascular Coagulation^[31]^[49]^[45]. Prognosis is generally worse than the prognosis in general population due to underlying immunosuppression and chronic co morbidities (eg. Hypertension, Diabetes, Chronic renal Failure etc, and the mortality rate in renal transplant patients with COVID-19 has been reported to be higher than the general population^[5]^[50]^[8].

Diagnosis

Diagnosis of Choice

Renal transplant patients present with similar CT an Chest X-Ray finding which are seen in the general population, although the features of COVID-19 infection may be atypical in such patients.
Renal Transplant patients who develop AKI can be diagnosed using KDIGO criteria:
- Increase in S. Creatinine: ≥0.3 mg/dl (≥26.5 μmol/l) within 48 hours
- Increase in S. Creatinine: ≥1.5 times baseline within the previous 7 days
- Urine volume < 0.5 ml/kg/h for >6 hours

Symptoms

Presenting symptoms in renal transplant patients are similar to those of non-renal transplant patients. Further symptomology depends on the clinical complications that develop due to COVID-19.

Respiratory symptoms
Fever
Hypoxia: SpO2 depends on the severity of COVID-19 infection. In moderate infection the SpO2 > or = 90%
Diarrhea
Fatigue
Features of Uremia and Azotemia may be present in severe renal compromise

Further classification of patients into the severity index can be done using the WHO guidelines.^[6]

Physical Examinationin

Physical examination of COVID-19 in renal transplant patients are similar to ones seen in general population.: COVID Physical Exam

If the patient develops Acute Kidney physical examination is remarkable for^[51]:

Signs of dehydration, such as tachycardia, tachypnea, hypotension, and dry mucosa
Fluid retention, leading to edema and swelling of periorbital and extremities
Confusion due to severe dehydration and electrolyte imbalances
Decrease in urine output:Oliguria or Anuria
cardiac arrhythmia due to electrolyte imbalances such as high level of Potassium

Past Medical History

Renal transplant patients usually have chronic co-morbidities^[8]
- Diabetes
- Hypertension
- Hyperlipidemia
- Chronic renal failure
- H/o Heart Disease
- H/o Liver Disease

Laboratory Findings

Lymphocyte count
- Lower baseline values of lymphocyte count and lymphocytes percentages have been reported in patients. Furthermore the lymphocyte count continued to decrease during the course of illness.^[5]
- Renal transplant patients generally have a low lymphocyte count due to immunosuppression, hence finding a further drop in the lymphocyte count can be of prognostic value.
D-dimer
Ferritin
Troponin
- Microvascular thrombosis and disseminated intravascular coagulation( with gut ischemia ) can occur later in the course of illness. They are characterized by marked increase in the levels of D-dimer particularly. D dimer, ferritin, and troponin should be measured in all patients with severe COVID-19 infection on admission and in those who fail to show any clinical improvement.^[52]
High C-Reactive Protein^[49] - C‐reactive protein (CRP) was significantly elevated in patients at the time of admission.^[5] The levels of CRP remained elevated during the admission^[5]

If the renal transplant patients reports AKI then following laboratory findings can be done^[53]:

Elevated serum creatinine
Elevated BUN level
- Plasma BUN-creatinine ratio> 20 in prerenal AKI
- Plasma BUN-creatinine ratio< 15 in intrinsic AKI or acute tubular necrosis
Fractional excretion of sodium (FENa)
- (FENa)< 1% in prerenal AKI
- (FENa)> 2% in intrinsic AKI or acute tubular necrosis
Urinary sediment
- Hyaline casts in prerenal AKI
- Granular or Muddy brown casts in intrinsic AKI or acute tubular necrosis
Several biomarkers have been found to diagnose and predict AKI that include^[54]^[55]^[56]:
- neutrophil gelatinase-associated lipocalin (NGAL)
- kidney injury molecule 1 (KIM-1)
- liver-type fatty acid-binding protein
- interleukin 18 (lL-18)
- insulin-like growth factor-binding protein 7
- tissue inhibitor of metalloproteinase 2 (TIMP-2)
- calprotectin
- urine angiotensinogen (AGT)
- urine microRNA

Electrocardiogram

There are no associated ECG findings due to COVID-19 complications in renal transplant patients. However hypokalemia due to AKI can cause ECG changes.
To view the electrocardiogram findings on COVID-19, click here.

X Ray

X-ray findings in the renal transplant patients were similar to the findings seen in the general population.
To view the x-ray finidings on COVID-19, click here.

Echocardiography or Ultrasound

If the renal transplant patient develops AKI, USG can help diagnose hydronephrosis and reduced renal blood flow.
To view the echocardiographic findings on COVID-19, click here.

CT

CT scan finding in renal transplant patients infected with COVID-19 were similar to those in the general population.
To view the CT scan findings on COVID-19, click here.

MRI

There are no MRI findings associated with COVID-19 in renal transplant patients.
To view the MRI findings on COVID-19, click here.

Other Imaging Findings

To view other imaging findings on COVID-19, click here.

Other Diagnostic Studies

To view other diagnostic studies for COVID-19, click here.

Treatment

Medical Therapy

Acute Pharmacotherapy

Currently, there are a variable number of protocols that have been described for the management of COVID-19 in renal transplant patients:-

According to the British Transplantation Society Guideline^[41]:-

• Follow local guidelines for use of PPE
• Do the general assessment of the patient and swab for SARS-Cov-2
• Exclude other causes like CMV, pneumocystis, community or hospital acquired pneumonia, influenza, urinary sepsis, lymphoma and fluid overload)

• If the patient doesn't require hospitalization

• Stop antiproliferative agents (MMF/azathioprine)
• Review total burden of immunosuppression and consider reduction of CNI
• High or increased dose steroid is NOT recommended at this stage
• Patients should self isolate in line with national guidance
• Closely monitor patients remotely for change in symptoms
• Consider restarting immunosuppression 14 days after onset of symptoms if symptom free in absence of anti-pyretics for minimum of 3 days

• Consider early monitoring of graft function when safe to do so and risk of transmissionto others is low

• If the patient is deteriorates or requires ventilatory support

• Stop antiproliferative agents (MMF/azathioprine)
• Dramatically reduce or stop CNI
• Consider high dose steroids in discussion with ITU team
• Ventilatory support in line with local or national guidance

• Adjunctive support or antivirals in line with local practice or clinical trials

• If the patient is unwell and requires admission

• Stop antiproliferative agents (MMF/azathioprine)
• Consider reducing or stopping CNI
• Consider increasing steroids if currently taking them.
• There is no evidence for benefit of high dose steroids at this stage
• Oxygen therapy to achieve saturations over 94% (unless COPD)
• Regular observations, especially saturations, to monitor for rapid deterioration
• Conservative fluid administration
• Consider adjunctive antibiotics if superadded bacterial infection is suspected

• Early discussion of ceilings of care

According to a protocol described in Iranian Medical Journal^[47]

Admitted Patients

O2 Saturation <93%

O2 saturation >93%

S. Creatinine is raised,Then Consider Kidney Biospy

•If there are signs of kidney rejection
• Stop Anti Metabolite Drug
• Prednisolone: 20 mg/d
• Cyclosporine Trough Level: 75-150ng/ml
• Tacrolimus Trough Level: 4 to 6 ng/mL
• IVIG: 1-2 g/kg Divided Doses in 5 Days
• Anti Viral Therapy According to Protocol
• Azithromycin: 500 mg Stat and 250 mg
• Daily for 4 Days

• Stop Anti Metabolite Drug
• Stop CNI
• IV Methyl Prednisolone: 40mg/d
• IVIG: 1-2 g/kg Divided Doses in 5 Days
• Anti Viral Therapy According to Protocol
• Azithromycin: 500 mg Stat and 250 mg
• Daily for 4 Days

• If S.Creatinine is Normal
• Stop Anti Metabolite Drug
• Prednisolone: 20 mg/d
• Cyclosporine Trough Level: 75-150ng/ml
• Tacrolimus Trough Level: 4 to 6 ng/mL
• Anti Viral Therapy According to Protocol
• Azithromycin: 500 mg Stat and 250 mg
• Daily for 4 Days

If No Sign of rejection then same protocol as for Normal Serum Creatinine and O2 sat. >93%

For general COVID-19 Medical Therapy click here

Chronic Pharmacotherapy

In renal transplant patients, the immune responses are altered, especially the T cell response, due to generalized immunosuppression. Due to recent timeframe of outbreak of COVID-19 and insufficient scientific evidence, there is limited evidence on decreasing or changing the pattern of immunosuppression in renal transplant patients who have been infected with COVID-19. ^[57]

Clinical presentation of COVID-19 infection in renal transplant patients are like the clinical presentations of infection in general population. ^[57].Moreover, renal transplant patients are generally immunocompromised, and this predisposes them to severe infection with COVID-19. Rejection of the graft can occur if immunosuppression is reduced in these patients. Hence given the high rate of mortality in COVID-19 infections, it is suggested that a careful risk vs benefits assessment of whether to continue immunosuppression should be done.^[58]
Managing the immunosuppression in renal transplant patients is difficult and should be based on^[58]
- Age
- Severity of COVID-19 infection
- Presence of Co-Morbidities
- Time since the transplant
In patients with mild to moderate infection, it has been a practice to continue or decrease the doses of immunosuppressive drugs, however this approach can cause high mortality in patients having COVID-19 infection.^[58]

Commonly followed protocols for the used immuno-suppressant drugs is as follows:-

Antiproliferative agents such as MMF and azathioprine ^[59]
- Should be stopped at the time of admission to hospital
Prednisolone^[59]
- The dosage can be either increased or left unchanged. These can provide immunological protection to the renal graft.
- Corticosteroids have beneficial effects such as
  - Immunomodulation and anti-inflammatory properties
    - Inhibition of proinflammatory cytokines
    - Reduction of white blood cell traffic
  - Vascular protective effects
    - Maintenance of integrity and permeability of endothelium. ^[60] ^[59]
Tacrolimus^[59]

- Low doses of tacrolimus can be given but more evidence is required.^[59]

- The dose should be reduced to 50%. Target levels for tacrolimus should be 3-5 ng/ml.^[61]
Tocilizumab.^[59]

- COVID-19 infection has been found to cause cytokine storm and inflammation due to antiviral immune response, hence trials of anti-interleukin 6 monoclonal antibody Tocilizumab and continuing steroids in infected patients has been considered.
Cyclosporine
- Cyclosporin A has been shown to have an inhibitory effect on proliferation of corona viruses and hepatitis C virus in vitro, not seen in tacrolimus. Cyclosporin A is thought to inhibit the replication of a diverse array of coronaviruses through its impact on cyclophilin A and B.^[62]^[63]
- Cyclosporine levels should be targeted at 25-50 ng/ml.^[61]

Surgery and Device Based Therapy

Currently there are no suurgical intervention required for COVID-19 infection in renal transplant patients.

Transplantation

The risk of the donor to recipient transmission is unknown.

The chances of a donor to recipient infection might be affected by exposure of the donor, the infectivity of the donor during the incubation period, and the degree of viremia as well as the viability of virus in the specific organ system. An avid knowledge of local epidemiology is required to identify donors and recipients who may recently be exposed. One method is to have both donor and recipient practice strict social distancing i.e. 2-week home segregation prior to transplant and PCR testing for both individuals, before transplant^[64]. The reason for swabbing at the end of the segregation period is to screen asymptomatic shedders.^[65]

In spite of the conceivable negative outcomes, temporary interruption of kidney transplantation might be needed in regions where the rate of infection is high.. ^[28]
If a life-saving procedure needs to be performed, then appropriate assessment of infection in donor and recipient must be done along with appropriate informed consent.^[66]
If a transplant candidate is found to be infected with COVID-19, the transplant should be delayed until the patient shows clinical improvement as well as no viral detection. Viral shedding for an increased duration of time has been reported^[8]^[67].
- Patients should be tested 10-14 days after symptom onset and only once all the symptoms have resolved.
- Patients should have 2 negative PCRs at least 24hrs apart^[68]

Primary Prevention

The kidney transplant population must comply with the recommended measures of protection in the general population. Physicians can recommend the use of a mask on an individual basis, especially when the patient goes to health center or other place with agglomeration. People who show symptoms of being infected with SARS-CoV-2 should wear masks to prevent the spread of the disease to others..^[69]
It is prudent to approve a sick leave in patients whose profession involves a high hazard for disease.^[69]
It is recommended to screen kidney transplant patients through teleconsultation so as to decrease the time spent in healthcare centers and decrease the risk of infection ^[69]
Maintenance of general hygiene. Washing your hands as often as possible with cleanser and water, or with a alcohol based hand sanitizer (60% alc), particularly: after utilizing the restroom, before eating, in the wake of blowing, coughing or sneezing and after direct contact with patient or their surroundings. Abstain from touching your eyes, nose and mouth before washing your hands.^[69]
Regular cleaning of home with disinfection of objects and surfaces.^[69]
Keep a distance of at least two metres from people with general symptoms such as fever, cough, malaise, sore throat or dyspnea). Abstain from sharing personal belongings.^[69]
During the lockdown circumstance you should stay at home aside from the specified exemptions, as indicated by the standards built up by the political and wellbeing specialists. Telephone the kidney transplant facility at your referral community or the telephone numbers approved by the wellbeing specialists.^[69]
Attempt to follow a right eating routine. Abstain from smoking and liquor. These substances weaken the immune system, and increase the risk of infectious diseases.^[69]

Secondary Prevention

All kidney transplant patients with suspected symptoms of COVID-19 are advised to contact their healthcare provider (ideally by phone), to discuss the full course of their treatment and other chronic conditions that they are having. Depending upon the symptoms :-

Mild symptoms ie
- without Dyspnea or Tachypnea
- Temperature <38°C
- Kidney receptor with adequate functional reserves
  - The patient can be asked to remain in contact via teleconsultation to have the diagnostic tests performed, monitor the symptoms and communicate alarming to the transplant team every 24–48h.
Moderate/Severe symptoms
- Temperature >38°C
- Presence of Dyspnea
- Presence of Tachypnea
- Fragile Kidney receptor
  - Patient can be asked to report to Emergency Department for clinical evaluation..^[69]

Cost Effectiveness of Therapy

Currently various investigational and experimental pharmacological therapies are being tested for COVID-19 treatment. The cost of treatment generally depends on the multitude of COVID-19 complications that an individual develops.

Future or Investigational Therapies

Various pharmacological therapies are currently under investigation as potentials to treat COVID-19

For detailed information click here

References

↑ https://www.cdc.gov/coronavirus/2019-ncov/about/index.html. Missing or empty |title= (help)
↑ Lu, Jian; Cui, Jie; Qian, Zhaohui; Wang, Yirong; Zhang, Hong; Duan, Yuange; Wu, Xinkai; Yao, Xinmin; Song, Yuhe; Li, Xiang; Wu, Changcheng; Tang, Xiaolu (2020). "On the origin and continuing evolution of SARS-CoV-2". National Science Review. doi:10.1093/nsr/nwaa036. ISSN 2095-5138.
↑ . doi:10.23750/abm.v91i1.9397. Missing or empty |title= (help)
↑ Chiu, Man-Chun (2003). "Suggested management of immunocompromized kidney patients suffering from SARS". Pediatric Nephrology. 18 (12): 1204–1205. doi:10.1007/s00467-003-1325-8. ISSN 0931-041X.
↑ ^5.0 ^5.1 ^5.2 ^5.3 ^5.4 ^5.5 Zhu, Lan; Xu, Xizhen; Ma, Ke; Yang, Junling; Guan, Hanxiong; Chen, Song; Chen, Zhishui; Chen, Gang (2020). "Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression". American Journal of Transplantation. 20 (7): 1859–1863. doi:10.1111/ajt.15869. ISSN 1600-6135.
↑ ^6.0 ^6.1 "Clinical management of COVID-19".
↑ ^7.0 ^7.1 ^7.2 Wang, Dawei; Hu, Bo; Hu, Chang; Zhu, Fangfang; Liu, Xing; Zhang, Jing; Wang, Binbin; Xiang, Hui; Cheng, Zhenshun; Xiong, Yong; Zhao, Yan; Li, Yirong; Wang, Xinghuan; Peng, Zhiyong (2020). "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China". JAMA. 323 (11): 1061. doi:10.1001/jama.2020.1585. ISSN 0098-7484.
↑ ^8.0 ^8.1 ^8.2 ^8.3 ^8.4 ^8.5 ^8.6 ^8.7 ^8.8 ^8.9 Zhou, Fei; Yu, Ting; Du, Ronghui; Fan, Guohui; Liu, Ying; Liu, Zhibo; Xiang, Jie; Wang, Yeming; Song, Bin; Gu, Xiaoying; Guan, Lulu; Wei, Yuan; Li, Hui; Wu, Xudong; Xu, Jiuyang; Tu, Shengjin; Zhang, Yi; Chen, Hua; Cao, Bin (2020). "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study". The Lancet. 395 (10229): 1054–1062. doi:10.1016/S0140-6736(20)30566-3. ISSN 0140-6736.
↑ Karuthu, Shamila; Blumberg, Emily A. (2012). "Common Infections in Kidney Transplant Recipients". Clinical Journal of the American Society of Nephrology. 7 (12): 2058–2070. doi:10.2215/CJN.04410512. ISSN 1555-9041.
↑ Aulagnon, Florence; Scemla, Anne; DeWolf, Susan; Legendre, Christophe; Zuber, Julien (2014). "Diarrhea After Kidney Transplantation". Transplantation. 98 (8): 806–816. doi:10.1097/TP.0000000000000335. ISSN 0041-1337.
↑ ^11.0 ^11.1 ^11.2 ^11.3 Li, Wenhui; Moore, Michael J.; Vasilieva, Natalya; Sui, Jianhua; Wong, Swee Kee; Berne, Michael A.; Somasundaran, Mohan; Sullivan, John L.; Luzuriaga, Katherine; Greenough, Thomas C.; Choe, Hyeryun; Farzan, Michael (2003). "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus". Nature. 426 (6965): 450–454. doi:10.1038/nature02145. ISSN 0028-0836.
↑ ^12.0 ^12.1 ^12.2 ^12.3 Raj, V. Stalin; Mou, Huihui; Smits, Saskia L.; Dekkers, Dick H. W.; Müller, Marcel A.; Dijkman, Ronald; Muth, Doreen; Demmers, Jeroen A. A.; Zaki, Ali; Fouchier, Ron A. M.; Thiel, Volker; Drosten, Christian; Rottier, Peter J. M.; Osterhaus, Albert D. M. E.; Bosch, Berend Jan; Haagmans, Bart L. (2013). "Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC". Nature. 495 (7440): 251–254. doi:10.1038/nature12005. ISSN 0028-0836.
↑ Shang, Jian; Ye, Gang; Shi, Ke; Wan, Yushun; Luo, Chuming; Aihara, Hideki; Geng, Qibin; Auerbach, Ashley; Li, Fang (2020). "Structural basis of receptor recognition by SARS-CoV-2". Nature. 581 (7807): 221–224. doi:10.1038/s41586-020-2179-y. ISSN 0028-0836.
↑ Yan, Renhong; Zhang, Yuanyuan; Li, Yaning; Xia, Lu; Guo, Yingying; Zhou, Qiang (2020). "Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2". Science. 367 (6485): 1444–1448. doi:10.1126/science.abb2762. ISSN 0036-8075.
↑ . doi:10.1016/j.cell.2020.1002.1058. Missing or empty |title= (help)
↑ Wrapp, Daniel; Wang, Nianshuang; Corbett, Kizzmekia S.; Goldsmith, Jory A.; Hsieh, Ching-Lin; Abiona, Olubukola; Graham, Barney S.; McLellan, Jason S. (2020). "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation". Science. 367 (6483): 1260–1263. doi:10.1126/science.abb2507. ISSN 0036-8075.
↑ Chen, Yun; Guo, Yao; Pan, Yihang; Zhao, Zhizhuang Joe (2020). "Structure analysis of the receptor binding of 2019-nCoV". Biochemical and Biophysical Research Communications. 525 (1): 135–140. doi:10.1016/j.bbrc.2020.02.071. ISSN 0006-291X.
↑ Malha, Line; Mueller, Franco B.; Pecker, Mark S.; Mann, Samuel J.; August, Phyllis; Feig, Peter U. (2020). "COVID-19 and the Renin-Angiotensin System". Kidney International Reports. 5 (5): 563–565. doi:10.1016/j.ekir.2020.03.024. ISSN 2468-0249.
↑ Pan, Xiu-wu; Xu, Da; Zhang, Hao; Zhou, Wang; Wang, Lin-hui; Cui, Xin-gang (2020). "Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis". Intensive Care Medicine. 46 (6): 1114–1116. doi:10.1007/s00134-020-06026-1. ISSN 0342-4642.
↑ ^20.0 ^20.1 Nguyen, Austin; David, Julianne K; Maden, Sean K; Wood, Mary A; Weeder, Benjamin R; Nellore, Abhinav; Thompson, Reid F (2020). doi:10.1101/2020.03.22.20040600. Missing or empty |title= (help)
↑ Yang, Xiaobo; Yu, Yuan; Xu, Jiqian; Shu, Huaqing; Xia, Jia'an; Liu, Hong; Wu, Yongran; Zhang, Lu; Yu, Zhui; Fang, Minghao; Yu, Ting; Wang, Yaxin; Pan, Shangwen; Zou, Xiaojing; Yuan, Shiying; Shang, You (2020). "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study". The Lancet Respiratory Medicine. 8 (5): 475–481. doi:10.1016/S2213-2600(20)30079-5. ISSN 2213-2600.
↑ Beddhu, Srinivasan (2004). "Hypothesis: The Body Mass Index Paradox and an Obesity, Inflammation, and Atherosclerosis Syndrome in Chronic Kidney Disease". Seminars in Dialysis. 17 (3): 229–232. doi:10.1111/j.0894-0959.2004.17311.x. ISSN 0894-0959.
↑ Mohamed, Muner MB; Lukitsch, Ivo; Torres-Ortiz, Aldo E; Walker, Joseph B; Varghese, Vipin; Hernandez-Arroyo, Cesar F; Alqudsi, Muhannad; LeDoux, Jason R; Velez, Juan Carlos Q (2020). "Acute Kidney Injury Associated with Coronavirus Disease 2019 in Urban New Orleans". Kidney360: 10.34067/KID.0002652020. doi:10.34067/KID.0002652020. ISSN 2641-7650.
↑ Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin (2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". The Lancet. 395 (10223): 497–506. doi:10.1016/S0140-6736(20)30183-5. ISSN 0140-6736.
↑ Pan, Xiu-wu; Xu, Da; Zhang, Hao; Zhou, Wang; Wang, Lin-hui; Cui, Xin-gang (2020). "Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis". Intensive Care Medicine. 46 (6): 1114–1116. doi:10.1007/s00134-020-06026-1. ISSN 0342-4642.
↑ Diao, Bo; Wang, Chenhui; Wang, Rongshuai; Feng, Zeqing; Tan, Yingjun; Wang, Huiming; Wang, Changsong; Liu, Liang; Liu, Ying; Liu, Yueping; Wang, Gang; Yuan, Zilin; Ren, Liang; Wu, Yuzhang; Chen, Yongwen (2020). doi:10.1101/2020.03.04.20031120. Missing or empty |title= (help)
↑ Ai, Tao; Yang, Zhenlu; Hou, Hongyan; Zhan, Chenao; Chen, Chong; Lv, Wenzhi; Tao, Qian; Sun, Ziyong; Xia, Liming (2020). "Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases". Radiology: 200642. doi:10.1148/radiol.2020200642. ISSN 0033-8419.
↑ ^28.0 ^28.1 Michaels, Marian G.; La Hoz, Ricardo M.; Danziger-Isakov, Lara; Blumberg, Emily A.; Kumar, Deepali; Green, Michael; Pruett, Timothy L.; Wolfe, Cameron R. (2020). "Coronavirus disease 2019: Implications of emerging infections for transplantation". American Journal of Transplantation. 20 (7): 1768–1772. doi:10.1111/ajt.15832. ISSN 1600-6135.
↑ Chen, Nanshan; Zhou, Min; Dong, Xuan; Qu, Jieming; Gong, Fengyun; Han, Yang; Qiu, Yang; Wang, Jingli; Liu, Ying; Wei, Yuan; Xia, Jia'an; Yu, Ting; Zhang, Xinxin; Zhang, Li (2020). "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". The Lancet. 395 (10223): 507–513. doi:10.1016/S0140-6736(20)30211-7. ISSN 0140-6736.
↑ . doi:10.1016/ S2213-2600(20)30079-5 Check |doi= value (help). Missing or empty |title= (help)
↑ ^31.0 ^31.1 Wu, Zunyou; McGoogan, Jennifer M. (2020). "Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China". JAMA. 323 (13): 1239. doi:10.1001/jama.2020.2648. ISSN 0098-7484.
↑ Yang, Xiaobo; Yu, Yuan; Xu, Jiqian; Shu, Huaqing; Xia, Jia'an; Liu, Hong; Wu, Yongran; Zhang, Lu; Yu, Zhui; Fang, Minghao; Yu, Ting; Wang, Yaxin; Pan, Shangwen; Zou, Xiaojing; Yuan, Shiying; Shang, You (2020). "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study". The Lancet Respiratory Medicine. 8 (5): 475–481. doi:10.1016/S2213-2600(20)30079-5. ISSN 2213-2600.
↑ ^33.0 ^33.1 Naicker, Saraladevi; Yang, Chih-Wei; Hwang, Shang-Jyh; Liu, Bi-Cheng; Chen, Jiang-Hua; Jha, Vivekanand (2020). "The Novel Coronavirus 2019 epidemic and kidneys". Kidney International. 97 (5): 824–828. doi:10.1016/j.kint.2020.03.001. ISSN 0085-2538.
↑ ^34.0 ^34.1 ^34.2 Bussalino, Elisabetta; De Maria, Andrea; Russo, Rodolfo; Paoletti, Ernesto (2020). "Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS‐CoV‐2 pneumonia: A case report". American Journal of Transplantation. 20 (7): 1922–1924. doi:10.1111/ajt.15920. ISSN 1600-6135.
↑ ^35.0 ^35.1 ^35.2 Seminari, Elena; Colaneri, Marta; Sambo, Margherita; Gallazzi, Ilaria; Di Matteo, Angela; Roda, Silvia; Bruno, Raffaele; Mondelli, Mario U.; Brunetti, Enrico; Maiocchi, Laura; Zuccaro, Valentina; Pagnucco, Layla; Mariani, Bianca; Ludovisi, Serena; Lissandrin, Raffaella; Parisi, Aldo; Sacchi, Paolo; Patruno, Savino F. A.; Michelone, Giuseppe; Gulminetti, Roberto; Zanaboni, Domenico; Novati, Stefano; Maserati, Renato; Orsolini, Paolo; Vecchia, Marco; Sciarra, Marco; Asperges, Erika; Di Filippo, Alessandro; Biscarini, Simona; Lupi, Matteo; Pieri, Teresa C.; Sachs, Michele; Valsecchi, Pietro; Perlini, Stefano; Alfano, Claudia; Bonzano, Marco; Briganti, Federica; Crescenzi, Giuseppe; Falchi, Anna G.; Guarnone, Roberta; Guglielmana, Barbara; Maggi, Elena; Martino, Ilaria; Pettenazza, Pietro; Pioli di Marco, Serena; Quaglia, Federica; Sabena, Anna; Salinaro, Francesco; Speciale, Francesco; Zunino, Ilaria; De Lorenzo, Marzia; Secco, Gianmarco; Dimitry, Lorenzo; Cappa, Giovanni; Maisak, Igor; Chiodi, Benedetta; Sciarrini, Massimiliano; Barcella, Bruno; Resta, Flavia; Moroni, Luca; Vezzoni, Giulia; Scattaglia, Lorenzo; Boscolo, Elisa; Zattera, Caterina; Fidel, Tassi M.; Vincenzo, Capozza; Vignaroli, Damiano; Bazzini, Marco; Iotti, Giorgio; Mojoli, Francesco; Belliato, Mirko; Perotti, Luciano; Mongodi, Silvia; Tavazzi, Guido; Marseglia, Gianluigi; Licari, Amelia; Brambilla, Ilaria; Daniela, Barbarini; Antonella, Bruno; Patrizia, Cambieri; Giulia, Campanini; Giuditta, Comolli; Marta, Corbella; Rossana, Daturi; Milena, Furione; Bianca, Mariani; Roberta, Maserati; Enza, Monzillo; Stefania, Paolucci; Maurizio, Parea; Elena, Percivalle; Antonio, Piralla; Francesca, Rovida; Antonella, Sarasini; Maurizio, Zavattoni; Guy, Adzasehoun; Laura, Bellotti; Ermanna, Cabano; Giuliana, Casali; Luca, Dossena; Gabriella, Frisco; Gabriella, Garbagnoli; Alessia, Girello; Viviana, Landini; Claudia, Lucchelli; Valentina, Maliardi; Simona, Pezzaia; Marta, Premoli; Alice, Bonetti; Giacomo, Caneva; Irene, Cassaniti; Alfonso, Corcione; Di Martino, Raffella; Di Napoli, Annapia; Alessandro, Ferrari; Guglielmo, Ferrari; Loretta, Fiorina; Federica, Giardina; Alessandra, Mercato; Federica, Novazzi; Giacomo, Ratano; Beatrice, Rossi; Maria, Sciabica I.; Monica, Tallarita; Edoardo, Vecchio N.; Cerino, Antonella; Varchetta, Stefania; Oliviero, Barbara; Mantovani, Stefania; Mele, Dalila; Calvi, Monica; Tizzonis, Michela; Nicora, Carlo; Triarico, Antonio; Petronella, Vincenzo; Marena, Carlo; Muzzi, Alba; Lago, Paolo; Comandatore, Francesco; Bissignandi, Gherard; Gaiarsa, Stefano; Rettani, Marco; Band, Claudio (2020). "SARS Cov‐2 infection in a renal‐transplanted patient: A case report". American Journal of Transplantation. 20 (7): 1882–1884. doi:10.1111/ajt.15902. ISSN 1600-6135.
↑ ^36.0 ^36.1 ^36.2 Marx, David; Moulin, Bruno; Fafi‐Kremer, Samira; Benotmane, Ilies; Gautier, Gabriela; Perrin, Peggy; Caillard, Sophie (2020). "First case of COVID‐19 in a kidney transplant recipient treated with belatacept". American Journal of Transplantation. 20 (7): 1944–1946. doi:10.1111/ajt.15919. ISSN 1600-6135.
↑ ^37.0 ^37.1 ^37.2 Gandolfini, Ilaria; Delsante, Marco; Fiaccadori, Enrico; Zaza, Gianluigi; Manenti, Lucio; Degli Antoni, Anna; Peruzzi, Licia; Riella, Leonardo V.; Cravedi, Paolo; Maggiore, Umberto (2020). "COVID‐19 in kidney transplant recipients". American Journal of Transplantation. 20 (7): 1941–1943. doi:10.1111/ajt.15891. ISSN 1600-6135.
↑ ^38.0 ^38.1 ^38.2 Guillen, Elena; Pineiro, Gaston J.; Revuelta, Ignacio; Rodriguez, Diana; Bodro, Marta; Moreno, Asunción; Campistol, Josep M.; Diekmann, Fritz; Ventura‐Aguiar, Pedro (2020). "Case report of COVID‐19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?". American Journal of Transplantation. 20 (7): 1875–1878. doi:10.1111/ajt.15874. ISSN 1600-6135.
↑ ^39.0 ^39.1 . doi:10.1016/ S2213-2600(20)30182-X Check |doi= value (help). Missing or empty |title= (help)
↑ ^40.0 ^40.1 ^40.2 Haberal, Mehmet (2020). "COVID-19 UPDATE". Experimental and Clinical Transplantation. 18 (2): 139–140. doi:10.6002/ect.2020.000e. ISSN 1304-0855.
↑ ^41.0 ^41.1 ^41.2 ^41.3 "bts.org.uk" (PDF).
↑ ^42.0 ^42.1 ^42.2 "www.europeanurology.com".
↑ ^43.0 ^43.1 Sharma, Garima; Volgman, Annabelle Santos; Michos, Erin D. (2020). "Sex Differences in Mortality From COVID-19 Pandemic". JACC: Case Reports. doi:10.1016/j.jaccas.2020.04.027. ISSN 2666-0849.
↑ ^44.0 ^44.1 ^44.2 ^44.3 Akalin, Enver; Azzi, Yorg; Bartash, Rachel; Seethamraju, Harish; Parides, Michael; Hemmige, Vagish; Ross, Michael; Forest, Stefanie; Goldstein, Yitz D.; Ajaimy, Maria; Liriano-Ward, Luz; Pynadath, Cindy; Loarte-Campos, Pablo; Nandigam, Purna B.; Graham, Jay; Le, Marie; Rocca, Juan; Kinkhabwala, Milan (2020). "Covid-19 and Kidney Transplantation". New England Journal of Medicine. 382 (25): 2475–2477. doi:10.1056/NEJMc2011117. ISSN 0028-4793.
↑ ^45.0 ^45.1 ^45.2 Banerjee, Debasish; Popoola, Joyce; Shah, Sapna; Ster, Irina Chis; Quan, Virginia; Phanish, Mysore (2020). "COVID-19 infection in kidney transplant recipients". Kidney International. 97 (6): 1076–1082. doi:10.1016/j.kint.2020.03.018. ISSN 0085-2538.
↑ ^46.0 ^46.1 ^46.2 Nacif, Lucas Souto; Zanini, Leonardo Y.; Waisberg, Daniel R.; Pinheiro, Rafael S.; Galvão, Flávio; Andraus, Wellington; D'Albuquerque, Luiz Carneiro (2020). "COVID-19 in solid organ transplantation patients: A systematic review". Clinics. 75. doi:10.6061/clinics/2020/e1983. ISSN 1807-5932.
↑ ^47.0 ^47.1 "Samavat".
↑ Selby, Nicholas M; Forni, Lui G; Laing, Christopher M; Horne, Kerry L; Evans, Rhys DR; Lucas, Bethany J; Fluck, Richard J (2020). "Covid-19 and acute kidney injury in hospital: summary of NICE guidelines". BMJ: m1963. doi:10.1136/bmj.m1963. ISSN 1756-1833.
↑ ^49.0 ^49.1 ^49.2 ^49.3 Banerjee, Debasish; Popoola, Joyce; Shah, Sapna; Ster, Irina Chis; Quan, Virginia; Phanish, Mysore (2020). "COVID-19 infection in kidney transplant recipients". Kidney International. 97 (6): 1076–1082. doi:10.1016/j.kint.2020.03.018. ISSN 0085-2538.
↑ ^50.0 ^50.1
↑ "Harrison's principles of internal medicine : Kasper, Dennis L : Free Download, Borrow, and Streaming : Internet Archive".
↑ Banerjee, Debasish; Popoola, Joyce; Shah, Sapna; Ster, Irina Chis; Quan, Virginia; Phanish, Mysore (2020). "COVID-19 infection in kidney transplant recipients". Kidney International. 97 (6): 1076–1082. doi:10.1016/j.kint.2020.03.018. ISSN 0085-2538.
↑ Ostermann, Marlies; Joannidis, Michael (2016). "Acute kidney injury 2016: diagnosis and diagnostic workup". Critical Care. 20 (1). doi:10.1186/s13054-016-1478-z. ISSN 1364-8535.
↑ Schrezenmeier, E. V.; Barasch, J.; Budde, K.; Westhoff, T.; Schmidt-Ott, K. M. (2017). "Biomarkers in acute kidney injury - pathophysiological basis and clinical performance". Acta Physiologica. 219 (3): 556–574. doi:10.1111/apha.12764. ISSN 1748-1708.
↑ Kashani, Kianoush; Cheungpasitporn, Wisit; Ronco, Claudio (2017). "Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption". Clinical Chemistry and Laboratory Medicine (CCLM). 55 (8): 1074–1089. doi:10.1515/cclm-2016-0973. ISSN 1437-4331.
↑ Oh, Dong-Jin (2020). "A long journey for acute kidney injury biomarkers". Renal Failure. 42 (1): 154–165. doi:10.1080/0886022X.2020.1721300. ISSN 0886-022X.
↑ ^57.0 ^57.1 Zhu, Lan; Xu, Xizhen; Ma, Ke; Yang, Junling; Guan, Hanxiong; Chen, Song; Chen, Zhishui; Chen, Gang (2020). "Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression". American Journal of Transplantation. doi:10.1111/ajt.15869. ISSN 1600-6135.
↑ ^58.0 ^58.1 ^58.2 Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M (June 2020). "COVID-19 infection in kidney transplant recipients". Kidney Int. 97 (6): 1076–1082. doi:10.1016/j.kint.2020.03.018. PMC 7142878 Check |pmc= value (help). PMID 32354637 Check |pmid= value (help).
↑ ^59.0 ^59.1 ^59.2 ^59.3 ^59.4 ^59.5 Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M (June 2020). "COVID-19 infection in kidney transplant recipients". Kidney Int. 97 (6): 1076–1082. doi:10.1016/j.kint.2020.03.018. PMC 7142878 Check |pmc= value (help). PMID 32354637 Check |pmid= value (help).
↑ Lansbury, Louise E.; Rodrigo, Chamira; Leonardi-Bee, Jo; Nguyen-Van-Tam, Jonathan; Shen Lim, Wei (2020). "Corticosteroids as Adjunctive Therapy in the Treatment of Influenza". Critical Care Medicine. 48 (2): e98–e106. doi:10.1097/CCM.0000000000004093. ISSN 0090-3493.
↑ ^61.0 ^61.1 "www.massgeneral.org" (PDF).
↑ de Wilde, Adriaan H.; Zevenhoven-Dobbe, Jessika C.; van der Meer, Yvonne; Thiel, Volker; Narayanan, Krishna; Makino, Shinji; Snijder, Eric J.; van Hemert, Martijn J. (2011). "Cyclosporin A inhibits the replication of diverse coronaviruses". Journal of General Virology. 92 (11): 2542–2548. doi:10.1099/vir.0.034983-0. ISSN 0022-1317.
↑ Tanaka, Yoshikazu; Sato, Yuka; Sasaki, Takashi (2013). "Suppression of Coronavirus Replication by Cyclophilin Inhibitors". Viruses. 5 (5): 1250–1260. doi:10.3390/v5051250. ISSN 1999-4915.
↑ Ho, Quan Yao; Chung, Shimin J.; Gan, Valerie H. L.; Ng, Lay Guat; Tan, Ban Hock; Kee, Terence Y. S. (2020). "High‐immunological risk living donor renal transplant during the COVID‐19 outbreak: Uncertainties and ethical dilemmas". American Journal of Transplantation. 20 (7): 1949–1951. doi:10.1111/ajt.15949. ISSN 1600-6135.
↑ Ma, Mai-Juan; Kang, Dian-Min; Duan, Li-Jun; Yao, Lin; Wang, Guo-Lin; Anderson, Benjamin D; Yao, Ming-Xiao; Pang, Bo; Lin, Can-Fang; Ji, Sheng-Xiang; Gao, Feng; Hang, Yang; Sun, Wen-Kui; Kou, Zeng-Qiang; Lei, Jie; Li, Cun-Bao; Zhao, Xiang-Na; Zhang, Xiao-Li; Jiang, Xiao-Lin (2020). "Transmission Potential of Asymptomatic and Paucisymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections: A 3-Family Cluster Study in China". The Journal of Infectious Diseases. 221 (12): 1948–1952. doi:10.1093/infdis/jiaa206. ISSN 0022-1899.
↑ "An Update and Guidance on 2019 Novel Coronavirus (2019-nCov) for Transplant ID Clinicians".
↑ Zhang, Sheng; Tong, Yi Xin; Xiao, Ai Tang (2020). "Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients". Clinical Infectious Diseases. doi:10.1093/cid/ciaa460. ISSN 1058-4838.
↑ . doi:10.3201/eid2608.201097. Check |doi= value (help). Missing or empty |title= (help)
↑ ^69.0 ^69.1 ^69.2 ^69.3 ^69.4 ^69.5 ^69.6 ^69.7 ^69.8 López, Verónica; Vázquez, Teresa; Alonso-Titos, Juana; Cabello, Mercedes; Alonso, Angel; Beneyto, Isabel; Crespo, Marta; Díaz-Corte, Carmen; Franco, Antonio; González-Roncero, Francisco; Gutiérrez, Elena; Guirado, Luis; Jiménez, Carlos; Jironda, Cristina; Lauzurica, Ricardo; Llorente, Santiago; Mazuecos, Auxiliadora; Paul, Javier; Rodríguez-Benot, Alberto; Ruiz, Juan Carlos; Sánchez-Fructuoso, Ana; Sola, Eugenia; Torregrosa, Vicente; Zárraga, Sofía; Hernández, Domingo (2020). "Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients". Nefrología (English Edition). doi:10.1016/j.nefroe.2020.03.017. ISSN 2013-2514.

[1] ttps://www.cdc.gov/coronavirus/2019-ncov/about/index.html. Missing or empty |title= (help)

[LuCui2020-2] Lu, Jian; Cui, Jie; Qian, Zhaohui; Wang, Yirong; Zhang, Hong; Duan, Yuange; Wu, Xinkai; Yao, Xinmin; Song, Yuhe; Li, Xiang; Wu, Changcheng; Tang, Xiaolu (2020). "On the origin and continuing evolution of SARS-CoV-2". National Science Review. doi:10.1093/nsr/nwaa036. ISSN 2095-5138.

[3] . doi:10.23750/abm.v91i1.9397. Missing or empty |title= (help)

[Chiu2003-4] Chiu, Man-Chun (2003). "Suggested management of immunocompromized kidney patients suffering from SARS". Pediatric Nephrology. 18 (12): 1204–1205. doi:10.1007/s00467-003-1325-8. ISSN 0931-041X.

[ZhuXu2020-5] 5.0 ^5.1 ^5.2 ^5.3 ^5.4 ^5.5 Zhu, Lan; Xu, Xizhen; Ma, Ke; Yang, Junling; Guan, Hanxiong; Chen, Song; Chen, Zhishui; Chen, Gang (2020). "Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression". American Journal of Transplantation. 20 (7): 1859–1863. doi:10.1111/ajt.15869. ISSN 1600-6135.

[urlClinical_management_of_COVID-19-6] 6.0 ^6.1 "Clinical management of COVID-19".

[WangHu2020-7] 7.0 ^7.1 ^7.2 Wang, Dawei; Hu, Bo; Hu, Chang; Zhu, Fangfang; Liu, Xing; Zhang, Jing; Wang, Binbin; Xiang, Hui; Cheng, Zhenshun; Xiong, Yong; Zhao, Yan; Li, Yirong; Wang, Xinghuan; Peng, Zhiyong (2020). "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China". JAMA. 323 (11): 1061. doi:10.1001/jama.2020.1585. ISSN 0098-7484.

[ZhouYu2020-8] 8.0 ^8.1 ^8.2 ^8.3 ^8.4 ^8.5 ^8.6 ^8.7 ^8.8 ^8.9 Zhou, Fei; Yu, Ting; Du, Ronghui; Fan, Guohui; Liu, Ying; Liu, Zhibo; Xiang, Jie; Wang, Yeming; Song, Bin; Gu, Xiaoying; Guan, Lulu; Wei, Yuan; Li, Hui; Wu, Xudong; Xu, Jiuyang; Tu, Shengjin; Zhang, Yi; Chen, Hua; Cao, Bin (2020). "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study". The Lancet. 395 (10229): 1054–1062. doi:10.1016/S0140-6736(20)30566-3. ISSN 0140-6736.

[KaruthuBlumberg2012-9] Karuthu, Shamila; Blumberg, Emily A. (2012). "Common Infections in Kidney Transplant Recipients". Clinical Journal of the American Society of Nephrology. 7 (12): 2058–2070. doi:10.2215/CJN.04410512. ISSN 1555-9041.

[AulagnonScemla2014-10] Aulagnon, Florence; Scemla, Anne; DeWolf, Susan; Legendre, Christophe; Zuber, Julien (2014). "Diarrhea After Kidney Transplantation". Transplantation. 98 (8): 806–816. doi:10.1097/TP.0000000000000335. ISSN 0041-1337.

[LiMoore2003-11] 11.0 ^11.1 ^11.2 ^11.3 Li, Wenhui; Moore, Michael J.; Vasilieva, Natalya; Sui, Jianhua; Wong, Swee Kee; Berne, Michael A.; Somasundaran, Mohan; Sullivan, John L.; Luzuriaga, Katherine; Greenough, Thomas C.; Choe, Hyeryun; Farzan, Michael (2003). "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus". Nature. 426 (6965): 450–454. doi:10.1038/nature02145. ISSN 0028-0836.

[RajMou2013-12] 12.0 ^12.1 ^12.2 ^12.3 Raj, V. Stalin; Mou, Huihui; Smits, Saskia L.; Dekkers, Dick H. W.; Müller, Marcel A.; Dijkman, Ronald; Muth, Doreen; Demmers, Jeroen A. A.; Zaki, Ali; Fouchier, Ron A. M.; Thiel, Volker; Drosten, Christian; Rottier, Peter J. M.; Osterhaus, Albert D. M. E.; Bosch, Berend Jan; Haagmans, Bart L. (2013). "Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC". Nature. 495 (7440): 251–254. doi:10.1038/nature12005. ISSN 0028-0836.

[ShangYe2020-13] Shang, Jian; Ye, Gang; Shi, Ke; Wan, Yushun; Luo, Chuming; Aihara, Hideki; Geng, Qibin; Auerbach, Ashley; Li, Fang (2020). "Structural basis of receptor recognition by SARS-CoV-2". Nature. 581 (7807): 221–224. doi:10.1038/s41586-020-2179-y. ISSN 0028-0836.

[YanZhang2020-14] Yan, Renhong; Zhang, Yuanyuan; Li, Yaning; Xia, Lu; Guo, Yingying; Zhou, Qiang (2020). "Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2". Science. 367 (6485): 1444–1448. doi:10.1126/science.abb2762. ISSN 0036-8075.

[15] . doi:10.1016/j.cell.2020.1002.1058. Missing or empty |title= (help)

[WrappWang2020-16] Wrapp, Daniel; Wang, Nianshuang; Corbett, Kizzmekia S.; Goldsmith, Jory A.; Hsieh, Ching-Lin; Abiona, Olubukola; Graham, Barney S.; McLellan, Jason S. (2020). "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation". Science. 367 (6483): 1260–1263. doi:10.1126/science.abb2507. ISSN 0036-8075.

[ChenGuo2020-17] Chen, Yun; Guo, Yao; Pan, Yihang; Zhao, Zhizhuang Joe (2020). "Structure analysis of the receptor binding of 2019-nCoV". Biochemical and Biophysical Research Communications. 525 (1): 135–140. doi:10.1016/j.bbrc.2020.02.071. ISSN 0006-291X.

[MalhaMueller2020-18] Malha, Line; Mueller, Franco B.; Pecker, Mark S.; Mann, Samuel J.; August, Phyllis; Feig, Peter U. (2020). "COVID-19 and the Renin-Angiotensin System". Kidney International Reports. 5 (5): 563–565. doi:10.1016/j.ekir.2020.03.024. ISSN 2468-0249.

[PanXu2020-19] Pan, Xiu-wu; Xu, Da; Zhang, Hao; Zhou, Wang; Wang, Lin-hui; Cui, Xin-gang (2020). "Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis". Intensive Care Medicine. 46 (6): 1114–1116. doi:10.1007/s00134-020-06026-1. ISSN 0342-4642.

[NguyenDavid2020-20] 20.0 ^20.1 Nguyen, Austin; David, Julianne K; Maden, Sean K; Wood, Mary A; Weeder, Benjamin R; Nellore, Abhinav; Thompson, Reid F (2020). doi:10.1101/2020.03.22.20040600. Missing or empty |title= (help)

[YangYu2020-21] Yang, Xiaobo; Yu, Yuan; Xu, Jiqian; Shu, Huaqing; Xia, Jia'an; Liu, Hong; Wu, Yongran; Zhang, Lu; Yu, Zhui; Fang, Minghao; Yu, Ting; Wang, Yaxin; Pan, Shangwen; Zou, Xiaojing; Yuan, Shiying; Shang, You (2020). "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study". The Lancet Respiratory Medicine. 8 (5): 475–481. doi:10.1016/S2213-2600(20)30079-5. ISSN 2213-2600.

[Beddhu2004-22] Beddhu, Srinivasan (2004). "Hypothesis: The Body Mass Index Paradox and an Obesity, Inflammation, and Atherosclerosis Syndrome in Chronic Kidney Disease". Seminars in Dialysis. 17 (3): 229–232. doi:10.1111/j.0894-0959.2004.17311.x. ISSN 0894-0959.

[MohamedLukitsch2020-23] Mohamed, Muner MB; Lukitsch, Ivo; Torres-Ortiz, Aldo E; Walker, Joseph B; Varghese, Vipin; Hernandez-Arroyo, Cesar F; Alqudsi, Muhannad; LeDoux, Jason R; Velez, Juan Carlos Q (2020). "Acute Kidney Injury Associated with Coronavirus Disease 2019 in Urban New Orleans". Kidney360: 10.34067/KID.0002652020. doi:10.34067/KID.0002652020. ISSN 2641-7650.

[HuangWang20202-24] Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin (2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". The Lancet. 395 (10223): 497–506. doi:10.1016/S0140-6736(20)30183-5. ISSN 0140-6736.

[PanXu20203-25] Pan, Xiu-wu; Xu, Da; Zhang, Hao; Zhou, Wang; Wang, Lin-hui; Cui, Xin-gang (2020). "Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis". Intensive Care Medicine. 46 (6): 1114–1116. doi:10.1007/s00134-020-06026-1. ISSN 0342-4642.

[DiaoWang20202-26] Diao, Bo; Wang, Chenhui; Wang, Rongshuai; Feng, Zeqing; Tan, Yingjun; Wang, Huiming; Wang, Changsong; Liu, Liang; Liu, Ying; Liu, Yueping; Wang, Gang; Yuan, Zilin; Ren, Liang; Wu, Yuzhang; Chen, Yongwen (2020). doi:10.1101/2020.03.04.20031120. Missing or empty |title= (help)

[AiYang2020-27] Ai, Tao; Yang, Zhenlu; Hou, Hongyan; Zhan, Chenao; Chen, Chong; Lv, Wenzhi; Tao, Qian; Sun, Ziyong; Xia, Liming (2020). "Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases". Radiology: 200642. doi:10.1148/radiol.2020200642. ISSN 0033-8419.

[MichaelsLa_Hoz2020-28] 28.0 ^28.1 Michaels, Marian G.; La Hoz, Ricardo M.; Danziger-Isakov, Lara; Blumberg, Emily A.; Kumar, Deepali; Green, Michael; Pruett, Timothy L.; Wolfe, Cameron R. (2020). "Coronavirus disease 2019: Implications of emerging infections for transplantation". American Journal of Transplantation. 20 (7): 1768–1772. doi:10.1111/ajt.15832. ISSN 1600-6135.

[ChenZhou2020-29] Chen, Nanshan; Zhou, Min; Dong, Xuan; Qu, Jieming; Gong, Fengyun; Han, Yang; Qiu, Yang; Wang, Jingli; Liu, Ying; Wei, Yuan; Xia, Jia'an; Yu, Ting; Zhang, Xinxin; Zhang, Li (2020). "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". The Lancet. 395 (10223): 507–513. doi:10.1016/S0140-6736(20)30211-7. ISSN 0140-6736.

[30] . doi:10.1016/ S2213-2600(20)30079-5 Check |doi= value (help). Missing or empty |title= (help)

[WuMcGoogan2020-31] 31.0 ^31.1 Wu, Zunyou; McGoogan, Jennifer M. (2020). "Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China". JAMA. 323 (13): 1239. doi:10.1001/jama.2020.2648. ISSN 0098-7484.

[YangYu20202-32] Yang, Xiaobo; Yu, Yuan; Xu, Jiqian; Shu, Huaqing; Xia, Jia'an; Liu, Hong; Wu, Yongran; Zhang, Lu; Yu, Zhui; Fang, Minghao; Yu, Ting; Wang, Yaxin; Pan, Shangwen; Zou, Xiaojing; Yuan, Shiying; Shang, You (2020). "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study". The Lancet Respiratory Medicine. 8 (5): 475–481. doi:10.1016/S2213-2600(20)30079-5. ISSN 2213-2600.

[NaickerYang2020-33] 33.0 ^33.1 Naicker, Saraladevi; Yang, Chih-Wei; Hwang, Shang-Jyh; Liu, Bi-Cheng; Chen, Jiang-Hua; Jha, Vivekanand (2020). "The Novel Coronavirus 2019 epidemic and kidneys". Kidney International. 97 (5): 824–828. doi:10.1016/j.kint.2020.03.001. ISSN 0085-2538.

[BussalinoDe_Maria2020-34] 34.0 ^34.1 ^34.2 Bussalino, Elisabetta; De Maria, Andrea; Russo, Rodolfo; Paoletti, Ernesto (2020). "Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS‐CoV‐2 pneumonia: A case report". American Journal of Transplantation. 20 (7): 1922–1924. doi:10.1111/ajt.15920. ISSN 1600-6135.

[SeminariColaneri2020-35] 35.0 ^35.1 ^35.2 Seminari, Elena; Colaneri, Marta; Sambo, Margherita; Gallazzi, Ilaria; Di Matteo, Angela; Roda, Silvia; Bruno, Raffaele; Mondelli, Mario U.; Brunetti, Enrico; Maiocchi, Laura; Zuccaro, Valentina; Pagnucco, Layla; Mariani, Bianca; Ludovisi, Serena; Lissandrin, Raffaella; Parisi, Aldo; Sacchi, Paolo; Patruno, Savino F. A.; Michelone, Giuseppe; Gulminetti, Roberto; Zanaboni, Domenico; Novati, Stefano; Maserati, Renato; Orsolini, Paolo; Vecchia, Marco; Sciarra, Marco; Asperges, Erika; Di Filippo, Alessandro; Biscarini, Simona; Lupi, Matteo; Pieri, Teresa C.; Sachs, Michele; Valsecchi, Pietro; Perlini, Stefano; Alfano, Claudia; Bonzano, Marco; Briganti, Federica; Crescenzi, Giuseppe; Falchi, Anna G.; Guarnone, Roberta; Guglielmana, Barbara; Maggi, Elena; Martino, Ilaria; Pettenazza, Pietro; Pioli di Marco, Serena; Quaglia, Federica; Sabena, Anna; Salinaro, Francesco; Speciale, Francesco; Zunino, Ilaria; De Lorenzo, Marzia; Secco, Gianmarco; Dimitry, Lorenzo; Cappa, Giovanni; Maisak, Igor; Chiodi, Benedetta; Sciarrini, Massimiliano; Barcella, Bruno; Resta, Flavia; Moroni, Luca; Vezzoni, Giulia; Scattaglia, Lorenzo; Boscolo, Elisa; Zattera, Caterina; Fidel, Tassi M.; Vincenzo, Capozza; Vignaroli, Damiano; Bazzini, Marco; Iotti, Giorgio; Mojoli, Francesco; Belliato, Mirko; Perotti, Luciano; Mongodi, Silvia; Tavazzi, Guido; Marseglia, Gianluigi; Licari, Amelia; Brambilla, Ilaria; Daniela, Barbarini; Antonella, Bruno; Patrizia, Cambieri; Giulia, Campanini; Giuditta, Comolli; Marta, Corbella; Rossana, Daturi; Milena, Furione; Bianca, Mariani; Roberta, Maserati; Enza, Monzillo; Stefania, Paolucci; Maurizio, Parea; Elena, Percivalle; Antonio, Piralla; Francesca, Rovida; Antonella, Sarasini; Maurizio, Zavattoni; Guy, Adzasehoun; Laura, Bellotti; Ermanna, Cabano; Giuliana, Casali; Luca, Dossena; Gabriella, Frisco; Gabriella, Garbagnoli; Alessia, Girello; Viviana, Landini; Claudia, Lucchelli; Valentina, Maliardi; Simona, Pezzaia; Marta, Premoli; Alice, Bonetti; Giacomo, Caneva; Irene, Cassaniti; Alfonso, Corcione; Di Martino, Raffella; Di Napoli, Annapia; Alessandro, Ferrari; Guglielmo, Ferrari; Loretta, Fiorina; Federica, Giardina; Alessandra, Mercato; Federica, Novazzi; Giacomo, Ratano; Beatrice, Rossi; Maria, Sciabica I.; Monica, Tallarita; Edoardo, Vecchio N.; Cerino, Antonella; Varchetta, Stefania; Oliviero, Barbara; Mantovani, Stefania; Mele, Dalila; Calvi, Monica; Tizzonis, Michela; Nicora, Carlo; Triarico, Antonio; Petronella, Vincenzo; Marena, Carlo; Muzzi, Alba; Lago, Paolo; Comandatore, Francesco; Bissignandi, Gherard; Gaiarsa, Stefano; Rettani, Marco; Band, Claudio (2020). "SARS Cov‐2 infection in a renal‐transplanted patient: A case report". American Journal of Transplantation. 20 (7): 1882–1884. doi:10.1111/ajt.15902. ISSN 1600-6135.

[MarxMoulin2020-36] 36.0 ^36.1 ^36.2 Marx, David; Moulin, Bruno; Fafi‐Kremer, Samira; Benotmane, Ilies; Gautier, Gabriela; Perrin, Peggy; Caillard, Sophie (2020). "First case of COVID‐19 in a kidney transplant recipient treated with belatacept". American Journal of Transplantation. 20 (7): 1944–1946. doi:10.1111/ajt.15919. ISSN 1600-6135.

[GandolfiniDelsante2020-37] 37.0 ^37.1 ^37.2 Gandolfini, Ilaria; Delsante, Marco; Fiaccadori, Enrico; Zaza, Gianluigi; Manenti, Lucio; Degli Antoni, Anna; Peruzzi, Licia; Riella, Leonardo V.; Cravedi, Paolo; Maggiore, Umberto (2020). "COVID‐19 in kidney transplant recipients". American Journal of Transplantation. 20 (7): 1941–1943. doi:10.1111/ajt.15891. ISSN 1600-6135.

[GuillenPineiro2020-38] 38.0 ^38.1 ^38.2 Guillen, Elena; Pineiro, Gaston J.; Revuelta, Ignacio; Rodriguez, Diana; Bodro, Marta; Moreno, Asunción; Campistol, Josep M.; Diekmann, Fritz; Ventura‐Aguiar, Pedro (2020). "Case report of COVID‐19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?". American Journal of Transplantation. 20 (7): 1875–1878. doi:10.1111/ajt.15874. ISSN 1600-6135.

[:0-39] 39.0 ^39.1 . doi:10.1016/ S2213-2600(20)30182-X Check |doi= value (help). Missing or empty |title= (help)

[Haberal2020-40] 40.0 ^40.1 ^40.2 Haberal, Mehmet (2020). "COVID-19 UPDATE". Experimental and Clinical Transplantation. 18 (2): 139–140. doi:10.6002/ect.2020.000e. ISSN 1304-0855.

[urlbts.org.uk-41] 41.0 ^41.1 ^41.2 ^41.3 "bts.org.uk" (PDF).

[urlwww.europeanurology.com-42] 42.0 ^42.1 ^42.2 "www.europeanurology.com".

[SharmaVolgman2020-43] 43.0 ^43.1 Sharma, Garima; Volgman, Annabelle Santos; Michos, Erin D. (2020). "Sex Differences in Mortality From COVID-19 Pandemic". JACC: Case Reports. doi:10.1016/j.jaccas.2020.04.027. ISSN 2666-0849.

[AkalinAzzi2020-44] 44.0 ^44.1 ^44.2 ^44.3 Akalin, Enver; Azzi, Yorg; Bartash, Rachel; Seethamraju, Harish; Parides, Michael; Hemmige, Vagish; Ross, Michael; Forest, Stefanie; Goldstein, Yitz D.; Ajaimy, Maria; Liriano-Ward, Luz; Pynadath, Cindy; Loarte-Campos, Pablo; Nandigam, Purna B.; Graham, Jay; Le, Marie; Rocca, Juan; Kinkhabwala, Milan (2020). "Covid-19 and Kidney Transplantation". New England Journal of Medicine. 382 (25): 2475–2477. doi:10.1056/NEJMc2011117. ISSN 0028-4793.

[BanerjeePopoola2020-45] 45.0 ^45.1 ^45.2 Banerjee, Debasish; Popoola, Joyce; Shah, Sapna; Ster, Irina Chis; Quan, Virginia; Phanish, Mysore (2020). "COVID-19 infection in kidney transplant recipients". Kidney International. 97 (6): 1076–1082. doi:10.1016/j.kint.2020.03.018. ISSN 0085-2538.

[NacifZanini2020-46] 46.0 ^46.1 ^46.2 Nacif, Lucas Souto; Zanini, Leonardo Y.; Waisberg, Daniel R.; Pinheiro, Rafael S.; Galvão, Flávio; Andraus, Wellington; D'Albuquerque, Luiz Carneiro (2020). "COVID-19 in solid organ transplantation patients: A systematic review". Clinics. 75. doi:10.6061/clinics/2020/e1983. ISSN 1807-5932.

[urlSamavat-47] 47.0 ^47.1 "Samavat".

[SelbyForni2020-48] Selby, Nicholas M; Forni, Lui G; Laing, Christopher M; Horne, Kerry L; Evans, Rhys DR; Lucas, Bethany J; Fluck, Richard J (2020). "Covid-19 and acute kidney injury in hospital: summary of NICE guidelines". BMJ: m1963. doi:10.1136/bmj.m1963. ISSN 1756-1833.

[BanerjeePopoola20202-49] 49.0 ^49.1 ^49.2 ^49.3 Banerjee, Debasish; Popoola, Joyce; Shah, Sapna; Ster, Irina Chis; Quan, Virginia; Phanish, Mysore (2020). "COVID-19 infection in kidney transplant recipients". Kidney International. 97 (6): 1076–1082. doi:10.1016/j.kint.2020.03.018. ISSN 0085-2538.

[pmid32171076-50] 50.0 ^50.1

[urlHarrisons_principles_of_internal_medicine_:_Kasper,_Dennis_L_:_Free_Download,_Borrow,_and_Streaming_:_Internet_Archive-51] "Harrison's principles of internal medicine : Kasper, Dennis L : Free Download, Borrow, and Streaming : Internet Archive".

[BanerjeePopoola202022-52] Banerjee, Debasish; Popoola, Joyce; Shah, Sapna; Ster, Irina Chis; Quan, Virginia; Phanish, Mysore (2020). "COVID-19 infection in kidney transplant recipients". Kidney International. 97 (6): 1076–1082. doi:10.1016/j.kint.2020.03.018. ISSN 0085-2538.

[OstermannJoannidis2016-53] Ostermann, Marlies; Joannidis, Michael (2016). "Acute kidney injury 2016: diagnosis and diagnostic workup". Critical Care. 20 (1). doi:10.1186/s13054-016-1478-z. ISSN 1364-8535.

[SchrezenmeierBarasch2017-54] Schrezenmeier, E. V.; Barasch, J.; Budde, K.; Westhoff, T.; Schmidt-Ott, K. M. (2017). "Biomarkers in acute kidney injury - pathophysiological basis and clinical performance". Acta Physiologica. 219 (3): 556–574. doi:10.1111/apha.12764. ISSN 1748-1708.

[KashaniCheungpasitporn2017-55] Kashani, Kianoush; Cheungpasitporn, Wisit; Ronco, Claudio (2017). "Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption". Clinical Chemistry and Laboratory Medicine (CCLM). 55 (8): 1074–1089. doi:10.1515/cclm-2016-0973. ISSN 1437-4331.

[Oh2020-56] Oh, Dong-Jin (2020). "A long journey for acute kidney injury biomarkers". Renal Failure. 42 (1): 154–165. doi:10.1080/0886022X.2020.1721300. ISSN 0886-022X.

[ZhuXu20202-57] 57.0 ^57.1 Zhu, Lan; Xu, Xizhen; Ma, Ke; Yang, Junling; Guan, Hanxiong; Chen, Song; Chen, Zhishui; Chen, Gang (2020). "Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression". American Journal of Transplantation. doi:10.1111/ajt.15869. ISSN 1600-6135.

[pmid32354637-58] 58.0 ^58.1 ^58.2 Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M (June 2020). "COVID-19 infection in kidney transplant recipients". Kidney Int. 97 (6): 1076–1082. doi:10.1016/j.kint.2020.03.018. PMC 7142878 Check |pmc= value (help). PMID 32354637 Check |pmid= value (help).

[pmid323546372-59] 59.0 ^59.1 ^59.2 ^59.3 ^59.4 ^59.5 Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M (June 2020). "COVID-19 infection in kidney transplant recipients". Kidney Int. 97 (6): 1076–1082. doi:10.1016/j.kint.2020.03.018. PMC 7142878 Check |pmc= value (help). PMID 32354637 Check |pmid= value (help).

[LansburyRodrigo2020-60] Lansbury, Louise E.; Rodrigo, Chamira; Leonardi-Bee, Jo; Nguyen-Van-Tam, Jonathan; Shen Lim, Wei (2020). "Corticosteroids as Adjunctive Therapy in the Treatment of Influenza". Critical Care Medicine. 48 (2): e98–e106. doi:10.1097/CCM.0000000000004093. ISSN 0090-3493.

[urlwww.massgeneral.org-61] 61.0 ^61.1 "www.massgeneral.org" (PDF).

[de_WildeZevenhoven-Dobbe2011-62] Wilde, Adriaan H.; Zevenhoven-Dobbe, Jessika C.; van der Meer, Yvonne; Thiel, Volker; Narayanan, Krishna; Makino, Shinji; Snijder, Eric J.; van Hemert, Martijn J. (2011). "Cyclosporin A inhibits the replication of diverse coronaviruses". Journal of General Virology. 92 (11): 2542–2548. doi:10.1099/vir.0.034983-0. ISSN 0022-1317.

[TanakaSato2013-63] Tanaka, Yoshikazu; Sato, Yuka; Sasaki, Takashi (2013). "Suppression of Coronavirus Replication by Cyclophilin Inhibitors". Viruses. 5 (5): 1250–1260. doi:10.3390/v5051250. ISSN 1999-4915.

[HoChung2020-64] Ho, Quan Yao; Chung, Shimin J.; Gan, Valerie H. L.; Ng, Lay Guat; Tan, Ban Hock; Kee, Terence Y. S. (2020). "High‐immunological risk living donor renal transplant during the COVID‐19 outbreak: Uncertainties and ethical dilemmas". American Journal of Transplantation. 20 (7): 1949–1951. doi:10.1111/ajt.15949. ISSN 1600-6135.

[MaKang2020-65] Ma, Mai-Juan; Kang, Dian-Min; Duan, Li-Jun; Yao, Lin; Wang, Guo-Lin; Anderson, Benjamin D; Yao, Ming-Xiao; Pang, Bo; Lin, Can-Fang; Ji, Sheng-Xiang; Gao, Feng; Hang, Yang; Sun, Wen-Kui; Kou, Zeng-Qiang; Lei, Jie; Li, Cun-Bao; Zhao, Xiang-Na; Zhang, Xiao-Li; Jiang, Xiao-Lin (2020). "Transmission Potential of Asymptomatic and Paucisymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections: A 3-Family Cluster Study in China". The Journal of Infectious Diseases. 221 (12): 1948–1952. doi:10.1093/infdis/jiaa206. ISSN 0022-1899.

[urlAn_Update_and_Guidance_on_2019_Novel_Coronavirus_(2019-nCov)_for_Transplant_ID_Clinicians-66] "An Update and Guidance on 2019 Novel Coronavirus (2019-nCov) for Transplant ID Clinicians".

[ZhangTong2020-67] Zhang, Sheng; Tong, Yi Xin; Xiao, Ai Tang (2020). "Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients". Clinical Infectious Diseases. doi:10.1093/cid/ciaa460. ISSN 1058-4838.

[68] . doi:10.3201/eid2608.201097. Check |doi= value (help). Missing or empty |title= (help)

[LópezVázquez2020-69] 69.0 ^69.1 ^69.2 ^69.3 ^69.4 ^69.5 ^69.6 ^69.7 ^69.8 López, Verónica; Vázquez, Teresa; Alonso-Titos, Juana; Cabello, Mercedes; Alonso, Angel; Beneyto, Isabel; Crespo, Marta; Díaz-Corte, Carmen; Franco, Antonio; González-Roncero, Francisco; Gutiérrez, Elena; Guirado, Luis; Jiménez, Carlos; Jironda, Cristina; Lauzurica, Ricardo; Llorente, Santiago; Mazuecos, Auxiliadora; Paul, Javier; Rodríguez-Benot, Alberto; Ruiz, Juan Carlos; Sánchez-Fructuoso, Ana; Sola, Eugenia; Torregrosa, Vicente; Zárraga, Sofía; Hernández, Domingo (2020). "Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients". Nefrología (English Edition). doi:10.1016/j.nefroe.2020.03.017. ISSN 2013-2514.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[29]

[30]

[31]

[32]

[33]

[34]

[35]

[36]

[37]

[38]

[39]

[40]

[41]

[42]

[43]

[44]

[45]

[46]

[47]

[48]

[49]

[50]

[51]

[52]

[53]

[54]

[55]

[56]

[57]

[58]

[59]

[60]

[61]

[62]

[63]

[64]

[65]

[66]

[67]

[68]

[69]

@@ Line 1: / Line 1: @@
 __NOTOC__
+{{Main article|COVID-19}}
+{{SI}}
 '''For COVID-19 frequently asked inpatient questions, click [[COVID-19 frequently asked inpatient questions|here]]'''<br>
 '''For COVID-19 frequently asked outpatient questions, click [[COVID-19 frequently asked outpatient questions|here]]'''<br>
-{{COVID-19}}
 {{CMG}}; {{AE}} {{GDS}}
@@ Line 10: / Line 12: @@
 ==Historical Perspectives==
-*In 1965, Tyrrell and Bynoe used cultures of human ciliated embryonal trachea to propagate the first human coronavirus (HCoV) in vitro.
+*In 1965, Tyrrell and Bynoe used cultures of human ciliated embryonal trachea to propagate the first human coronavirus (HCoV) in vitro.<ref>{{Cite web|url=https://www.cdc.gov/coronavirus/2019-ncov/about/index.html|title=|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref><ref name="LuCui2020">{{cite journal|last1=Lu|first1=Jian|last2=Cui|first2=Jie|last3=Qian|first3=Zhaohui|last4=Wang|first4=Yirong|last5=Zhang|first5=Hong|last6=Duan|first6=Yuange|last7=Wu|first7=Xinkai|last8=Yao|first8=Xinmin|last9=Song|first9=Yuhe|last10=Li|first10=Xiang|last11=Wu|first11=Changcheng|last12=Tang|first12=Xiaolu|title=On the origin and continuing evolution of SARS-CoV-2|journal=National Science Review|year=2020|issn=2095-5138|doi=10.1093/nsr/nwaa036}}</ref>
-*The etiological agent involved is [[SARS-CoV-2|severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)]], causing [[coronavirus disease 2019 (COVID-19)]], first detected in Wuhan, China. On March 12, 2020 the World Health Organization declared the [[COVID-19]] outbreak a pandemic.
+*The etiological agent involved is [[SARS-CoV-2|severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)]], causing [[coronavirus disease 2019 (COVID-19)]], first detected in Wuhan, China. On March 12, 2020 the World Health Organization declared the [[COVID-19]] outbreak a pandemic.<ref>{{cite journal|doi=10.23750/abm.v91i1.9397}}</ref>
-*The earlier [[SARS-CoV|SARS]] epidemic of Hong Kong  is known to affect both pediatric and adult [[Kidney transplantation|renal transplant]] patients where the severity of disease in adult patients was more than that in pediatric patients
+*The earlier [[SARS-CoV|SARS]] epidemic of Hong Kong  is known to affect both pediatric and adult [[Kidney transplantation|renal transplant]] patients where the severity of disease in adult patients was more than that in pediatric patients<ref name="Chiu2003">{{cite journal|last1=Chiu|first1=Man-Chun|title=Suggested management of immunocompromized kidney patients suffering from SARS|journal=Pediatric Nephrology|volume=18|issue=12|year=2003|pages=1204–1205|issn=0931-041X|doi=10.1007/s00467-003-1325-8}}</ref>
-*The first reported case of [[COVID-19]] infection in [[Kidney transplantation|renal transplant]] patient, was a 52‐year‐old man who received living‐related [[kidney transplantation]] 12 years for chronic [[glomerulonephritis]], in Wuhan, China. He made a successful recovery and was discharged on day 13.
+*The first reported case of [[COVID-19]] infection in [[Kidney transplantation|renal transplant]] patient, was a 52‐year‐old man who received living‐related [[kidney transplantation]] 12 years for chronic [[glomerulonephritis]], in Wuhan, China. He made a successful recovery and was discharged on day 13.<ref name="ZhuXu2020">{{cite journal|last1=Zhu|first1=Lan|last2=Xu|first2=Xizhen|last3=Ma|first3=Ke|last4=Yang|first4=Junling|last5=Guan|first5=Hanxiong|last6=Chen|first6=Song|last7=Chen|first7=Zhishui|last8=Chen|first8=Gang|title=Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1859–1863|issn=1600-6135|doi=10.1111/ajt.15869}}</ref>
 ==Classification==
-COVID-19 infection may be classified according to [[World Health Organization|WHO]] into four subtypes based on severity. Classification of COVID-19 infection in renal transplant [[patients]] depends on the severity of COVID-19 manifestations is following:
+COVID-19 infection may be classified according to [[World Health Organization|WHO]] into four subtypes based on severity. Classification of COVID-19 infection in renal transplant [[patients]] depends on the severity of COVID-19 manifestations is following:<ref name="urlClinical management of COVID-19">{{cite web |url=https://www.who.int/publications/i/item/clinical-management-of-covid-19 |title=Clinical management of COVID-19 |format= |work= |accessdate=}}</ref>
 {| class="wikitable"
 |Mild [[Disease]]
@@ Line 140: / Line 142: @@
 == Pathophysiology==
-The normal physiology of in renal [[Kidney transplantation|transplant]] patients can be understood as follows to that in general population. However, the [[Kidney transplantation|renal transplant]] recipients are at remain at higher risk to catch [[COVID-19]]<nowiki/>and develop severe complications due to chronic [[immunosuppressed]] state which is implicated in various viral infections such as [[cytomegalovirus]], [[herpes zoster]], [[norovirus]] infections.<ref name="ZhouYu2020" />
+The normal physiology of in renal [[Kidney transplantation|transplant]] patients can be understood as follows to that in general population<ref name="WangHu2020">{{cite journal|last1=Wang|first1=Dawei|last2=Hu|first2=Bo|last3=Hu|first3=Chang|last4=Zhu|first4=Fangfang|last5=Liu|first5=Xing|last6=Zhang|first6=Jing|last7=Wang|first7=Binbin|last8=Xiang|first8=Hui|last9=Cheng|first9=Zhenshun|last10=Xiong|first10=Yong|last11=Zhao|first11=Yan|last12=Li|first12=Yirong|last13=Wang|first13=Xinghuan|last14=Peng|first14=Zhiyong|title=Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China|journal=JAMA|volume=323|issue=11|year=2020|pages=1061|issn=0098-7484|doi=10.1001/jama.2020.1585}}</ref>. However, the [[Kidney transplantation|renal transplant]] recipients are at remain at higher risk to catch [[COVID-19]]<ref name="ZhouYu2020">{{cite journal|last1=Zhou|first1=Fei|last2=Yu|first2=Ting|last3=Du|first3=Ronghui|last4=Fan|first4=Guohui|last5=Liu|first5=Ying|last6=Liu|first6=Zhibo|last7=Xiang|first7=Jie|last8=Wang|first8=Yeming|last9=Song|first9=Bin|last10=Gu|first10=Xiaoying|last11=Guan|first11=Lulu|last12=Wei|first12=Yuan|last13=Li|first13=Hui|last14=Wu|first14=Xudong|last15=Xu|first15=Jiuyang|last16=Tu|first16=Shengjin|last17=Zhang|first17=Yi|last18=Chen|first18=Hua|last19=Cao|first19=Bin|title=Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study|journal=The Lancet|volume=395|issue=10229|year=2020|pages=1054–1062|issn=01406736|doi=10.1016/S0140-6736(20)30566-3}}</ref>and develop severe complications due to chronic immunosuppressed state which is implicated in various viral infections such as [[cytomegalovirus]], [[herpes zoster]], [[norovirus]] infections.<ref name="ZhouYu2020" /><ref name="KaruthuBlumberg2012">{{cite journal|last1=Karuthu|first1=Shamila|last2=Blumberg|first2=Emily A.|title=Common Infections in Kidney Transplant Recipients|journal=Clinical Journal of the American Society of Nephrology|volume=7|issue=12|year=2012|pages=2058–2070|issn=1555-9041|doi=10.2215/CJN.04410512}}</ref><ref name="AulagnonScemla2014">{{cite journal|last1=Aulagnon|first1=Florence|last2=Scemla|first2=Anne|last3=DeWolf|first3=Susan|last4=Legendre|first4=Christophe|last5=Zuber|first5=Julien|title=Diarrhea After Kidney Transplantation|journal=Transplantation|volume=98|issue=8|year=2014|pages=806–816|issn=0041-1337|doi=10.1097/TP.0000000000000335}}</ref>
 === Genetics ===
 *The [[Angiotensin-converting enzyme 2]] and Dipeptidyl peptidase has been associated with the development of  [[Coronavirus|SARS-Cov]] and [[Middle East respiratory syndrome coronavirus infection|MERS-CoV]]<ref name="LiMoore2003" /><ref name="RajMou2013" />
-*[[Angiotensin-converting enzyme 2]] and Dipeptidyl peptidase have been implicated in the uptake of [[Coronavirus|SARS-Cov]] and [[Middle East respiratory syndrome coronavirus infection|MERS-CoV]]
+*[[Angiotensin-converting enzyme 2]] and Dipeptidyl peptidase have been implicated in the uptake of [[Coronavirus|SARS-Cov]] and [[Middle East respiratory syndrome coronavirus infection|MERS-CoV]]<ref name="LiMoore2003">{{cite journal|last1=Li|first1=Wenhui|last2=Moore|first2=Michael J.|last3=Vasilieva|first3=Natalya|last4=Sui|first4=Jianhua|last5=Wong|first5=Swee Kee|last6=Berne|first6=Michael A.|last7=Somasundaran|first7=Mohan|last8=Sullivan|first8=John L.|last9=Luzuriaga|first9=Katherine|last10=Greenough|first10=Thomas C.|last11=Choe|first11=Hyeryun|last12=Farzan|first12=Michael|title=Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus|journal=Nature|volume=426|issue=6965|year=2003|pages=450–454|issn=0028-0836|doi=10.1038/nature02145}}</ref><ref name="RajMou2013">{{cite journal|last1=Raj|first1=V. Stalin|last2=Mou|first2=Huihui|last3=Smits|first3=Saskia L.|last4=Dekkers|first4=Dick H. W.|last5=Müller|first5=Marcel A.|last6=Dijkman|first6=Ronald|last7=Muth|first7=Doreen|last8=Demmers|first8=Jeroen A. A.|last9=Zaki|first9=Ali|last10=Fouchier|first10=Ron A. M.|last11=Thiel|first11=Volker|last12=Drosten|first12=Christian|last13=Rottier|first13=Peter J. M.|last14=Osterhaus|first14=Albert D. M. E.|last15=Bosch|first15=Berend Jan|last16=Haagmans|first16=Bart L.|title=Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC|journal=Nature|volume=495|issue=7440|year=2013|pages=251–254|issn=0028-0836|doi=10.1038/nature12005}}</ref>
-*Several studies have indicated that viral S-protein RBD interacts with host ACE2 receptor. S protein changes thus make the human cells permissive to [[SARS-CoV]] and [[SARS-CoV-2]] infection    ACE2: ACE ratio is higher in the [[Kidney|kidneys]] compared to the [[respiratory system]]. (1:1 in the [[Kidney|kidneys]] VS 1:20 in the [[respiratory system]]).These receptors are found in the proximal tubules of [[kidney]]<ref name="LiMoore2003">{{cite journal|last1=Li|first1=Wenhui|last2=Moore|first2=Michael J.|last3=Vasilieva|first3=Natalya|last4=Sui|first4=Jianhua|last5=Wong|first5=Swee Kee|last6=Berne|first6=Michael A.|last7=Somasundaran|first7=Mohan|last8=Sullivan|first8=John L.|last9=Luzuriaga|first9=Katherine|last10=Greenough|first10=Thomas C.|last11=Choe|first11=Hyeryun|last12=Farzan|first12=Michael|title=Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus|journal=Nature|volume=426|issue=6965|year=2003|pages=450–454|issn=0028-0836|doi=10.1038/nature02145}}</ref><ref name="RajMou2013">{{cite journal|last1=Raj|first1=V. Stalin|last2=Mou|first2=Huihui|last3=Smits|first3=Saskia L.|last4=Dekkers|first4=Dick H. W.|last5=Müller|first5=Marcel A.|last6=Dijkman|first6=Ronald|last7=Muth|first7=Doreen|last8=Demmers|first8=Jeroen A. A.|last9=Zaki|first9=Ali|last10=Fouchier|first10=Ron A. M.|last11=Thiel|first11=Volker|last12=Drosten|first12=Christian|last13=Rottier|first13=Peter J. M.|last14=Osterhaus|first14=Albert D. M. E.|last15=Bosch|first15=Berend Jan|last16=Haagmans|first16=Bart L.|title=Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC|journal=Nature|volume=495|issue=7440|year=2013|pages=251–254|issn=0028-0836|doi=10.1038/nature12005}}</ref>[[SARS-CoV-2|SARS-CoV2]] spike(S) protein is cleaved and activated by transmembrane serine protease family (TMPRSS) after attaching to [[Angiotensin-converting enzyme 2|angiotensin-converting enzyme]] 2 (ACE2) receptors. This allows the virus to release fusion peptide that aides in membrane fusion..
+*Several studies have indicated that viral S-protein RBD interacts with host ACE2 receptor. S protein changes thus make the human cells permissive to [[SARS-CoV]] and [[SARS-CoV-2]] infection<ref name="ShangYe2020">{{cite journal|last1=Shang|first1=Jian|last2=Ye|first2=Gang|last3=Shi|first3=Ke|last4=Wan|first4=Yushun|last5=Luo|first5=Chuming|last6=Aihara|first6=Hideki|last7=Geng|first7=Qibin|last8=Auerbach|first8=Ashley|last9=Li|first9=Fang|title=Structural basis of receptor recognition by SARS-CoV-2|journal=Nature|volume=581|issue=7807|year=2020|pages=221–224|issn=0028-0836|doi=10.1038/s41586-020-2179-y}}</ref> <ref name="YanZhang2020">{{cite journal|last1=Yan|first1=Renhong|last2=Zhang|first2=Yuanyuan|last3=Li|first3=Yaning|last4=Xia|first4=Lu|last5=Guo|first5=Yingying|last6=Zhou|first6=Qiang|title=Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2|journal=Science|volume=367|issue=6485|year=2020|pages=1444–1448|issn=0036-8075|doi=10.1126/science.abb2762}}</ref> <ref>{{cite journal|doi=10.1016/j.cell.2020.1002.1058}}</ref> <ref name="WrappWang2020">{{cite journal|last1=Wrapp|first1=Daniel|last2=Wang|first2=Nianshuang|last3=Corbett|first3=Kizzmekia S.|last4=Goldsmith|first4=Jory A.|last5=Hsieh|first5=Ching-Lin|last6=Abiona|first6=Olubukola|last7=Graham|first7=Barney S.|last8=McLellan|first8=Jason S.|title=Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation|journal=Science|volume=367|issue=6483|year=2020|pages=1260–1263|issn=0036-8075|doi=10.1126/science.abb2507}}</ref> <ref name="ChenGuo2020">{{cite journal|last1=Chen|first1=Yun|last2=Guo|first2=Yao|last3=Pan|first3=Yihang|last4=Zhao|first4=Zhizhuang Joe|title=Structure analysis of the receptor binding of 2019-nCoV|journal=Biochemical and Biophysical Research Communications|volume=525|issue=1|year=2020|pages=135–140|issn=0006291X|doi=10.1016/j.bbrc.2020.02.071}}</ref>ACE2: ACE ratio is higher in the [[Kidney|kidneys]] compared to the [[respiratory system]]. (1:1 in the [[Kidney|kidneys]] VS 1:20 in the [[respiratory system]]).<ref name="MalhaMueller2020">{{cite journal|last1=Malha|first1=Line|last2=Mueller|first2=Franco B.|last3=Pecker|first3=Mark S.|last4=Mann|first4=Samuel J.|last5=August|first5=Phyllis|last6=Feig|first6=Peter U.|title=COVID-19 and the Renin-Angiotensin System|journal=Kidney International Reports|volume=5|issue=5|year=2020|pages=563–565|issn=24680249|doi=10.1016/j.ekir.2020.03.024}}</ref>These receptors are found in the proximal tubules of [[kidney]]<ref name="LiMoore2003">{{cite journal|last1=Li|first1=Wenhui|last2=Moore|first2=Michael J.|last3=Vasilieva|first3=Natalya|last4=Sui|first4=Jianhua|last5=Wong|first5=Swee Kee|last6=Berne|first6=Michael A.|last7=Somasundaran|first7=Mohan|last8=Sullivan|first8=John L.|last9=Luzuriaga|first9=Katherine|last10=Greenough|first10=Thomas C.|last11=Choe|first11=Hyeryun|last12=Farzan|first12=Michael|title=Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus|journal=Nature|volume=426|issue=6965|year=2003|pages=450–454|issn=0028-0836|doi=10.1038/nature02145}}</ref><ref name="RajMou2013">{{cite journal|last1=Raj|first1=V. Stalin|last2=Mou|first2=Huihui|last3=Smits|first3=Saskia L.|last4=Dekkers|first4=Dick H. W.|last5=Müller|first5=Marcel A.|last6=Dijkman|first6=Ronald|last7=Muth|first7=Doreen|last8=Demmers|first8=Jeroen A. A.|last9=Zaki|first9=Ali|last10=Fouchier|first10=Ron A. M.|last11=Thiel|first11=Volker|last12=Drosten|first12=Christian|last13=Rottier|first13=Peter J. M.|last14=Osterhaus|first14=Albert D. M. E.|last15=Bosch|first15=Berend Jan|last16=Haagmans|first16=Bart L.|title=Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC|journal=Nature|volume=495|issue=7440|year=2013|pages=251–254|issn=0028-0836|doi=10.1038/nature12005}}</ref>[[SARS-CoV-2|SARS-CoV2]] spike(S) protein is cleaved and activated by transmembrane serine protease family (TMPRSS) after attaching to [[Angiotensin-converting enzyme 2|angiotensin-converting enzyme]] 2 (ACE2) receptors. This allows the virus to release fusion peptide that aides in membrane fusion..<ref name="PanXu2020">{{cite journal|last1=Pan|first1=Xiu-wu|last2=Xu|first2=Da|last3=Zhang|first3=Hao|last4=Zhou|first4=Wang|last5=Wang|first5=Lin-hui|last6=Cui|first6=Xin-gang|title=Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis|journal=Intensive Care Medicine|volume=46|issue=6|year=2020|pages=1114–1116|issn=0342-4642|doi=10.1007/s00134-020-06026-1}}</ref>
-*There is a possibility of association between MHC class I(HLA A, B & C) with incidence of COVID-19 infection as well as severity of complications
+*There is a possibility of association between MHC class I(HLA A, B & C) with incidence of COVID-19 infection as well as severity of complications<ref name="NguyenDavid2020">{{cite journal|last1=Nguyen|first1=Austin|last2=David|first2=Julianne K|last3=Maden|first3=Sean K|last4=Wood|first4=Mary A|last5=Weeder|first5=Benjamin R|last6=Nellore|first6=Abhinav|last7=Thompson|first7=Reid F|year=2020|doi=10.1101/2020.03.22.20040600}}</ref>
 *HLA-B*46:01 gene product is believed to show lowest binding to SARS-CoV-2 indicating decreased viral presentation to immune system. Whereas HLA-B*15:03 shows increased affinity to SARS-CoV-2<ref name="NguyenDavid2020">{{cite journal|last1=Nguyen|first1=Austin|last2=David|first2=Julianne K|last3=Maden|first3=Sean K|last4=Wood|first4=Mary A|last5=Weeder|first5=Benjamin R|last6=Nellore|first6=Abhinav|last7=Thompson|first7=Reid F|year=2020|doi=10.1101/2020.03.22.20040600}}</ref>leading to higher likelihood in developing immunity.
 === Associated Conditions===
-*[[Acute kidney injury|Acute Kidney Injury]] has been reported in patients with [[COVID-19]] infection along with presence of [[proteinuria]], [[hematuria]]. In a case observation, 4 out of 7 patients had [[Acute kidney injury|AKI]] which may indicate that [[Kidney transplantation|renal transplant]] patients are at higher risk [[Acute kidney injury|AKI]] on being infected with [[COVID-19]] whereas only 29% [[Acute kidney injury|AKI]] was seen in critically ill patients of general population.
+*[[Acute kidney injury|Acute Kidney Injury]] has been reported in patients with [[COVID-19]] infection along with presence of [[proteinuria]], [[hematuria]]. In a case observation, 4 out of 7 patients had [[Acute kidney injury|AKI]] which may indicate that [[Kidney transplantation|renal transplant]] patients are at higher risk [[Acute kidney injury|AKI]] on being infected with [[COVID-19]] whereas only 29% [[Acute kidney injury|AKI]] was seen in critically ill patients of general population.<ref name="YangYu2020">{{cite journal|last1=Yang|first1=Xiaobo|last2=Yu|first2=Yuan|last3=Xu|first3=Jiqian|last4=Shu|first4=Huaqing|last5=Xia|first5=Jia'an|last6=Liu|first6=Hong|last7=Wu|first7=Yongran|last8=Zhang|first8=Lu|last9=Yu|first9=Zhui|last10=Fang|first10=Minghao|last11=Yu|first11=Ting|last12=Wang|first12=Yaxin|last13=Pan|first13=Shangwen|last14=Zou|first14=Xiaojing|last15=Yuan|first15=Shiying|last16=Shang|first16=You|title=Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study|journal=The Lancet Respiratory Medicine|volume=8|issue=5|year=2020|pages=475–481|issn=22132600|doi=10.1016/S2213-2600(20)30079-5}}</ref>
-*[[Acute kidney injury|Acute Kidney Injury]] seen in [[COVID-19]] infection can be from the cytotropic effect (Uptake of [[COVID-19|SARS-Cov-2]] virus into proximal tubule cells is possible explanation for the [[Acute kidney injury|AKI]] seen in [[COVID-19|COVID]] patients<ref name="LiMoore2003">{{cite journal|last1=Li|first1=Wenhui|last2=Moore|first2=Michael J.|last3=Vasilieva|first3=Natalya|last4=Sui|first4=Jianhua|last5=Wong|first5=Swee Kee|last6=Berne|first6=Michael A.|last7=Somasundaran|first7=Mohan|last8=Sullivan|first8=John L.|last9=Luzuriaga|first9=Katherine|last10=Greenough|first10=Thomas C.|last11=Choe|first11=Hyeryun|last12=Farzan|first12=Michael|title=Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus|journal=Nature|volume=426|issue=6965|year=2003|pages=450–454|issn=0028-0836|doi=10.1038/nature02145}}</ref><ref name="RajMou2013">{{cite journal|last1=Raj|first1=V. Stalin|last2=Mou|first2=Huihui|last3=Smits|first3=Saskia L.|last4=Dekkers|first4=Dick H. W.|last5=Müller|first5=Marcel A.|last6=Dijkman|first6=Ronald|last7=Muth|first7=Doreen|last8=Demmers|first8=Jeroen A. A.|last9=Zaki|first9=Ali|last10=Fouchier|first10=Ron A. M.|last11=Thiel|first11=Volker|last12=Drosten|first12=Christian|last13=Rottier|first13=Peter J. M.|last14=Osterhaus|first14=Albert D. M. E.|last15=Bosch|first15=Berend Jan|last16=Haagmans|first16=Bart L.|title=Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC|journal=Nature|volume=495|issue=7440|year=2013|pages=251–254|issn=0028-0836|doi=10.1038/nature12005}}</ref>) of the viral particles as well as systemic inflammatory response induced by the cytokines. Patients admitted with severe disease, [[acute respiratory distress syndrome]] ([[Acute respiratory distress syndrome|ARDS]]) or in patients admitted to ICU have a higher incidence of [[Acute kidney injury|AKI]] . <ref name="ZhouYu2020">{{cite journal|last1=Zhou|first1=Fei|last2=Yu|first2=Ting|last3=Du|first3=Ronghui|last4=Fan|first4=Guohui|last5=Liu|first5=Ying|last6=Liu|first6=Zhibo|last7=Xiang|first7=Jie|last8=Wang|first8=Yeming|last9=Song|first9=Bin|last10=Gu|first10=Xiaoying|last11=Guan|first11=Lulu|last12=Wei|first12=Yuan|last13=Li|first13=Hui|last14=Wu|first14=Xudong|last15=Xu|first15=Jiuyang|last16=Tu|first16=Shengjin|last17=Zhang|first17=Yi|last18=Chen|first18=Hua|last19=Cao|first19=Bin|title=Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study|journal=The Lancet|volume=395|issue=10229|year=2020|pages=1054–1062|issn=01406736|doi=10.1016/S0140-6736(20)30566-3}}</ref>.  Other possible reasons that can play a role in [[Acute kidney injury|AKI]] development, are multi-organ failure resulting in [[acute tubular necrosis]] ([[Acute tubular necrosis|ATN]]), volume reduction causing prerenal [[Acute tubular necrosis|ATN]], high [[fever]], drug toxicity, [[hypotension]], and contrast exposure.
+*[[Acute kidney injury|Acute Kidney Injury]] seen in [[COVID-19]] infection can be from the cytotropic effect (Uptake of [[COVID-19|SARS-Cov-2]] virus into proximal tubule cells is possible explanation for the [[Acute kidney injury|AKI]] seen in [[COVID-19|COVID]] patients<ref name="LiMoore2003">{{cite journal|last1=Li|first1=Wenhui|last2=Moore|first2=Michael J.|last3=Vasilieva|first3=Natalya|last4=Sui|first4=Jianhua|last5=Wong|first5=Swee Kee|last6=Berne|first6=Michael A.|last7=Somasundaran|first7=Mohan|last8=Sullivan|first8=John L.|last9=Luzuriaga|first9=Katherine|last10=Greenough|first10=Thomas C.|last11=Choe|first11=Hyeryun|last12=Farzan|first12=Michael|title=Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus|journal=Nature|volume=426|issue=6965|year=2003|pages=450–454|issn=0028-0836|doi=10.1038/nature02145}}</ref><ref name="RajMou2013">{{cite journal|last1=Raj|first1=V. Stalin|last2=Mou|first2=Huihui|last3=Smits|first3=Saskia L.|last4=Dekkers|first4=Dick H. W.|last5=Müller|first5=Marcel A.|last6=Dijkman|first6=Ronald|last7=Muth|first7=Doreen|last8=Demmers|first8=Jeroen A. A.|last9=Zaki|first9=Ali|last10=Fouchier|first10=Ron A. M.|last11=Thiel|first11=Volker|last12=Drosten|first12=Christian|last13=Rottier|first13=Peter J. M.|last14=Osterhaus|first14=Albert D. M. E.|last15=Bosch|first15=Berend Jan|last16=Haagmans|first16=Bart L.|title=Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC|journal=Nature|volume=495|issue=7440|year=2013|pages=251–254|issn=0028-0836|doi=10.1038/nature12005}}</ref>) of the viral particles as well as systemic inflammatory response induced by the cytokines. Patients admitted with severe disease, [[acute respiratory distress syndrome]] ([[Acute respiratory distress syndrome|ARDS]]) or in patients admitted to ICU have a higher incidence of [[Acute kidney injury|AKI]] . <ref name="ZhouYu2020">{{cite journal|last1=Zhou|first1=Fei|last2=Yu|first2=Ting|last3=Du|first3=Ronghui|last4=Fan|first4=Guohui|last5=Liu|first5=Ying|last6=Liu|first6=Zhibo|last7=Xiang|first7=Jie|last8=Wang|first8=Yeming|last9=Song|first9=Bin|last10=Gu|first10=Xiaoying|last11=Guan|first11=Lulu|last12=Wei|first12=Yuan|last13=Li|first13=Hui|last14=Wu|first14=Xudong|last15=Xu|first15=Jiuyang|last16=Tu|first16=Shengjin|last17=Zhang|first17=Yi|last18=Chen|first18=Hua|last19=Cao|first19=Bin|title=Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study|journal=The Lancet|volume=395|issue=10229|year=2020|pages=1054–1062|issn=01406736|doi=10.1016/S0140-6736(20)30566-3}}</ref>.  Other possible reasons that can play a role in [[Acute kidney injury|AKI]] development, are multi-organ failure resulting in [[acute tubular necrosis]] ([[Acute tubular necrosis|ATN]]), volume reduction causing prerenal [[Acute tubular necrosis|ATN]], high [[fever]], drug toxicity, [[hypotension]], and contrast exposure. <ref name="Beddhu2004">{{cite journal|last1=Beddhu|first1=Srinivasan|title=Hypothesis: The Body Mass Index Paradox and an Obesity, Inflammation, and Atherosclerosis Syndrome in Chronic Kidney Disease|journal=Seminars in Dialysis|volume=17|issue=3|year=2004|pages=229–232|issn=08940959|doi=10.1111/j.0894-0959.2004.17311.x}}</ref> <ref name="MohamedLukitsch2020">{{cite journal|last1=Mohamed|first1=Muner MB|last2=Lukitsch|first2=Ivo|last3=Torres-Ortiz|first3=Aldo E|last4=Walker|first4=Joseph B|last5=Varghese|first5=Vipin|last6=Hernandez-Arroyo|first6=Cesar F|last7=Alqudsi|first7=Muhannad|last8=LeDoux|first8=Jason R|last9=Velez|first9=Juan Carlos Q|title=Acute Kidney Injury Associated with Coronavirus Disease 2019 in Urban New Orleans|journal=Kidney360|year=2020|pages=10.34067/KID.0002652020|issn=2641-7650|doi=10.34067/KID.0002652020}}</ref>
-*Pro-inflammatory [[cytokine]] levels are elevated in the [[COVID-19]] infection and there is activation of [[T cell|T-cell]] response.
+*Pro-inflammatory [[cytokine]] levels are elevated in the [[COVID-19]] infection and there is activation of [[T cell|T-cell]] response.   <ref name="HuangWang20202">{{cite journal|last1=Huang|first1=Chaolin|last2=Wang|first2=Yeming|last3=Li|first3=Xingwang|last4=Ren|first4=Lili|last5=Zhao|first5=Jianping|last6=Hu|first6=Yi|last7=Zhang|first7=Li|last8=Fan|first8=Guohui|last9=Xu|first9=Jiuyang|last10=Gu|first10=Xiaoying|last11=Cheng|first11=Zhenshun|last12=Yu|first12=Ting|last13=Xia|first13=Jiaan|last14=Wei|first14=Yuan|last15=Wu|first15=Wenjuan|last16=Xie|first16=Xuelei|last17=Yin|first17=Wen|last18=Li|first18=Hui|last19=Liu|first19=Min|last20=Xiao|first20=Yan|last21=Gao|first21=Hong|last22=Guo|first22=Li|last23=Xie|first23=Jungang|last24=Wang|first24=Guangfa|last25=Jiang|first25=Rongmeng|last26=Gao|first26=Zhancheng|last27=Jin|first27=Qi|last28=Wang|first28=Jianwei|last29=Cao|first29=Bin|title=Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China|journal=The Lancet|volume=395|issue=10223|year=2020|pages=497–506|issn=01406736|doi=10.1016/S0140-6736(20)30183-5}}</ref>
-*There is higher [[cytokine]] levels and  there is occurrence of [[cytokine storm]] in severe cases. In [[cytokine storm]] the, the immune system damages the healthy tissue rather than virus. According to an autopsy report of six patients, the light microscopy indicated CD68+ macrophage infiltration of the tubulointerstitium and severe [[Acute tubular necrosis|ATN]]. The tubules showed [[complement]] 5b-9 deposition in all six cases, but deposition in glomeruli and capillaries were seldom seen. Some [[Cytotoxic T cell|CD8+]] T lymphocyte cells and CD56+ ([[Natural killer cell|natural killer]]) cells were seen in kidney tissue
+*There is higher [[cytokine]] levels and  there is occurrence of [[cytokine storm]] in severe cases. In [[cytokine storm]] the, the immune system damages the healthy tissue rather than virus.<ref name="PanXu20203">{{cite journal|last1=Pan|first1=Xiu-wu|last2=Xu|first2=Da|last3=Zhang|first3=Hao|last4=Zhou|first4=Wang|last5=Wang|first5=Lin-hui|last6=Cui|first6=Xin-gang|title=Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis|journal=Intensive Care Medicine|volume=46|issue=6|year=2020|pages=1114–1116|issn=0342-4642|doi=10.1007/s00134-020-06026-1}}</ref> According to an autopsy report of six patients, the light microscopy indicated CD68+ macrophage infiltration of the tubulointerstitium and severe [[Acute tubular necrosis|ATN]]. The tubules showed complement 5b-9 deposition in all six cases, but deposition in glomeruli and capillaries were seldom seen. Some [[Cytotoxic T cell|CD8+]] T lymphocyte cells and CD56+ ([[Natural killer cell|natural killer]]) cells were seen in kidney tissue<ref name="DiaoWang20202">{{cite journal|last1=Diao|first1=Bo|last2=Wang|first2=Chenhui|last3=Wang|first3=Rongshuai|last4=Feng|first4=Zeqing|last5=Tan|first5=Yingjun|last6=Wang|first6=Huiming|last7=Wang|first7=Changsong|last8=Liu|first8=Liang|last9=Liu|first9=Ying|last10=Liu|first10=Yueping|last11=Wang|first11=Gang|last12=Yuan|first12=Zilin|last13=Ren|first13=Liang|last14=Wu|first14=Yuzhang|last15=Chen|first15=Yongwen|year=2020|doi=10.1101/2020.03.04.20031120}}</ref>
 == Causes ==
@@ Line 157: / Line 159: @@
 ===Life Threatening Causes===
-* Even though the CT findings in [[COVID-19]] [[pneumonia]] were similar in [[Kidney transplantation|renal transplant]] recipients and general population, due to [[Chronic (medical)|chronic]] immunosuppression, the clinical features of [[COVID-19]] in [[Kidney transplantation|renal transplant]] patients may be atypical.
+* Even though the CT findings in [[COVID-19]] [[pneumonia]] were similar in [[Kidney transplantation|renal transplant]] recipients and general population, due to [[Chronic (medical)|chronic]] immunosuppression, the clinical features of [[COVID-19]] in [[Kidney transplantation|renal transplant]] patients may be atypical.<ref name="AiYang2020">{{cite journal|last1=Ai|first1=Tao|last2=Yang|first2=Zhenlu|last3=Hou|first3=Hongyan|last4=Zhan|first4=Chenao|last5=Chen|first5=Chong|last6=Lv|first6=Wenzhi|last7=Tao|first7=Qian|last8=Sun|first8=Ziyong|last9=Xia|first9=Liming|title=Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease                     2019 (COVID-19) in China: A Report of 1014 Cases|journal=Radiology|year=2020|pages=200642|issn=0033-8419|doi=10.1148/radiol.2020200642}}</ref><ref name="MichaelsLa Hoz2020">{{cite journal|last1=Michaels|first1=Marian G.|last2=La Hoz|first2=Ricardo M.|last3=Danziger-Isakov|first3=Lara|last4=Blumberg|first4=Emily A.|last5=Kumar|first5=Deepali|last6=Green|first6=Michael|last7=Pruett|first7=Timothy L.|last8=Wolfe|first8=Cameron R.|title=Coronavirus disease 2019: Implications of emerging infections for transplantation|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1768–1772|issn=1600-6135|doi=10.1111/ajt.15832}}</ref>
-* In one of the study, nine of the 10 patients had [[fever]], [[cough]], [[Dyspnea|shortness of breath]], and [[fatigue]]; three had [[diarrhea]]; eight had [[Lymphocytopenia|lymphopenia]]; six had [[renal injury]]; and six had [[Liver damage|liver function damage]].<ref name="WangHu2020">{{cite journal|last1=Wang|first1=Dawei|last2=Hu|first2=Bo|last3=Hu|first3=Chang|last4=Zhu|first4=Fangfang|last5=Liu|first5=Xing|last6=Zhang|first6=Jing|last7=Wang|first7=Binbin|last8=Xiang|first8=Hui|last9=Cheng|first9=Zhenshun|last10=Xiong|first10=Yong|last11=Zhao|first11=Yan|last12=Li|first12=Yirong|last13=Wang|first13=Xinghuan|last14=Peng|first14=Zhiyong|title=Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China|journal=JAMA|volume=323|issue=11|year=2020|pages=1061|issn=0098-7484|doi=10.1001/jama.2020.1585}}</ref>
+* In one of the study, nine of the 10 patients had [[fever]], [[cough]], [[Dyspnea|shortness of breath]], and [[fatigue]]; three had [[diarrhea]]; eight had [[Lymphocytopenia|lymphopenia]]; six had [[renal injury]]; and six had liver function damage.<ref name="ChenZhou2020">{{cite journal|last1=Chen|first1=Nanshan|last2=Zhou|first2=Min|last3=Dong|first3=Xuan|last4=Qu|first4=Jieming|last5=Gong|first5=Fengyun|last6=Han|first6=Yang|last7=Qiu|first7=Yang|last8=Wang|first8=Jingli|last9=Liu|first9=Ying|last10=Wei|first10=Yuan|last11=Xia|first11=Jia'an|last12=Yu|first12=Ting|last13=Zhang|first13=Xinxin|last14=Zhang|first14=Li|title=Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study|journal=The Lancet|volume=395|issue=10223|year=2020|pages=507–513|issn=01406736|doi=10.1016/S0140-6736(20)30211-7}}</ref><ref>{{cite journal|doi=10.1016/ S2213-2600(20)30079-5}}</ref><ref name="WangHu2020">{{cite journal|last1=Wang|first1=Dawei|last2=Hu|first2=Bo|last3=Hu|first3=Chang|last4=Zhu|first4=Fangfang|last5=Liu|first5=Xing|last6=Zhang|first6=Jing|last7=Wang|first7=Binbin|last8=Xiang|first8=Hui|last9=Cheng|first9=Zhenshun|last10=Xiong|first10=Yong|last11=Zhao|first11=Yan|last12=Li|first12=Yirong|last13=Wang|first13=Xinghuan|last14=Peng|first14=Zhiyong|title=Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China|journal=JAMA|volume=323|issue=11|year=2020|pages=1061|issn=0098-7484|doi=10.1001/jama.2020.1585}}</ref>
-* It needs to be verified whether the severity of [[COVID-19]] [[pneumonia]] differs in [[immunocompromised]] [[Kidney transplantation|transplant patients]] than non-[[immunocompromised]] population. According to a report from China’s Infectious Disease Information system, out of 72,314 [[COVID-19]] cases in general population, 81% were reported as mild, whereas 19% were either severe or critical. And, in report from study in [[Kidney transplantation|renal transplant]] patients, the number of severe cases were 80% compared to only 10% in their infected family members and 19% in general population. Moreover, average duration of illness was nearly twice i.e. 35 days compared to 18 days in control group and 17-20 days reported in general population.<ref name="WangHu2020">{{cite journal|last1=Wang|first1=Dawei|last2=Hu|first2=Bo|last3=Hu|first3=Chang|last4=Zhu|first4=Fangfang|last5=Liu|first5=Xing|last6=Zhang|first6=Jing|last7=Wang|first7=Binbin|last8=Xiang|first8=Hui|last9=Cheng|first9=Zhenshun|last10=Xiong|first10=Yong|last11=Zhao|first11=Yan|last12=Li|first12=Yirong|last13=Wang|first13=Xinghuan|last14=Peng|first14=Zhiyong|title=Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China|journal=JAMA|volume=323|issue=11|year=2020|pages=1061|issn=0098-7484|doi=10.1001/jama.2020.1585}}</ref>
+* It needs to be verified whether the severity of [[COVID-19]] [[pneumonia]] differs in immunocompromised transplant patients than non-immunocompromised population. According to a report from China’s Infectious Disease Information system, out of 72,314 [[COVID-19]] cases in general population, 81% were reported as mild, whereas 19% were either severe or critical. And, in report from study in [[Kidney transplantation|renal transplant]] patients, the number of severe cases were 80% compared to only 10% in their infected family members and 19% in general population. Moreover, average duration of illness was nearly twice i.e. 35 days compared to 18 days in control group and 17-20 days reported in general population.<ref name="WuMcGoogan2020">{{cite journal|last1=Wu|first1=Zunyou|last2=McGoogan|first2=Jennifer M.|title=Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China|journal=JAMA|volume=323|issue=13|year=2020|pages=1239|issn=0098-7484|doi=10.1001/jama.2020.2648}}</ref><ref name="WangHu2020">{{cite journal|last1=Wang|first1=Dawei|last2=Hu|first2=Bo|last3=Hu|first3=Chang|last4=Zhu|first4=Fangfang|last5=Liu|first5=Xing|last6=Zhang|first6=Jing|last7=Wang|first7=Binbin|last8=Xiang|first8=Hui|last9=Cheng|first9=Zhenshun|last10=Xiong|first10=Yong|last11=Zhao|first11=Yan|last12=Li|first12=Yirong|last13=Wang|first13=Xinghuan|last14=Peng|first14=Zhiyong|title=Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China|journal=JAMA|volume=323|issue=11|year=2020|pages=1061|issn=0098-7484|doi=10.1001/jama.2020.1585}}</ref>
 <br />
@@ Line 172: / Line 174: @@
 == Epidemiology and Demographics ==
 === Incidence ===
 * Due to the lack of broad [[Screening (medicine)|screening]] that includes the general population (including asymptomatic patients) and the lack of [[PCR]] and antibody tests with acceptable [[Sensitivity (tests)|sensitivity]] and [[Specificity (tests)|specificity]], an accurate estimate of the [[Incidence (epidemiology)|incidence rate]] of [[coronavirus]] disease 2019 ([[COVID-19]]) cannot be accurately estimated.
-* Data indicates that the rate of severe complications of [[COVID-19]] is almost 25%, and [[kidney]] is also one of the main organs affected in severe illness.<ref name="YangYu202022">{{cite journal|last1=Yang|first1=Xiaobo|last2=Yu|first2=Yuan|last3=Xu|first3=Jiqian|last4=Shu|first4=Huaqing|last5=Xia|first5=Jia'an|last6=Liu|first6=Hong|last7=Wu|first7=Yongran|last8=Zhang|first8=Lu|last9=Yu|first9=Zhui|last10=Fang|first10=Minghao|last11=Yu|first11=Ting|last12=Wang|first12=Yaxin|last13=Pan|first13=Shangwen|last14=Zou|first14=Xiaojing|last15=Yuan|first15=Shiying|last16=Shang|first16=You|title=Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study|journal=The Lancet Respiratory Medicine|volume=8|issue=5|year=2020|pages=475–481|issn=22132600|doi=10.1016/S2213-2600(20)30079-5}}</ref>. The risk is further increased in patients having [[Chronic renal failure|chronic kidney disease]](CKD), patients on chronic replacement therapies, and patients with kidney transplants.<ref name="NaickerYang20202">{{cite journal|last1=Naicker|first1=Saraladevi|last2=Yang|first2=Chih-Wei|last3=Hwang|first3=Shang-Jyh|last4=Liu|first4=Bi-Cheng|last5=Chen|first5=Jiang-Hua|last6=Jha|first6=Vivekanand|title=The Novel Coronavirus 2019 epidemic and kidneys|journal=Kidney International|volume=97|issue=5|year=2020|pages=824–828|issn=00852538|doi=10.1016/j.kint.2020.03.001}}</ref>
+* Data indicates that the rate of severe complications of [[COVID-19]] is almost 25%, and [[kidney]] is also one of the main organs affected in severe illness.<ref name="YangYu20202">{{cite journal|last1=Yang|first1=Xiaobo|last2=Yu|first2=Yuan|last3=Xu|first3=Jiqian|last4=Shu|first4=Huaqing|last5=Xia|first5=Jia'an|last6=Liu|first6=Hong|last7=Wu|first7=Yongran|last8=Zhang|first8=Lu|last9=Yu|first9=Zhui|last10=Fang|first10=Minghao|last11=Yu|first11=Ting|last12=Wang|first12=Yaxin|last13=Pan|first13=Shangwen|last14=Zou|first14=Xiaojing|last15=Yuan|first15=Shiying|last16=Shang|first16=You|title=Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study|journal=The Lancet Respiratory Medicine|volume=8|issue=5|year=2020|pages=475–481|issn=22132600|doi=10.1016/S2213-2600(20)30079-5}}</ref>. The risk is further increased in patients having [[Chronic renal failure|chronic kidney disease]](CKD), patients on chronic replacement therapies, and patients with kidney transplants.<ref name="NaickerYang2020">{{cite journal|last1=Naicker|first1=Saraladevi|last2=Yang|first2=Chih-Wei|last3=Hwang|first3=Shang-Jyh|last4=Liu|first4=Bi-Cheng|last5=Chen|first5=Jiang-Hua|last6=Jha|first6=Vivekanand|title=The Novel Coronavirus 2019 epidemic and kidneys|journal=Kidney International|volume=97|issue=5|year=2020|pages=824–828|issn=00852538|doi=10.1016/j.kint.2020.03.001}}</ref>
-* [[Acute kidney injury|AKI]] is seen in 5-15% of the [[Coronavirus|SARS-CoV]] and [[Middle East respiratory syndrome coronavirus infection causes|MERS-CoV]] infection<ref name="NaickerYang20202" />
+* [[Acute kidney injury|AKI]] is seen in 5-15% of the [[Coronavirus|SARS-CoV]] and [[Middle East respiratory syndrome coronavirus infection causes|MERS-CoV]] infection<ref name="NaickerYang2020" />
 === Prevalence ===
@@ Line 184: / Line 185: @@
 * As it is prevalent in all the continents of the world, [[World Health Organization|World Health Organization (WHO)]] has declared [[COVID-19]] [[outbreak]] a [[pandemic]].
 * Among patients with [[influenza]]-like-illness and without risk factors for [[COVID-19]], 5% were positive for [[COVID-19]].
-* In an analysis of 14 articles<ref name="BussalinoDe Maria20202">{{cite journal|last1=Bussalino|first1=Elisabetta|last2=De Maria|first2=Andrea|last3=Russo|first3=Rodolfo|last4=Paoletti|first4=Ernesto|title=Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS‐CoV‐2 pneumonia: A case report|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1922–1924|issn=1600-6135|doi=10.1111/ajt.15920}}</ref><ref name="SeminariColaneri20202">{{cite journal|last1=Seminari|first1=Elena|last2=Colaneri|first2=Marta|last3=Sambo|first3=Margherita|last4=Gallazzi|first4=Ilaria|last5=Di Matteo|first5=Angela|last6=Roda|first6=Silvia|last7=Bruno|first7=Raffaele|last8=Mondelli|first8=Mario U.|last9=Brunetti|first9=Enrico|last10=Maiocchi|first10=Laura|last11=Zuccaro|first11=Valentina|last12=Pagnucco|first12=Layla|last13=Mariani|first13=Bianca|last14=Ludovisi|first14=Serena|last15=Lissandrin|first15=Raffaella|last16=Parisi|first16=Aldo|last17=Sacchi|first17=Paolo|last18=Patruno|first18=Savino F. A.|last19=Michelone|first19=Giuseppe|last20=Gulminetti|first20=Roberto|last21=Zanaboni|first21=Domenico|last22=Novati|first22=Stefano|last23=Maserati|first23=Renato|last24=Orsolini|first24=Paolo|last25=Vecchia|first25=Marco|last26=Sciarra|first26=Marco|last27=Asperges|first27=Erika|last28=Di Filippo|first28=Alessandro|last29=Biscarini|first29=Simona|last30=Lupi|first30=Matteo|last31=Pieri|first31=Teresa C.|last32=Sachs|first32=Michele|last33=Valsecchi|first33=Pietro|last34=Perlini|first34=Stefano|last35=Alfano|first35=Claudia|last36=Bonzano|first36=Marco|last37=Briganti|first37=Federica|last38=Crescenzi|first38=Giuseppe|last39=Falchi|first39=Anna G.|last40=Guarnone|first40=Roberta|last41=Guglielmana|first41=Barbara|last42=Maggi|first42=Elena|last43=Martino|first43=Ilaria|last44=Pettenazza|first44=Pietro|last45=Pioli di Marco|first45=Serena|last46=Quaglia|first46=Federica|last47=Sabena|first47=Anna|last48=Salinaro|first48=Francesco|last49=Speciale|first49=Francesco|last50=Zunino|first50=Ilaria|last51=De Lorenzo|first51=Marzia|last52=Secco|first52=Gianmarco|last53=Dimitry|first53=Lorenzo|last54=Cappa|first54=Giovanni|last55=Maisak|first55=Igor|last56=Chiodi|first56=Benedetta|last57=Sciarrini|first57=Massimiliano|last58=Barcella|first58=Bruno|last59=Resta|first59=Flavia|last60=Moroni|first60=Luca|last61=Vezzoni|first61=Giulia|last62=Scattaglia|first62=Lorenzo|last63=Boscolo|first63=Elisa|last64=Zattera|first64=Caterina|last65=Fidel|first65=Tassi M.|last66=Vincenzo|first66=Capozza|last67=Vignaroli|first67=Damiano|last68=Bazzini|first68=Marco|last69=Iotti|first69=Giorgio|last70=Mojoli|first70=Francesco|last71=Belliato|first71=Mirko|last72=Perotti|first72=Luciano|last73=Mongodi|first73=Silvia|last74=Tavazzi|first74=Guido|last75=Marseglia|first75=Gianluigi|last76=Licari|first76=Amelia|last77=Brambilla|first77=Ilaria|last78=Daniela|first78=Barbarini|last79=Antonella|first79=Bruno|last80=Patrizia|first80=Cambieri|last81=Giulia|first81=Campanini|last82=Giuditta|first82=Comolli|last83=Marta|first83=Corbella|last84=Rossana|first84=Daturi|last85=Milena|first85=Furione|last86=Bianca|first86=Mariani|last87=Roberta|first87=Maserati|last88=Enza|first88=Monzillo|last89=Stefania|first89=Paolucci|last90=Maurizio|first90=Parea|last91=Elena|first91=Percivalle|last92=Antonio|first92=Piralla|last93=Francesca|first93=Rovida|last94=Antonella|first94=Sarasini|last95=Maurizio|first95=Zavattoni|last96=Guy|first96=Adzasehoun|last97=Laura|first97=Bellotti|last98=Ermanna|first98=Cabano|last99=Giuliana|first99=Casali|last100=Luca|first100=Dossena|last101=Gabriella|first101=Frisco|last102=Gabriella|first102=Garbagnoli|last103=Alessia|first103=Girello|last104=Viviana|first104=Landini|last105=Claudia|first105=Lucchelli|last106=Valentina|first106=Maliardi|last107=Simona|first107=Pezzaia|last108=Marta|first108=Premoli|last109=Alice|first109=Bonetti|last110=Giacomo|first110=Caneva|last111=Irene|first111=Cassaniti|last112=Alfonso|first112=Corcione|last113=Di Martino|first113=Raffella|last114=Di Napoli|first114=Annapia|last115=Alessandro|first115=Ferrari|last116=Guglielmo|first116=Ferrari|last117=Loretta|first117=Fiorina|last118=Federica|first118=Giardina|last119=Alessandra|first119=Mercato|last120=Federica|first120=Novazzi|last121=Giacomo|first121=Ratano|last122=Beatrice|first122=Rossi|last123=Maria|first123=Sciabica I.|last124=Monica|first124=Tallarita|last125=Edoardo|first125=Vecchio N.|last126=Cerino|first126=Antonella|last127=Varchetta|first127=Stefania|last128=Oliviero|first128=Barbara|last129=Mantovani|first129=Stefania|last130=Mele|first130=Dalila|last131=Calvi|first131=Monica|last132=Tizzonis|first132=Michela|last133=Nicora|first133=Carlo|last134=Triarico|first134=Antonio|last135=Petronella|first135=Vincenzo|last136=Marena|first136=Carlo|last137=Muzzi|first137=Alba|last138=Lago|first138=Paolo|last139=Comandatore|first139=Francesco|last140=Bissignandi|first140=Gherard|last141=Gaiarsa|first141=Stefano|last142=Rettani|first142=Marco|last143=Band|first143=Claudio|title=SARS Cov‐2 infection in a renal‐transplanted patient: A case report|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1882–1884|issn=1600-6135|doi=10.1111/ajt.15902}}</ref><ref name="MarxMoulin20202">{{cite journal|last1=Marx|first1=David|last2=Moulin|first2=Bruno|last3=Fafi‐Kremer|first3=Samira|last4=Benotmane|first4=Ilies|last5=Gautier|first5=Gabriela|last6=Perrin|first6=Peggy|last7=Caillard|first7=Sophie|title=First case of COVID‐19 in a kidney transplant recipient treated with belatacept|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1944–1946|issn=1600-6135|doi=10.1111/ajt.15919}}</ref> <ref name="GandolfiniDelsante20202">{{cite journal|last1=Gandolfini|first1=Ilaria|last2=Delsante|first2=Marco|last3=Fiaccadori|first3=Enrico|last4=Zaza|first4=Gianluigi|last5=Manenti|first5=Lucio|last6=Degli Antoni|first6=Anna|last7=Peruzzi|first7=Licia|last8=Riella|first8=Leonardo V.|last9=Cravedi|first9=Paolo|last10=Maggiore|first10=Umberto|title=COVID‐19 in kidney transplant recipients|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1941–1943|issn=1600-6135|doi=10.1111/ajt.15891}}</ref> <ref name="GuillenPineiro20202">{{cite journal|last1=Guillen|first1=Elena|last2=Pineiro|first2=Gaston J.|last3=Revuelta|first3=Ignacio|last4=Rodriguez|first4=Diana|last5=Bodro|first5=Marta|last6=Moreno|first6=Asunción|last7=Campistol|first7=Josep M.|last8=Diekmann|first8=Fritz|last9=Ventura‐Aguiar|first9=Pedro|title=Case report of COVID‐19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1875–1878|issn=1600-6135|doi=10.1111/ajt.15874}}</ref> <ref name=":02">{{cite journal|doi=10.1016/ S2213-2600(20)30182-X}}</ref> <ref name="Haberal20202">{{cite journal|last1=Haberal|first1=Mehmet|title=COVID-19 UPDATE|journal=Experimental and Clinical Transplantation|volume=18|issue=2|year=2020|pages=139–140|issn=13040855|doi=10.6002/ect.2020.000e}}</ref> <ref name="urlbts.org.uk2">{{cite web |url=https://bts.org.uk/wp-content/uploads/2020/03/Clinical_management_transplant_recipients.pdf |title=bts.org.uk |format= |work= |accessdate=}}</ref><ref name="urlwww.europeanurology.com2">{{cite web |url=https://www.europeanurology.com/article/S0302-2838(20)30211-6/pdf |title=www.europeanurology.com |format= |work= |accessdate=}}</ref>,
+* In an analysis of 14 articles<ref name="BussalinoDe Maria2020">{{cite journal|last1=Bussalino|first1=Elisabetta|last2=De Maria|first2=Andrea|last3=Russo|first3=Rodolfo|last4=Paoletti|first4=Ernesto|title=Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS‐CoV‐2 pneumonia: A case report|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1922–1924|issn=1600-6135|doi=10.1111/ajt.15920}}</ref><ref name="SeminariColaneri2020">{{cite journal|last1=Seminari|first1=Elena|last2=Colaneri|first2=Marta|last3=Sambo|first3=Margherita|last4=Gallazzi|first4=Ilaria|last5=Di Matteo|first5=Angela|last6=Roda|first6=Silvia|last7=Bruno|first7=Raffaele|last8=Mondelli|first8=Mario U.|last9=Brunetti|first9=Enrico|last10=Maiocchi|first10=Laura|last11=Zuccaro|first11=Valentina|last12=Pagnucco|first12=Layla|last13=Mariani|first13=Bianca|last14=Ludovisi|first14=Serena|last15=Lissandrin|first15=Raffaella|last16=Parisi|first16=Aldo|last17=Sacchi|first17=Paolo|last18=Patruno|first18=Savino F. A.|last19=Michelone|first19=Giuseppe|last20=Gulminetti|first20=Roberto|last21=Zanaboni|first21=Domenico|last22=Novati|first22=Stefano|last23=Maserati|first23=Renato|last24=Orsolini|first24=Paolo|last25=Vecchia|first25=Marco|last26=Sciarra|first26=Marco|last27=Asperges|first27=Erika|last28=Di Filippo|first28=Alessandro|last29=Biscarini|first29=Simona|last30=Lupi|first30=Matteo|last31=Pieri|first31=Teresa C.|last32=Sachs|first32=Michele|last33=Valsecchi|first33=Pietro|last34=Perlini|first34=Stefano|last35=Alfano|first35=Claudia|last36=Bonzano|first36=Marco|last37=Briganti|first37=Federica|last38=Crescenzi|first38=Giuseppe|last39=Falchi|first39=Anna G.|last40=Guarnone|first40=Roberta|last41=Guglielmana|first41=Barbara|last42=Maggi|first42=Elena|last43=Martino|first43=Ilaria|last44=Pettenazza|first44=Pietro|last45=Pioli di Marco|first45=Serena|last46=Quaglia|first46=Federica|last47=Sabena|first47=Anna|last48=Salinaro|first48=Francesco|last49=Speciale|first49=Francesco|last50=Zunino|first50=Ilaria|last51=De Lorenzo|first51=Marzia|last52=Secco|first52=Gianmarco|last53=Dimitry|first53=Lorenzo|last54=Cappa|first54=Giovanni|last55=Maisak|first55=Igor|last56=Chiodi|first56=Benedetta|last57=Sciarrini|first57=Massimiliano|last58=Barcella|first58=Bruno|last59=Resta|first59=Flavia|last60=Moroni|first60=Luca|last61=Vezzoni|first61=Giulia|last62=Scattaglia|first62=Lorenzo|last63=Boscolo|first63=Elisa|last64=Zattera|first64=Caterina|last65=Fidel|first65=Tassi M.|last66=Vincenzo|first66=Capozza|last67=Vignaroli|first67=Damiano|last68=Bazzini|first68=Marco|last69=Iotti|first69=Giorgio|last70=Mojoli|first70=Francesco|last71=Belliato|first71=Mirko|last72=Perotti|first72=Luciano|last73=Mongodi|first73=Silvia|last74=Tavazzi|first74=Guido|last75=Marseglia|first75=Gianluigi|last76=Licari|first76=Amelia|last77=Brambilla|first77=Ilaria|last78=Daniela|first78=Barbarini|last79=Antonella|first79=Bruno|last80=Patrizia|first80=Cambieri|last81=Giulia|first81=Campanini|last82=Giuditta|first82=Comolli|last83=Marta|first83=Corbella|last84=Rossana|first84=Daturi|last85=Milena|first85=Furione|last86=Bianca|first86=Mariani|last87=Roberta|first87=Maserati|last88=Enza|first88=Monzillo|last89=Stefania|first89=Paolucci|last90=Maurizio|first90=Parea|last91=Elena|first91=Percivalle|last92=Antonio|first92=Piralla|last93=Francesca|first93=Rovida|last94=Antonella|first94=Sarasini|last95=Maurizio|first95=Zavattoni|last96=Guy|first96=Adzasehoun|last97=Laura|first97=Bellotti|last98=Ermanna|first98=Cabano|last99=Giuliana|first99=Casali|last100=Luca|first100=Dossena|last101=Gabriella|first101=Frisco|last102=Gabriella|first102=Garbagnoli|last103=Alessia|first103=Girello|last104=Viviana|first104=Landini|last105=Claudia|first105=Lucchelli|last106=Valentina|first106=Maliardi|last107=Simona|first107=Pezzaia|last108=Marta|first108=Premoli|last109=Alice|first109=Bonetti|last110=Giacomo|first110=Caneva|last111=Irene|first111=Cassaniti|last112=Alfonso|first112=Corcione|last113=Di Martino|first113=Raffella|last114=Di Napoli|first114=Annapia|last115=Alessandro|first115=Ferrari|last116=Guglielmo|first116=Ferrari|last117=Loretta|first117=Fiorina|last118=Federica|first118=Giardina|last119=Alessandra|first119=Mercato|last120=Federica|first120=Novazzi|last121=Giacomo|first121=Ratano|last122=Beatrice|first122=Rossi|last123=Maria|first123=Sciabica I.|last124=Monica|first124=Tallarita|last125=Edoardo|first125=Vecchio N.|last126=Cerino|first126=Antonella|last127=Varchetta|first127=Stefania|last128=Oliviero|first128=Barbara|last129=Mantovani|first129=Stefania|last130=Mele|first130=Dalila|last131=Calvi|first131=Monica|last132=Tizzonis|first132=Michela|last133=Nicora|first133=Carlo|last134=Triarico|first134=Antonio|last135=Petronella|first135=Vincenzo|last136=Marena|first136=Carlo|last137=Muzzi|first137=Alba|last138=Lago|first138=Paolo|last139=Comandatore|first139=Francesco|last140=Bissignandi|first140=Gherard|last141=Gaiarsa|first141=Stefano|last142=Rettani|first142=Marco|last143=Band|first143=Claudio|title=SARS Cov‐2 infection in a renal‐transplanted patient: A case report|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1882–1884|issn=1600-6135|doi=10.1111/ajt.15902}}</ref><ref name="MarxMoulin2020">{{cite journal|last1=Marx|first1=David|last2=Moulin|first2=Bruno|last3=Fafi‐Kremer|first3=Samira|last4=Benotmane|first4=Ilies|last5=Gautier|first5=Gabriela|last6=Perrin|first6=Peggy|last7=Caillard|first7=Sophie|title=First case of COVID‐19 in a kidney transplant recipient treated with belatacept|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1944–1946|issn=1600-6135|doi=10.1111/ajt.15919}}</ref><ref name="GandolfiniDelsante2020">{{cite journal|last1=Gandolfini|first1=Ilaria|last2=Delsante|first2=Marco|last3=Fiaccadori|first3=Enrico|last4=Zaza|first4=Gianluigi|last5=Manenti|first5=Lucio|last6=Degli Antoni|first6=Anna|last7=Peruzzi|first7=Licia|last8=Riella|first8=Leonardo V.|last9=Cravedi|first9=Paolo|last10=Maggiore|first10=Umberto|title=COVID‐19 in kidney transplant recipients|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1941–1943|issn=1600-6135|doi=10.1111/ajt.15891}}</ref>
-** Median interval of transplantation - 4 years. (range .25-30.1)
+<ref name="GuillenPineiro2020">{{cite journal|last1=Guillen|first1=Elena|last2=Pineiro|first2=Gaston J.|last3=Revuelta|first3=Ignacio|last4=Rodriguez|first4=Diana|last5=Bodro|first5=Marta|last6=Moreno|first6=Asunción|last7=Campistol|first7=Josep M.|last8=Diekmann|first8=Fritz|last9=Ventura‐Aguiar|first9=Pedro|title=Case report of COVID‐19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1875–1878|issn=1600-6135|doi=10.1111/ajt.15874}}</ref>
+<ref name=":0">{{cite journal|doi=10.1016/ S2213-2600(20)30182-X}}</ref>
+<ref name="Haberal2020">{{cite journal|last1=Haberal|first1=Mehmet|title=COVID-19 UPDATE|journal=Experimental and Clinical Transplantation|volume=18|issue=2|year=2020|pages=139–140|issn=13040855|doi=10.6002/ect.2020.000e}}</ref>
+<ref name="urlbts.org.uk">{{cite web |url=https://bts.org.uk/wp-content/uploads/2020/03/Clinical_management_transplant_recipients.pdf |title=bts.org.uk |format= |work= |accessdate=}}</ref><ref name="urlwww.europeanurology.com">{{cite web |url=https://www.europeanurology.com/article/S0302-2838(20)30211-6/pdf |title=www.europeanurology.com |format= |work= |accessdate=}}</ref>,
+**Median interval of transplantation - 4 years. (range .25-30.1)  <br />
 === Case-fatality rate ===
 * Due to limited testing of asymptomatic individuals, the potential inaccuracies of early [[Polymerase chain reaction|PCR]] tests and antibody tests, the inconsistent reporting and lack of organized data, an accurate [[case-fatality rate]] of [[COVID-19]] has yet to be established.
-* According to analysis of recent studies<ref name="BussalinoDe Maria20202" /><ref name="SeminariColaneri20202" /><ref name="MarxMoulin20202" /> <ref name="GandolfiniDelsante20202" /> <ref name="GuillenPineiro20202" /> <ref name=":02" /> <ref name="Haberal20202" /> <ref name="urlbts.org.uk2" /><ref name="urlwww.europeanurology.com2" />, a fatality rate of 17.4% (4/23) in renal transplant patients was reported
+* According to analysis of recent studies<ref name="BussalinoDe Maria2020" /><ref name="SeminariColaneri2020" /><ref name="MarxMoulin2020" /><ref name="GandolfiniDelsante2020" />
+<ref name="GuillenPineiro2020" />
+<ref name=":0" />
+<ref name="Haberal2020" />
+<ref name="urlbts.org.uk" /><ref name="urlwww.europeanurology.com" />, a fatality rate of 17.4% (4/23) in renal transplant patients was reported
 ===Age===
 *Renal transplant patients of all ages are at a higher risk of [[COVID-19]] due to immunosuppression.
-*The youngest renal transplant patient who died of [[COVID-19]] according to recent studies was 71 years old.<ref name="BussalinoDe Maria20202" /><ref name="SeminariColaneri20202" /> <ref name="MarxMoulin20202" /> <ref name="GandolfiniDelsante20202" /> <ref name="GuillenPineiro20202" /> <ref>{{cite journal|doi=10.1016/ S2213-2600(20)30182-X}}</ref> <ref name="Haberal20202" /> <ref name="urlbts.org.uk2" /><ref name="urlwww.europeanurology.com2" />
+*The youngest renal transplant patient who died of [[COVID-19]] according to recent studies was 71 years old.<ref name="BussalinoDe Maria2020">{{cite journal|last1=Bussalino|first1=Elisabetta|last2=De Maria|first2=Andrea|last3=Russo|first3=Rodolfo|last4=Paoletti|first4=Ernesto|title=Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS‐CoV‐2 pneumonia: A case report|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1922–1924|issn=1600-6135|doi=10.1111/ajt.15920}}</ref><ref name="SeminariColaneri2020">{{cite journal|last1=Seminari|first1=Elena|last2=Colaneri|first2=Marta|last3=Sambo|first3=Margherita|last4=Gallazzi|first4=Ilaria|last5=Di Matteo|first5=Angela|last6=Roda|first6=Silvia|last7=Bruno|first7=Raffaele|last8=Mondelli|first8=Mario U.|last9=Brunetti|first9=Enrico|last10=Maiocchi|first10=Laura|last11=Zuccaro|first11=Valentina|last12=Pagnucco|first12=Layla|last13=Mariani|first13=Bianca|last14=Ludovisi|first14=Serena|last15=Lissandrin|first15=Raffaella|last16=Parisi|first16=Aldo|last17=Sacchi|first17=Paolo|last18=Patruno|first18=Savino F. A.|last19=Michelone|first19=Giuseppe|last20=Gulminetti|first20=Roberto|last21=Zanaboni|first21=Domenico|last22=Novati|first22=Stefano|last23=Maserati|first23=Renato|last24=Orsolini|first24=Paolo|last25=Vecchia|first25=Marco|last26=Sciarra|first26=Marco|last27=Asperges|first27=Erika|last28=Di Filippo|first28=Alessandro|last29=Biscarini|first29=Simona|last30=Lupi|first30=Matteo|last31=Pieri|first31=Teresa C.|last32=Sachs|first32=Michele|last33=Valsecchi|first33=Pietro|last34=Perlini|first34=Stefano|last35=Alfano|first35=Claudia|last36=Bonzano|first36=Marco|last37=Briganti|first37=Federica|last38=Crescenzi|first38=Giuseppe|last39=Falchi|first39=Anna G.|last40=Guarnone|first40=Roberta|last41=Guglielmana|first41=Barbara|last42=Maggi|first42=Elena|last43=Martino|first43=Ilaria|last44=Pettenazza|first44=Pietro|last45=Pioli di Marco|first45=Serena|last46=Quaglia|first46=Federica|last47=Sabena|first47=Anna|last48=Salinaro|first48=Francesco|last49=Speciale|first49=Francesco|last50=Zunino|first50=Ilaria|last51=De Lorenzo|first51=Marzia|last52=Secco|first52=Gianmarco|last53=Dimitry|first53=Lorenzo|last54=Cappa|first54=Giovanni|last55=Maisak|first55=Igor|last56=Chiodi|first56=Benedetta|last57=Sciarrini|first57=Massimiliano|last58=Barcella|first58=Bruno|last59=Resta|first59=Flavia|last60=Moroni|first60=Luca|last61=Vezzoni|first61=Giulia|last62=Scattaglia|first62=Lorenzo|last63=Boscolo|first63=Elisa|last64=Zattera|first64=Caterina|last65=Fidel|first65=Tassi M.|last66=Vincenzo|first66=Capozza|last67=Vignaroli|first67=Damiano|last68=Bazzini|first68=Marco|last69=Iotti|first69=Giorgio|last70=Mojoli|first70=Francesco|last71=Belliato|first71=Mirko|last72=Perotti|first72=Luciano|last73=Mongodi|first73=Silvia|last74=Tavazzi|first74=Guido|last75=Marseglia|first75=Gianluigi|last76=Licari|first76=Amelia|last77=Brambilla|first77=Ilaria|last78=Daniela|first78=Barbarini|last79=Antonella|first79=Bruno|last80=Patrizia|first80=Cambieri|last81=Giulia|first81=Campanini|last82=Giuditta|first82=Comolli|last83=Marta|first83=Corbella|last84=Rossana|first84=Daturi|last85=Milena|first85=Furione|last86=Bianca|first86=Mariani|last87=Roberta|first87=Maserati|last88=Enza|first88=Monzillo|last89=Stefania|first89=Paolucci|last90=Maurizio|first90=Parea|last91=Elena|first91=Percivalle|last92=Antonio|first92=Piralla|last93=Francesca|first93=Rovida|last94=Antonella|first94=Sarasini|last95=Maurizio|first95=Zavattoni|last96=Guy|first96=Adzasehoun|last97=Laura|first97=Bellotti|last98=Ermanna|first98=Cabano|last99=Giuliana|first99=Casali|last100=Luca|first100=Dossena|last101=Gabriella|first101=Frisco|last102=Gabriella|first102=Garbagnoli|last103=Alessia|first103=Girello|last104=Viviana|first104=Landini|last105=Claudia|first105=Lucchelli|last106=Valentina|first106=Maliardi|last107=Simona|first107=Pezzaia|last108=Marta|first108=Premoli|last109=Alice|first109=Bonetti|last110=Giacomo|first110=Caneva|last111=Irene|first111=Cassaniti|last112=Alfonso|first112=Corcione|last113=Di Martino|first113=Raffella|last114=Di Napoli|first114=Annapia|last115=Alessandro|first115=Ferrari|last116=Guglielmo|first116=Ferrari|last117=Loretta|first117=Fiorina|last118=Federica|first118=Giardina|last119=Alessandra|first119=Mercato|last120=Federica|first120=Novazzi|last121=Giacomo|first121=Ratano|last122=Beatrice|first122=Rossi|last123=Maria|first123=Sciabica I.|last124=Monica|first124=Tallarita|last125=Edoardo|first125=Vecchio N.|last126=Cerino|first126=Antonella|last127=Varchetta|first127=Stefania|last128=Oliviero|first128=Barbara|last129=Mantovani|first129=Stefania|last130=Mele|first130=Dalila|last131=Calvi|first131=Monica|last132=Tizzonis|first132=Michela|last133=Nicora|first133=Carlo|last134=Triarico|first134=Antonio|last135=Petronella|first135=Vincenzo|last136=Marena|first136=Carlo|last137=Muzzi|first137=Alba|last138=Lago|first138=Paolo|last139=Comandatore|first139=Francesco|last140=Bissignandi|first140=Gherard|last141=Gaiarsa|first141=Stefano|last142=Rettani|first142=Marco|last143=Band|first143=Claudio|title=SARS Cov‐2 infection in a renal‐transplanted patient: A case report|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1882–1884|issn=1600-6135|doi=10.1111/ajt.15902}}</ref><ref name="MarxMoulin2020">{{cite journal|last1=Marx|first1=David|last2=Moulin|first2=Bruno|last3=Fafi‐Kremer|first3=Samira|last4=Benotmane|first4=Ilies|last5=Gautier|first5=Gabriela|last6=Perrin|first6=Peggy|last7=Caillard|first7=Sophie|title=First case of COVID‐19 in a kidney transplant recipient treated with belatacept|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1944–1946|issn=1600-6135|doi=10.1111/ajt.15919}}</ref>
+<ref name="GandolfiniDelsante2020">{{cite journal|last1=Gandolfini|first1=Ilaria|last2=Delsante|first2=Marco|last3=Fiaccadori|first3=Enrico|last4=Zaza|first4=Gianluigi|last5=Manenti|first5=Lucio|last6=Degli Antoni|first6=Anna|last7=Peruzzi|first7=Licia|last8=Riella|first8=Leonardo V.|last9=Cravedi|first9=Paolo|last10=Maggiore|first10=Umberto|title=COVID‐19 in kidney transplant recipients|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1941–1943|issn=1600-6135|doi=10.1111/ajt.15891}}</ref>
+<ref name="GuillenPineiro2020">{{cite journal|last1=Guillen|first1=Elena|last2=Pineiro|first2=Gaston J.|last3=Revuelta|first3=Ignacio|last4=Rodriguez|first4=Diana|last5=Bodro|first5=Marta|last6=Moreno|first6=Asunción|last7=Campistol|first7=Josep M.|last8=Diekmann|first8=Fritz|last9=Ventura‐Aguiar|first9=Pedro|title=Case report of COVID‐19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1875–1878|issn=1600-6135|doi=10.1111/ajt.15874}}</ref><ref name="Haberal2020">{{cite journal|last1=Haberal|first1=Mehmet|title=COVID-19 UPDATE|journal=Experimental and Clinical Transplantation|volume=18|issue=2|year=2020|pages=139–140|issn=13040855|doi=10.6002/ect.2020.000e}}</ref>
+<ref name="urlbts.org.uk">{{cite web |url=https://bts.org.uk/wp-content/uploads/2020/03/Clinical_management_transplant_recipients.pdf |title=bts.org.uk |format= |work= |accessdate=}}</ref><ref name="urlwww.europeanurology.com">{{cite web |url=https://www.europeanurology.com/article/S0302-2838(20)30211-6/pdf |title=www.europeanurology.com |format= |work= |accessdate=}}</ref>
-*In general population, [[COVID-19]] associated [[Acute kidney injury|AKI]] has higher incidence in elderly.<ref name="PeiZhang20202">{{cite journal|last1=Pei|first1=Guangchang|last2=Zhang|first2=Zhiguo|last3=Peng|first3=Jing|last4=Liu|first4=Liu|last5=Zhang|first5=Chunxiu|last6=Yu|first6=Chong|last7=Ma|first7=Zufu|last8=Huang|first8=Yi|last9=Liu|first9=Wei|last10=Yao|first10=Ying|last11=Zeng|first11=Rui|last12=Xu|first12=Gang|title=Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia|journal=Journal of the American Society of Nephrology|volume=31|issue=6|year=2020|pages=1157–1165|issn=1046-6673|doi=10.1681/ASN.2020030276}}</ref>
+*In general population, [[COVID-19]] associated [[Acute kidney injury|AKI]] has higher incidence in elderly.
 ===Gender===
-*[[Male]] are more commonly affected by [[COVID-19]] than [[female]].
+*[[Male]] are more commonly affected by [[COVID-19]] than [[female]].<ref name="SharmaVolgman2020">{{cite journal|last1=Sharma|first1=Garima|last2=Volgman|first2=Annabelle Santos|last3=Michos|first3=Erin D.|title=Sex Differences in Mortality From COVID-19 Pandemic|journal=JACC: Case Reports|year=2020|issn=26660849|doi=10.1016/j.jaccas.2020.04.027}}</ref>
 *Female dying from [[COVID-19]] are generally elder than men(median age: 82 vs. 79 years for women vs. men, respectively).<ref name="SharmaVolgman2020">{{cite journal|last1=Sharma|first1=Garima|last2=Volgman|first2=Annabelle Santos|last3=Michos|first3=Erin D.|title=Sex Differences in Mortality From COVID-19 Pandemic|journal=JACC: Case Reports|year=2020|issn=26660849|doi=10.1016/j.jaccas.2020.04.027}}</ref>
 ===Race===
-*According to study done in New York, 14 recipients affected by [[COVID-19]], (39%) were black, and 15 recipients (42%) were Hispanic.
+*According to study done in New York, 14 recipients affected by [[COVID-19]], (39%) were black, and 15 recipients (42%) were Hispanic.<ref name="AkalinAzzi2020">{{cite journal|last1=Akalin|first1=Enver|last2=Azzi|first2=Yorg|last3=Bartash|first3=Rachel|last4=Seethamraju|first4=Harish|last5=Parides|first5=Michael|last6=Hemmige|first6=Vagish|last7=Ross|first7=Michael|last8=Forest|first8=Stefanie|last9=Goldstein|first9=Yitz D.|last10=Ajaimy|first10=Maria|last11=Liriano-Ward|first11=Luz|last12=Pynadath|first12=Cindy|last13=Loarte-Campos|first13=Pablo|last14=Nandigam|first14=Purna B.|last15=Graham|first15=Jay|last16=Le|first16=Marie|last17=Rocca|first17=Juan|last18=Kinkhabwala|first18=Milan|title=Covid-19 and Kidney Transplantation|journal=New England Journal of Medicine|volume=382|issue=25|year=2020|pages=2475–2477|issn=0028-4793|doi=10.1056/NEJMc2011117}}</ref>
 == Risk Factors ==
-Common risk factors in the development of [[Kidney transplantation|transplant patients]] to [[COVID-19]] are:
+Common risk factors in the development of transplant patients to COVID-19 are:
 *[[Immunosuppression]]<ref name="ZhouYu2020">{{cite journal|last1=Zhou|first1=Fei|last2=Yu|first2=Ting|last3=Du|first3=Ronghui|last4=Fan|first4=Guohui|last5=Liu|first5=Ying|last6=Liu|first6=Zhibo|last7=Xiang|first7=Jie|last8=Wang|first8=Yeming|last9=Song|first9=Bin|last10=Gu|first10=Xiaoying|last11=Guan|first11=Lulu|last12=Wei|first12=Yuan|last13=Li|first13=Hui|last14=Wu|first14=Xudong|last15=Xu|first15=Jiuyang|last16=Tu|first16=Shengjin|last17=Zhang|first17=Yi|last18=Chen|first18=Hua|last19=Cao|first19=Bin|title=Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study|journal=The Lancet|volume=395|issue=10229|year=2020|pages=1054–1062|issn=01406736|doi=10.1016/S0140-6736(20)30566-3}}</ref>
-*[[Chronic renal failure|Chronic Renal Failure]]<ref name="ZhouYu2020">{{cite journal|last1=Zhou|first1=Fei|last2=Yu|first2=Ting|last3=Du|first3=Ronghui|last4=Fan|first4=Guohui|last5=Liu|first5=Ying|last6=Liu|first6=Zhibo|last7=Xiang|first7=Jie|last8=Wang|first8=Yeming|last9=Song|first9=Bin|last10=Gu|first10=Xiaoying|last11=Guan|first11=Lulu|last12=Wei|first12=Yuan|last13=Li|first13=Hui|last14=Wu|first14=Xudong|last15=Xu|first15=Jiuyang|last16=Tu|first16=Shengjin|last17=Zhang|first17=Yi|last18=Chen|first18=Hua|last19=Cao|first19=Bin|title=Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study|journal=The Lancet|volume=395|issue=10229|year=2020|pages=1054–1062|issn=01406736|doi=10.1016/S0140-6736(20)30566-3}}</ref>
+*[[Chronic renal failure|Chronic Renal Failure]]<ref name="ZhouYu2020">{{cite journal|last1=Zhou|first1=Fei|last2=Yu|first2=Ting|last3=Du|first3=Ronghui|last4=Fan|first4=Guohui|last5=Liu|first5=Ying|last6=Liu|first6=Zhibo|last7=Xiang|first7=Jie|last8=Wang|first8=Yeming|last9=Song|first9=Bin|last10=Gu|first10=Xiaoying|last11=Guan|first11=Lulu|last12=Wei|first12=Yuan|last13=Li|first13=Hui|last14=Wu|first14=Xudong|last15=Xu|first15=Jiuyang|last16=Tu|first16=Shengjin|last17=Zhang|first17=Yi|last18=Chen|first18=Hua|last19=Cao|first19=Bin|title=Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study|journal=The Lancet|volume=395|issue=10229|year=2020|pages=1054–1062|issn=01406736|doi=10.1016/S0140-6736(20)30566-3}}</ref><ref name="BanerjeePopoola2020">{{cite journal|last1=Banerjee|first1=Debasish|last2=Popoola|first2=Joyce|last3=Shah|first3=Sapna|last4=Ster|first4=Irina Chis|last5=Quan|first5=Virginia|last6=Phanish|first6=Mysore|title=COVID-19 infection in kidney transplant recipients|journal=Kidney International|volume=97|issue=6|year=2020|pages=1076–1082|issn=00852538|doi=10.1016/j.kint.2020.03.018}}</ref>
 * Co-Morbidities<ref name="ZhouYu2020">{{cite journal|last1=Zhou|first1=Fei|last2=Yu|first2=Ting|last3=Du|first3=Ronghui|last4=Fan|first4=Guohui|last5=Liu|first5=Ying|last6=Liu|first6=Zhibo|last7=Xiang|first7=Jie|last8=Wang|first8=Yeming|last9=Song|first9=Bin|last10=Gu|first10=Xiaoying|last11=Guan|first11=Lulu|last12=Wei|first12=Yuan|last13=Li|first13=Hui|last14=Wu|first14=Xudong|last15=Xu|first15=Jiuyang|last16=Tu|first16=Shengjin|last17=Zhang|first17=Yi|last18=Chen|first18=Hua|last19=Cao|first19=Bin|title=Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study|journal=The Lancet|volume=395|issue=10229|year=2020|pages=1054–1062|issn=01406736|doi=10.1016/S0140-6736(20)30566-3}}</ref>
 **[[Diabetes mellitus|Diabetes]]
@@ Line 215: / Line 227: @@
 **[[Hyperlipidemia]]
 ** H/o [[Heart disease|Heart Disease]]
-* Male Sex<ref name="AkalinAzzi2020">{{cite journal|last1=Akalin|first1=Enver|last2=Azzi|first2=Yorg|last3=Bartash|first3=Rachel|last4=Seethamraju|first4=Harish|last5=Parides|first5=Michael|last6=Hemmige|first6=Vagish|last7=Ross|first7=Michael|last8=Forest|first8=Stefanie|last9=Goldstein|first9=Yitz D.|last10=Ajaimy|first10=Maria|last11=Liriano-Ward|first11=Luz|last12=Pynadath|first12=Cindy|last13=Loarte-Campos|first13=Pablo|last14=Nandigam|first14=Purna B.|last15=Graham|first15=Jay|last16=Le|first16=Marie|last17=Rocca|first17=Juan|last18=Kinkhabwala|first18=Milan|title=Covid-19 and Kidney Transplantation|journal=New England Journal of Medicine|volume=382|issue=25|year=2020|pages=2475–2477|issn=0028-4793|doi=10.1056/NEJMc2011117}}</ref>
+* Male Sex<ref name="AkalinAzzi2020">{{cite journal|last1=Akalin|first1=Enver|last2=Azzi|first2=Yorg|last3=Bartash|first3=Rachel|last4=Seethamraju|first4=Harish|last5=Parides|first5=Michael|last6=Hemmige|first6=Vagish|last7=Ross|first7=Michael|last8=Forest|first8=Stefanie|last9=Goldstein|first9=Yitz D.|last10=Ajaimy|first10=Maria|last11=Liriano-Ward|first11=Luz|last12=Pynadath|first12=Cindy|last13=Loarte-Campos|first13=Pablo|last14=Nandigam|first14=Purna B.|last15=Graham|first15=Jay|last16=Le|first16=Marie|last17=Rocca|first17=Juan|last18=Kinkhabwala|first18=Milan|title=Covid-19 and Kidney Transplantation|journal=New England Journal of Medicine|volume=382|issue=25|year=2020|pages=2475–2477|issn=0028-4793|doi=10.1056/NEJMc2011117}}</ref><ref name="NacifZanini2020">{{cite journal|last1=Nacif|first1=Lucas Souto|last2=Zanini|first2=Leonardo Y.|last3=Waisberg|first3=Daniel R.|last4=Pinheiro|first4=Rafael S.|last5=Galvão|first5=Flávio|last6=Andraus|first6=Wellington|last7=D'Albuquerque|first7=Luiz Carneiro|title=COVID-19 in solid organ transplantation patients: A systematic review|journal=Clinics|volume=75|year=2020|issn=1807-5932|doi=10.6061/clinics/2020/e1983}}</ref>
 * Old Age<ref name="AkalinAzzi2020">{{cite journal|last1=Akalin|first1=Enver|last2=Azzi|first2=Yorg|last3=Bartash|first3=Rachel|last4=Seethamraju|first4=Harish|last5=Parides|first5=Michael|last6=Hemmige|first6=Vagish|last7=Ross|first7=Michael|last8=Forest|first8=Stefanie|last9=Goldstein|first9=Yitz D.|last10=Ajaimy|first10=Maria|last11=Liriano-Ward|first11=Luz|last12=Pynadath|first12=Cindy|last13=Loarte-Campos|first13=Pablo|last14=Nandigam|first14=Purna B.|last15=Graham|first15=Jay|last16=Le|first16=Marie|last17=Rocca|first17=Juan|last18=Kinkhabwala|first18=Milan|title=Covid-19 and Kidney Transplantation|journal=New England Journal of Medicine|volume=382|issue=25|year=2020|pages=2475–2477|issn=0028-4793|doi=10.1056/NEJMc2011117}}</ref><ref name="NacifZanini2020">{{cite journal|last1=Nacif|first1=Lucas Souto|last2=Zanini|first2=Leonardo Y.|last3=Waisberg|first3=Daniel R.|last4=Pinheiro|first4=Rafael S.|last5=Galvão|first5=Flávio|last6=Andraus|first6=Wellington|last7=D'Albuquerque|first7=Luiz Carneiro|title=COVID-19 in solid organ transplantation patients: A systematic review|journal=Clinics|volume=75|year=2020|issn=1807-5932|doi=10.6061/clinics/2020/e1983}}</ref>
-* Current or h/o [[smoking]] tobacco<ref name="AkalinAzzi2020">{{cite journal|last1=Akalin|first1=Enver|last2=Azzi|first2=Yorg|last3=Bartash|first3=Rachel|last4=Seethamraju|first4=Harish|last5=Parides|first5=Michael|last6=Hemmige|first6=Vagish|last7=Ross|first7=Michael|last8=Forest|first8=Stefanie|last9=Goldstein|first9=Yitz D.|last10=Ajaimy|first10=Maria|last11=Liriano-Ward|first11=Luz|last12=Pynadath|first12=Cindy|last13=Loarte-Campos|first13=Pablo|last14=Nandigam|first14=Purna B.|last15=Graham|first15=Jay|last16=Le|first16=Marie|last17=Rocca|first17=Juan|last18=Kinkhabwala|first18=Milan|title=Covid-19 and Kidney Transplantation|journal=New England Journal of Medicine|volume=382|issue=25|year=2020|pages=2475–2477|issn=0028-4793|doi=10.1056/NEJMc2011117}}</ref>
+* Current or h/o smoking tobacco<ref name="AkalinAzzi2020">{{cite journal|last1=Akalin|first1=Enver|last2=Azzi|first2=Yorg|last3=Bartash|first3=Rachel|last4=Seethamraju|first4=Harish|last5=Parides|first5=Michael|last6=Hemmige|first6=Vagish|last7=Ross|first7=Michael|last8=Forest|first8=Stefanie|last9=Goldstein|first9=Yitz D.|last10=Ajaimy|first10=Maria|last11=Liriano-Ward|first11=Luz|last12=Pynadath|first12=Cindy|last13=Loarte-Campos|first13=Pablo|last14=Nandigam|first14=Purna B.|last15=Graham|first15=Jay|last16=Le|first16=Marie|last17=Rocca|first17=Juan|last18=Kinkhabwala|first18=Milan|title=Covid-19 and Kidney Transplantation|journal=New England Journal of Medicine|volume=382|issue=25|year=2020|pages=2475–2477|issn=0028-4793|doi=10.1056/NEJMc2011117}}</ref>
 * Possible a/w donor [[COVID-19]] infection<ref name="NacifZanini2020">{{cite journal|last1=Nacif|first1=Lucas Souto|last2=Zanini|first2=Leonardo Y.|last3=Waisberg|first3=Daniel R.|last4=Pinheiro|first4=Rafael S.|last5=Galvão|first5=Flávio|last6=Andraus|first6=Wellington|last7=D'Albuquerque|first7=Luiz Carneiro|title=COVID-19 in solid organ transplantation patients: A systematic review|journal=Clinics|volume=75|year=2020|issn=1807-5932|doi=10.6061/clinics/2020/e1983}}</ref>
 == Screening ==
-According to one of the COVID-19 Rapid Guidelines for renal transplant patients:
+According to one of the [[COVID-19]] Rapid Guidelines for [[Kidney transplantation|renal transplant patients]]:<ref name="urlSamavat">{{cite web |url=http://www.ijkd.org/index.php/ijkd/article/view/5511/1156 |title=Samavat |format= |work= |accessdate=}}</ref>
 {{Family tree/start}}
-{{Family tree | | | | | | | | | | A01 | | | |A01= Patient presents with Sore throat,Dry cough or Fever}}
+{{Family tree | | | | | | | | | | A01 | | | |A01= Patient presents with [[Sore throat]],[[Dry cough]] or [[Fever]]}}
 {{Family tree | | | | | | | | | | |!| | | | | }}
 {{Family tree | | | | | | | | | | |!| | | | | }}
 {{Family tree | | | | | | | | | | |!| | | | | }}
-{{Family tree | | | | | | | | | | B01 |-| B02 | |B01= Dysnea, RR>30/min, SpO2<93%| B02= If Present Then refer for admission}}
+{{Family tree | | | | | | | | | | B01 |-| B02 | |B01= [[Dypsnea]], RR>30/min, SpO2<93%| B02= If Present Then refer for admission}}
 {{Family tree | | | | | | | | | | |!| | | | | }}
 {{Family tree | | | | | | | | | | |!| | | | | }}
 {{Family tree | | | | | | | | | | |!| | | | | }}
-{{Family tree | | | | C01 |-|-|-| C02 |-|-|-|C03 |-| C04 | |C01= Creatinine is raised but no Lymphopenia or No Abnormality on CT chest| C02=If not, check Creatinine, C-RP, CXR & CT chest|C03 = Lymphopenia but Creatinine normal and Ct chest normal |C04= Admit in usual ward and evaluate Lymphopenia}}
+{{Family tree | | | | C01 |-|-|-| C02 |-|-|-|C03 |-| C04 | |C01= [[Creatinine]] is raised but no [[Lymphopenia]] or No Abnormality on [[CT chest]]| C02=If not, check [[Creatinine]], [[C-RP]], [[CXR]] & [[CT chest]]|C03 = [[Lymphopenia]] but [[Creatinine]] normal and [[Ct chest]] normal |C04= Admit in usual ward and evaluate [[Lymphopenia]]}}
 {{Family tree | | | | |!| | | | | |!| | }}
-{{Family tree | | | | D01 | | | | D02 |-|-| D03 |-| D04 | |D01= Evaluate the Causes of rise in creatinine | D02= Is Xray positive for COVID-19? | D03= If No, then Do CT Chest |D04= If CT Chest is negative then refer patient for Home Care, Medical Treatment, Diagnostic Test, and Daily Follow-ups   }}
+{{Family tree | | | | D01 | | | | D02 |-|-| D03 |-| D04 | |D01= Evaluate the Causes of rise in [[creatinine]] | D02= Is [[Xray]] positive for [[COVID-19]]? | D03= If No, then Do [[CT Chest]] |D04= If [[CT Chest]] is negative then refer a patient for Home Care, Medical Treatment, Diagnostic Test, and Daily Follow-ups   }}
 {{Family tree | | | | | | | | | | |!| | | | |!|}}
-{{Family tree | | | | | | | | | | E02 |-|-|-|'| E02= If Chest Xray or CT chest is indicative of COVID-19 infection: Admit the patient|}}
+{{Family tree | | | | | | | | | | E02 |-|-|-|'| E02= If [[Chest Xray]] or [[CT chest]] is indicative of [[COVID-19]] infection: Admit the patient|}}
 {{familytree/end}}
 === Screening for [[AKI]] ===
-Serial monitoring of kidney function tests should be considered in [[Kidney transplantation|renal transplant]] patients''''
+Serial monitoring of kidney function tests should be considered in [[Kidney transplantation|renal transplant]] patients''<ref name="SelbyForni2020">{{cite journal|last1=Selby|first1=Nicholas M|last2=Forni|first2=Lui G|last3=Laing|first3=Christopher M|last4=Horne|first4=Kerry L|last5=Evans|first5=Rhys DR|last6=Lucas|first6=Bethany J|last7=Fluck|first7=Richard J|title=Covid-19 and acute kidney injury in hospital: summary of NICE guidelines|journal=BMJ|year=2020|pages=m1963|issn=1756-1833|doi=10.1136/bmj.m1963}}</ref>''
 *[[BUN]]
 *[[Creatinine]]
@@ Line 252: / Line 264: @@
 == Natural History, Complications and Prognosis==
-The majority of renal transplant recipients with [[COVID-19]] present with same course of infection as in general population<ref name="BanerjeePopoola20202" />.
+The majority of [[Kidney transplantation|renal transplant]] recipients with [[COVID-19]] present with same course of infection as in general population<ref name="BanerjeePopoola20202" />.
-The clinical features in renal transplant recipients may be atypical due to chronic state of suppressed immune system and other chronic co-morbidities in transplant patients<ref name="ZhouYu2020" /><ref name="pmid32171076" /><ref name="ZhuXu2020" />. Early clinical features include cough, [[fever]], [[fatigue]], [[diarrhea]], [[sore throat]], and [[shortness of breath]].
+The clinical features in [[Kidney transplantation|renal transplant]] recipients may be atypical due to chronic state of suppressed [[immune system]] and other chronic co-morbidities in transplant patients<ref name="ZhouYu2020" /><ref name="pmid32171076" /><ref name="ZhuXu2020" />. Early clinical features include [[cough]], [[fever]], [[fatigue]], [[diarrhea]], [[sore throat]], and shortness of breath.
-If left untreated, [[COVID-19]] in transplant recipients may progress to develop dysnea, [[hypoxemia]], [[oliguria]], [[confusion]], [[fluid retention]] and pro coagulative state<ref name="BanerjeePopoola20202" />.
+If left untreated, [[COVID-19]] in transplant recipients may progress to develop [[Dyspnea|dypsnea]], [[hypoxemia]], [[oliguria]], [[confusion]], [[fluid retention]] and pro coagulative state<ref name="BanerjeePopoola20202" />.
-Common complications of COVID-19 in renal patients may include [[Pneumonia]], [[Acute respiratory distress syndrome|Acute Respiratory Distress Syndrome]], [[Acute Kidney Injury]] and [[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]<ref name="WuMcGoogan2020" /><ref name="BanerjeePopoola20202" /><ref name="BanerjeePopoola2020" />.
+Common complications of [[COVID-19]] in renal patients may include [[Pneumonia]], [[Acute respiratory distress syndrome|Acute Respiratory Distress Syndrome]], [[Acute kidney injury|Acute Kidney Injury]] and [[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]<ref name="WuMcGoogan2020" /><ref name="BanerjeePopoola20202" /><ref name="BanerjeePopoola2020" />.
-Prognosis is generally worse than the prognosis in general population due to underlying immunosuppression and chronic co morbidities (eg. [[Hypertension]], [[Diabetes]], Chronic renal Failure etc, and the mortality rate in renal transplant patients with [[COVID-19]] has been reported to be higher than the general population<ref name="ZhuXu2020" /><ref name="pmid32171076" /><ref name="ZhouYu2020" />.
+Prognosis is generally worse than the prognosis in general population due to underlying [[immunosuppression]] and chronic co morbidities (eg. [[Hypertension]], [[Diabetes]], [[Chronic renal failure|Chronic renal Failure]] etc, and the mortality rate in renal transplant patients with [[COVID-19]] has been reported to be higher than the general population<ref name="ZhuXu2020" /><ref name="pmid32171076" /><ref name="ZhouYu2020" />.
 == Diagnosis ==
@@ Line 287: / Line 299: @@
-If the patient develops Acute Kidney physical examination is remarkable for:
+If the patient develops Acute Kidney physical examination is remarkable for<ref name="urlHarrisons principles of internal medicine : Kasper, Dennis L : Free Download, Borrow, and Streaming : Internet Archive">{{cite web |url=https://archive.org/details/harrisonsprincip00kasp/page/n1681/mode/2up |title=Harrison's principles of internal medicine : Kasper, Dennis L : Free Download, Borrow, and Streaming : Internet Archive |format= |work= |accessdate=}}</ref>:
 * Signs of [[dehydration]], such as [[tachycardia]], [[tachypnea]], [[hypotension]], and dry [[mucosa]]
@@ Line 296: / Line 308: @@
 <br />
 ===Past Medical History===
 *[[Kidney transplantation|Renal transplant]] patients usually have chronic co-morbidities<ref name="ZhouYu2020">{{cite journal|last1=Zhou|first1=Fei|last2=Yu|first2=Ting|last3=Du|first3=Ronghui|last4=Fan|first4=Guohui|last5=Liu|first5=Ying|last6=Liu|first6=Zhibo|last7=Xiang|first7=Jie|last8=Wang|first8=Yeming|last9=Song|first9=Bin|last10=Gu|first10=Xiaoying|last11=Guan|first11=Lulu|last12=Wei|first12=Yuan|last13=Li|first13=Hui|last14=Wu|first14=Xudong|last15=Xu|first15=Jiuyang|last16=Tu|first16=Shengjin|last17=Zhang|first17=Yi|last18=Chen|first18=Hua|last19=Cao|first19=Bin|title=Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study|journal=The Lancet|volume=395|issue=10229|year=2020|pages=1054–1062|issn=01406736|doi=10.1016/S0140-6736(20)30566-3}}</ref>
@@ Line 313: / Line 326: @@
 *[[Ferritin]]
 *[[Troponin]]
-**Microvascular [[thrombosis]] and [[disseminated intravascular coagulation]]( with gut [[ischemia]] ) can occur later in the course of illness. They are characterized by marked increase in the levels of D-[[dimer]] particularly.  [[D-dimer|D dimer]], [[ferritin]], and [[troponin]] should be measured in all patients with severe [[COVID-19]] infection on admission and in those who fail to show any clinical improvement.
+**Microvascular [[thrombosis]] and [[disseminated intravascular coagulation]]( with gut [[ischemia]] ) can occur later in the course of illness. They are characterized by marked increase in the levels of D-[[dimer]] particularly.  [[D-dimer|D dimer]], [[ferritin]], and [[troponin]] should be measured in all patients with severe [[COVID-19]] infection on admission and in those who fail to show any clinical improvement.<ref name="BanerjeePopoola202022">{{cite journal|last1=Banerjee|first1=Debasish|last2=Popoola|first2=Joyce|last3=Shah|first3=Sapna|last4=Ster|first4=Irina Chis|last5=Quan|first5=Virginia|last6=Phanish|first6=Mysore|title=COVID-19 infection in kidney transplant recipients|journal=Kidney International|volume=97|issue=6|year=2020|pages=1076–1082|issn=00852538|doi=10.1016/j.kint.2020.03.018}}</ref>
-*High [[C-reactive protein|C-Reactive Protein]] -
+*High [[C-reactive protein|C-Reactive Protein]]<ref name="BanerjeePopoola20202">{{cite journal|last1=Banerjee|first1=Debasish|last2=Popoola|first2=Joyce|last3=Shah|first3=Sapna|last4=Ster|first4=Irina Chis|last5=Quan|first5=Virginia|last6=Phanish|first6=Mysore|title=COVID-19 infection in kidney transplant recipients|journal=Kidney International|volume=97|issue=6|year=2020|pages=1076–1082|issn=00852538|doi=10.1016/j.kint.2020.03.018}}</ref> - C‐reactive protein ([[C-reactive protein|CRP]]) was significantly elevated in patients at the time of admission.<ref name="ZhuXu2020">{{cite journal|last1=Zhu|first1=Lan|last2=Xu|first2=Xizhen|last3=Ma|first3=Ke|last4=Yang|first4=Junling|last5=Guan|first5=Hanxiong|last6=Chen|first6=Song|last7=Chen|first7=Zhishui|last8=Chen|first8=Gang|title=Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1859–1863|issn=1600-6135|doi=10.1111/ajt.15869}}</ref> The levels of [[C-reactive protein|CRP]] remained elevated during the admission<ref name="ZhuXu2020">{{cite journal|last1=Zhu|first1=Lan|last2=Xu|first2=Xizhen|last3=Ma|first3=Ke|last4=Yang|first4=Junling|last5=Guan|first5=Hanxiong|last6=Chen|first6=Song|last7=Chen|first7=Zhishui|last8=Chen|first8=Gang|title=Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1859–1863|issn=1600-6135|doi=10.1111/ajt.15869}}</ref>
-**C‐reactive protein ([[C-reactive protein|CRP]]) was significantly elevated in patients at the time of admission.<ref name="ZhuXu2020">{{cite journal|last1=Zhu|first1=Lan|last2=Xu|first2=Xizhen|last3=Ma|first3=Ke|last4=Yang|first4=Junling|last5=Guan|first5=Hanxiong|last6=Chen|first6=Song|last7=Chen|first7=Zhishui|last8=Chen|first8=Gang|title=Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1859–1863|issn=1600-6135|doi=10.1111/ajt.15869}}</ref>
-**The levels of [[C-reactive protein|CRP]] remained elevated during the admission<ref name="ZhuXu2020">{{cite journal|last1=Zhu|first1=Lan|last2=Xu|first2=Xizhen|last3=Ma|first3=Ke|last4=Yang|first4=Junling|last5=Guan|first5=Hanxiong|last6=Chen|first6=Song|last7=Chen|first7=Zhishui|last8=Chen|first8=Gang|title=Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1859–1863|issn=1600-6135|doi=10.1111/ajt.15869}}</ref>.
+'''If the renal transplant patients reports AKI then following laboratory findings can be done'''<ref name="OstermannJoannidis2016">{{cite journal|last1=Ostermann|first1=Marlies|last2=Joannidis|first2=Michael|title=Acute kidney injury 2016: diagnosis and diagnostic workup|journal=Critical Care|volume=20|issue=1|year=2016|issn=1364-8535|doi=10.1186/s13054-016-1478-z}}</ref>:
-'''If the renal transplant patients reports AKI then following laboratory findings can be done''':
 * Elevated serum [[creatinine]]
@@ Line 332: / Line 342: @@
 ** Hyaline casts in prerenal [[AKI]]
 ** Granular or Muddy brown [[casts]] in intrinsic [[AKI]] or [[acute tubular necrosis]]
-* Several [[biomarkers]] have been found to diagnose and predict [[AKI]] that include:
+* Several [[biomarkers]] have been found to diagnose and predict [[AKI]] that include<ref name="SchrezenmeierBarasch2017">{{cite journal|last1=Schrezenmeier|first1=E. V.|last2=Barasch|first2=J.|last3=Budde|first3=K.|last4=Westhoff|first4=T.|last5=Schmidt-Ott|first5=K. M.|title=Biomarkers in acute kidney injury - pathophysiological basis and clinical performance|journal=Acta Physiologica|volume=219|issue=3|year=2017|pages=556–574|issn=17481708|doi=10.1111/apha.12764}}</ref><ref name="KashaniCheungpasitporn2017">{{cite journal|last1=Kashani|first1=Kianoush|last2=Cheungpasitporn|first2=Wisit|last3=Ronco|first3=Claudio|title=Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption|journal=Clinical Chemistry and Laboratory Medicine (CCLM)|volume=55|issue=8|year=2017|pages=1074–1089|issn=1437-4331|doi=10.1515/cclm-2016-0973}}</ref><ref name="Oh2020">{{cite journal|last1=Oh|first1=Dong-Jin|title=A long journey for acute kidney injury biomarkers|journal=Renal Failure|volume=42|issue=1|year=2020|pages=154–165|issn=0886-022X|doi=10.1080/0886022X.2020.1721300}}</ref>:
 **[[neutrophil gelatinase-associated lipocalin]] (NGAL)
 ** kidney injury molecule 1 (KIM-1)
 ** liver-type fatty acid-binding protein
 ** [[interleukin 18]] (lL-18)
-**<nowiki/>[[Insulin-like growth factor|insulin-like growth facto]]<nowiki/>r-binding protein 7
+**[[Insulin-like growth factor|insulin-like growth facto]]<nowiki/>r-binding protein 7
-**tissue inhibitor of metal<nowiki/>loproteinase 2 (TIMP-2)
+** tissue inhibitor of metalloproteinase 2 (TIMP-2)
 ** calprotectin
 ** [[urine]] [[angiotensinogen]] (AGT)
@@ Line 348: / Line 358: @@
 * X-ray findings in the [[Kidney transplantation|renal transplan]]<nowiki/>t patients were similar to the findings seen in the general population.
 * To view the x-ray finidings on COVID-19, [[COVID-19 x ray|click here]].<br />
 ===Echocardiography or Ultrasound===
 * If the [[Kidney transplantation|renal transplant]] patient develops [[Acute kidney injury|AKI]], USG can help diagnose [[hydronephrosis]] and reduced [[renal blood flow]].
@@ Line 371: / Line 382: @@
 {{familytree/start |summary=Sample 6}}
-{{familytree | | | | | | | | A01 |A01=• '''Follow local guidelines for use of PPE<br>• Do the general assessment of the patient and swab for SARS-Cov-2<br>• Exclude other causes like CMV, pneumocystis, community or hospital acquired pneumonia, influenza, urinary sepsis, lymphoma and fluid overload)}}
+{{familytree | | | | | | | | A01 |A01=• '''Follow local guidelines for use of [[PPE]]<br>• Do the general assessment of the patient and swab for [[SARS-Cov-2]]<br>• Exclude other causes like [[CMV]], [[pneumocystis]], [[community or hospital acquired pneumonia]], [[influenza]], [[urinary sepsis]], [[lymphoma]] and [[fluid overload]])}}
 {{familytree | | | | |,|-|-|-|+|-|-|-|-|.| | | }}
 {{familytree | | | B01 | | | |!| | | | B02 | | |B01=• '''If the patient doesn't require hospitalization''' <br>
-• Stop antiproliferative agents (MMF/azathioprine)<br>
+• Stop [[antiproliferative agents]] ([[MMF]]/[[azathioprine]])<br>
-• Review total burden of immunosuppression and consider reduction of CNI<br>
+• Review total burden of [[immunosuppression]] and consider reduction of [[CNI]]<br>
-• High or increased dose steroid is NOT recommended at this stage<br>
+• High or increased dose [[steroid]] is NOT recommended at this stage<br>
 • Patients should self isolate in line with national guidance<br>
 • Closely monitor patients remotely for change in symptoms<br>
-• Consider restarting immunosuppression 14 days after onset of symptoms if symptom free in absence of anti-pyretics for minimum of 3 days<br>
+• Consider restarting [[immunosuppression]] 14 days after onset of symptoms if symptom free in absence of [[anti-pyretics]] for minimum of 3 days<br>
 • Consider early monitoring of graft function when safe to do so and risk of transmissionto others is low<br>|B02=• '''If the patient is deteriorates or requires ventilatory support'''<br>
-• Stop antiproliferative agents (MMF/azathioprine)<br>
+• Stop [[antiproliferative]] agents ([[MMF]]/[[azathioprine]])<br>
-• Dramatically reduce or stop CNI<br>
+• Dramatically reduce or stop [[CNI]]<br>
-• Consider high dose steroids in discussion with ITU team<br>
+• Consider high dose [[steroids]] in discussion with ITU team<br>
 • Ventilatory support in line with local or national guidance<br>
-• Adjunctive support or antivirals in line with local practice or clinical trials<br>}}
+• Adjunctive support or [[antivirals]] in line with local practice or clinical trials<br>}}
 {{familytree | | | | | | | | C01 | | | | | | |C01= • '''If the patient is unwell and requires admission'''<br>
 • Stop antiproliferative agents
-(MMF/azathioprine)<br>
+(MMF/[[azathioprine]])<br>
-• Consider reducing or stopping CNI<br>
+• Consider reducing or stopping [[CNI]]<br>
-• Consider increasing steroids if currently
+• Consider increasing [[steroids]] if currently
 taking them.<br>
 • There is no evidence for benefit of
-high dose steroids at this stage<br>
+high dose [[steroids]] at this stage<br>
 • Oxygen therapy to achieve saturations over
 % (unless COPD)<br>
@@ Line 399: / Line 410: @@
 to monitor for rapid deterioration<br>
 • Conservative fluid administration<br>
-• Consider adjunctive antibiotics if superadded
+• Consider adjunctive [[antibiotics]] if superadded
-bacterial infection is suspected<br>
+bacterial [[infection]] is suspected<br>
 • Early discussion of ceilings of care<br>}}
 {{familytree/end}}
@@ Line 409: / Line 420: @@
 {{Family tree | | | | A01 | | | | | | | | | A01= Admitted Patients}}
 {{Family tree | |,|-|-|^|-|-|.| | | | | | | }}
-{{Family tree | C01 | | | | C02 |-|-| C03 |-|-| C04 |C01= O2 Saturation <93% | C02= O2 saturation >93%  |C03='''S. Creaitnine is raised''',Then Consider Kidney Biospy |C04= •'''If there are signs of kidney rejection'''<br>• Stop Anti Metabolite Drug<br>•  Prednisolone: 20 mg/d<br>• Cyclosporine Trough Level: 75-150ng/ml<br>• Tacrolimus Trough Level: 4 to 6 ng/mL<br>• IVIG: 1-2 g/kg Divided Doses in 5 Days<br>• Anti Viral Therapy According to Protocol<br>• Azithromycin: 500 mg Stat and 250 mg<br>• Daily for 4 Days }}
+{{Family tree | C01 | | | | C02 |-|-| C03 |-|-| C04 |C01= O2 Saturation <93% | C02= O2 saturation >93%  |C03='''S. [[Creatinine]] is raised''',Then Consider [[Kidney Biospy]] |C04= •'''If there are signs of [[kidney]] rejection'''<br>• Stop [[Anti Metabolite Drug]]<br>•  [[Prednisolone]]: 20 mg/d<br>• [[Cyclosporine]] Trough Level: 75-150ng/ml<br>• [[Tacrolimus]] Trough Level: 4 to 6 ng/mL<br>• [[IVIG]]: 1-2 g/kg Divided Doses in 5 Days<br>• [[Anti Viral]] Therapy According to Protocol<br>• [[Azithromycin]]: 500 mg Stat and 250 mg<br>• Daily for 4 Days }}
 {{Family tree | |!| | | | | |!| | | | |!| | | | | | |}}
 {{Family tree | |!| | | | | |!| | | | |!| | | | | | |}}
-{{Family tree | D01 | | | | D02 | | | D03 | | |D01=• Stop Anti Metabolite Drug<br>• Stop CNI<br> • IV Methyl Prednisolone: 40mg/d<br>• IVIG: 1-2 g/kg Divided Doses in 5 Days<br>• Anti Viral Therapy According to Protocol<br>• Azithromycin: 500 mg Stat and 250 mg<br>• Daily for 4 Days||D02=• If '''S.Creatinine is Normal'''<br>• Stop Anti Metabolite Drug<br>• Prednisolone: 20 mg/d<br>• Cyclosporine Trough Level: 75-150ng/ml<br>• Tacrolimus Trough Level: 4 to 6 ng/mL<br>• Anti Viral Therapy According to Protocol<br>• Azithromycin: 500 mg Stat and 250 mg<br>• Daily for 4 Days |D03= If '''No Sign of rejection''' then same protocol as for '''Normal Serum Creatinine and O2 sat. >93%''' }}
+{{Family tree | D01 | | | | D02 | | | D03 | | |D01=• Stop [[Anti Metabolite]] Drug<br>• Stop [[CNI]]<br> • IV Methyl [[Prednisolone]]: 40mg/d<br>• [[IVIG]]: 1-2 g/kg Divided Doses in 5 Days<br>• [[Anti Viral]] Therapy According to Protocol<br>• [[Azithromycin]]: 500 mg Stat and 250 mg<br>• Daily for 4 Days||D02=• If '''S.[[Creatinine]] is Normal'''<br>• Stop [[Anti Metabolite]] Drug<br>• [[Prednisolone]]: 20 mg/d<br>• [[Cyclosporine]] Trough Level: 75-150ng/ml<br>• [[Tacrolimus]] Trough Level: 4 to 6 ng/mL<br>• [[Anti Viral]] Therapy According to Protocol<br>• [[Azithromycin]]: 500 mg Stat and 250 mg<br>• Daily for 4 Days |D03= If '''No Sign of rejection''' then same protocol as for '''Normal Serum [[Creatinine]] and O2 sat. >93%''' }}
 {{Family tree/end}}
+For general COVID-19 Medical Therapy [[COVID-19 medical therapy|click here]]
 ==== Chronic Pharmacotherapy ====
-In [[Kidney transplantation|renal transplant]] patients, the immune responses are altered, especially the T cell response, due to generalized [[immunosuppression]]. Due to recent timeframe of outbreak of [[COVID-19]] and insufficient scientific evidence, there is limited evidence on decreasing or changing the pattern of [[immunosuppression]] in [[Kidney transplantation|renal transplant]] patients who have been infected with [[COVID-19]].
+In [[Kidney transplantation|renal transplant]] patients, the immune responses are altered, especially the T cell response, due to generalized [[immunosuppression]]. Due to recent timeframe of outbreak of [[COVID-19]] and insufficient scientific evidence, there is limited evidence on decreasing or changing the pattern of [[immunosuppression]] in [[Kidney transplantation|renal transplant]] patients who have been infected with [[COVID-19]]. <ref name="ZhuXu20202">{{cite journal|last1=Zhu|first1=Lan|last2=Xu|first2=Xizhen|last3=Ma|first3=Ke|last4=Yang|first4=Junling|last5=Guan|first5=Hanxiong|last6=Chen|first6=Song|last7=Chen|first7=Zhishui|last8=Chen|first8=Gang|title=Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression|journal=American Journal of Transplantation|year=2020|issn=1600-6135|doi=10.1111/ajt.15869}}</ref>
-*Clinical presentation of [[COVID-19]] infection in [[Kidney transplantation|renal transplant]] patients are like the clinical presentations of infection in general population. <ref name="ZhuXu20202">{{cite journal|last1=Zhu|first1=Lan|last2=Xu|first2=Xizhen|last3=Ma|first3=Ke|last4=Yang|first4=Junling|last5=Guan|first5=Hanxiong|last6=Chen|first6=Song|last7=Chen|first7=Zhishui|last8=Chen|first8=Gang|title=Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression|journal=American Journal of Transplantation|year=2020|issn=1600-6135|doi=10.1111/ajt.15869}}</ref>.Moreover, [[Kidney transplantation|renal transplant]] patients are generally [[Immunodeficiency|immunocompromised]], and this predisposes them to severe infection with [[COVID-19]]. Rejection of the graft can occur if [[immunosuppression]] is reduced in these patients.  Hence given the high rate of mortality in [[COVID-19]] infections, it is suggested that a careful risk vs benefits assessment of whether to continue [[immunosuppression]] should be done.
+*Clinical presentation of [[COVID-19]] infection in [[Kidney transplantation|renal transplant]] patients are like the clinical presentations of infection in general population. <ref name="ZhuXu20202">{{cite journal|last1=Zhu|first1=Lan|last2=Xu|first2=Xizhen|last3=Ma|first3=Ke|last4=Yang|first4=Junling|last5=Guan|first5=Hanxiong|last6=Chen|first6=Song|last7=Chen|first7=Zhishui|last8=Chen|first8=Gang|title=Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression|journal=American Journal of Transplantation|year=2020|issn=1600-6135|doi=10.1111/ajt.15869}}</ref>.Moreover, renal transplant patients are generally [[Immunodeficiency|immunocompromised]], and this predisposes them to severe infection with [[COVID-19]]. Rejection of the graft can occur if [[immunosuppression]] is reduced in these patients.  Hence given the high rate of mortality in [[COVID-19]] infections, it is suggested that a careful risk vs benefits assessment of whether to continue [[immunosuppression]] should be done.<ref name="pmid32354637">{{cite journal |vauthors=Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M |title=COVID-19 infection in kidney transplant recipients |journal=Kidney Int. |volume=97 |issue=6 |pages=1076–1082 |date=June 2020 |pmid=32354637 |pmc=7142878 |doi=10.1016/j.kint.2020.03.018 |url=}}</ref>
 *''Managing the [[immunosuppression]] in [[Kidney transplantation|renal transplant]] patients is difficult and should be based on''<ref name="pmid32354637">{{cite journal |vauthors=Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M |title=COVID-19 infection in kidney transplant recipients |journal=Kidney Int. |volume=97 |issue=6 |pages=1076–1082 |date=June 2020 |pmid=32354637 |pmc=7142878 |doi=10.1016/j.kint.2020.03.018 |url=}}</ref>
 **Age
 **Severity of [[COVID-19]] infection
 **Presence of Co-Morbidities
-**Time since the [[Organ transplant|transplant]]
+**Time since the transplant
 *''In patients with mild to moderate infection, it has been a practice to continue or decrease the doses of [[Immunosuppression|immunosuppressive]] drugs, however this approach can cause high mortality in patients having [[COVID-19]] infection.''<ref name="pmid32354637">{{cite journal |vauthors=Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M |title=COVID-19 infection in kidney transplant recipients |journal=Kidney Int. |volume=97 |issue=6 |pages=1076–1082 |date=June 2020 |pmid=32354637 |pmc=7142878 |doi=10.1016/j.kint.2020.03.018 |url=}}</ref>
 '''Commonly followed protocols for the used immuno-suppressant drugs is as follows''':-
-*'''Antiproliferative agents such as MMF and [[azathioprine]] '''
+*'''Antiproliferative agents such as MMF and [[azathioprine]] '''<ref name="pmid323546372">{{cite journal |vauthors=Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M |title=COVID-19 infection in kidney transplant recipients |journal=Kidney Int. |volume=97 |issue=6 |pages=1076–1082 |date=June 2020 |pmid=32354637 |pmc=7142878 |doi=10.1016/j.kint.2020.03.018 |url=}}</ref>
 ** Should be stopped at the time of admission to hospital
 *'''[[Prednisolone]]'''<ref name="pmid323546372">{{cite journal |vauthors=Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M |title=COVID-19 infection in kidney transplant recipients |journal=Kidney Int. |volume=97 |issue=6 |pages=1076–1082 |date=June 2020 |pmid=32354637 |pmc=7142878 |doi=10.1016/j.kint.2020.03.018 |url=}}</ref>
@@ Line 437: / Line 448: @@
 ***''Immunomodulation and [[anti-inflammatory]] properties''
 ****Inhibition of proinflammatory [[Cytokine|cytokines]]
-****Reduction of [[White blood cells|white blood cell]] traffic
+****Reduction of white blood cell traffic
 ***''Vascular protective effects''
-**** Maintenance of integrity and permeability of [[endothelium]].   <ref name="pmid323546372">{{cite journal |vauthors=Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M |title=COVID-19 infection in kidney transplant recipients |journal=Kidney Int. |volume=97 |issue=6 |pages=1076–1082 |date=June 2020 |pmid=32354637 |pmc=7142878 |doi=10.1016/j.kint.2020.03.018 |url=}}</ref>
+**** Maintenance of integrity and permeability of [[endothelium]].  <ref name="LansburyRodrigo2020">{{cite journal|last1=Lansbury|first1=Louise E.|last2=Rodrigo|first2=Chamira|last3=Leonardi-Bee|first3=Jo|last4=Nguyen-Van-Tam|first4=Jonathan|last5=Shen Lim|first5=Wei|title=Corticosteroids as Adjunctive Therapy in the Treatment of Influenza|journal=Critical Care Medicine|volume=48|issue=2|year=2020|pages=e98–e106|issn=0090-3493|doi=10.1097/CCM.0000000000004093}}</ref> <ref name="pmid323546372">{{cite journal |vauthors=Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M |title=COVID-19 infection in kidney transplant recipients |journal=Kidney Int. |volume=97 |issue=6 |pages=1076–1082 |date=June 2020 |pmid=32354637 |pmc=7142878 |doi=10.1016/j.kint.2020.03.018 |url=}}</ref>
 *'''[[Tacrolimus]]'''<ref name="pmid323546372">{{cite journal |vauthors=Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M |title=COVID-19 infection in kidney transplant recipients |journal=Kidney Int. |volume=97 |issue=6 |pages=1076–1082 |date=June 2020 |pmid=32354637 |pmc=7142878 |doi=10.1016/j.kint.2020.03.018 |url=}}</ref>
 **Low doses of [[tacrolimus]] can be given but more evidence is required.<ref name="pmid323546372">{{cite journal |vauthors=Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M |title=COVID-19 infection in kidney transplant recipients |journal=Kidney Int. |volume=97 |issue=6 |pages=1076–1082 |date=June 2020 |pmid=32354637 |pmc=7142878 |doi=10.1016/j.kint.2020.03.018 |url=}}</ref>
-**The dose should be reduced to 50%. Target levels for [[tacrolimus]] should be 3-5 ng/ml.
+**The dose should be reduced to 50%. Target levels for [[tacrolimus]] should be 3-5 ng/ml.<ref name="urlwww.massgeneral.org">{{cite web |url=https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/mass-general-COVID-19-treatment-guidance.pdf |title=www.massgeneral.org |format= |work= |accessdate=}}</ref>
 *'''[[Tocilizumab]]'''.<ref name="pmid323546372">{{cite journal |vauthors=Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M |title=COVID-19 infection in kidney transplant recipients |journal=Kidney Int. |volume=97 |issue=6 |pages=1076–1082 |date=June 2020 |pmid=32354637 |pmc=7142878 |doi=10.1016/j.kint.2020.03.018 |url=}}</ref>
-**COVID-19 infection has been found to cause cytokine storm and inflammation due to antiviral immune response, hence trials of anti-interleukin 6 monoclonal antibody Tocilizumab and continuing steroids in infected patients has been considered.
+**COVID-19 infection has been found to cause [[cytokine storm]] and inflammation due to [[antiviral]] [[immune response]], hence trials of anti-interleukin 6 [[monoclonal antibody]] [[Tocilizumab]] and continuing steroids in infected patients has been considered.
 *'''[[Cyclosporine]]'''
-**[[Cyclosporine|Cyclosporin A]] has been shown to have an inhibitory effect on proliferation of [[SARS-CoV-2|corona viruses]] and [[hepatitis C virus]] in vitro, not seen in [[tacrolimus]]. [[Cyclosporine|Cyclosporin A]] is thought to inhibit the replication of a diverse array of coronaviruses through its impact on cyclophilin A and B.
+**[[Cyclosporine|Cyclosporin]] A has been shown to have an inhibitory effect on proliferation of [[Coronavirus|corona viruses]] and [[hepatitis C virus]] in vitro, not seen in tacrolimus. Cyclosporin A is thought to inhibit the replication of a diverse array of [[Coronavirus|coronaviruses]] through its impact on [[cyclophilin]] A and B.<ref name="de WildeZevenhoven-Dobbe2011">{{cite journal|last1=de Wilde|first1=Adriaan H.|last2=Zevenhoven-Dobbe|first2=Jessika C.|last3=van der Meer|first3=Yvonne|last4=Thiel|first4=Volker|last5=Narayanan|first5=Krishna|last6=Makino|first6=Shinji|last7=Snijder|first7=Eric J.|last8=van Hemert|first8=Martijn J.|title=Cyclosporin A inhibits the replication of diverse coronaviruses|journal=Journal of General Virology|volume=92|issue=11|year=2011|pages=2542–2548|issn=0022-1317|doi=10.1099/vir.0.034983-0}}</ref><ref name="TanakaSato2013">{{cite journal|last1=Tanaka|first1=Yoshikazu|last2=Sato|first2=Yuka|last3=Sasaki|first3=Takashi|title=Suppression of Coronavirus Replication by Cyclophilin Inhibitors|journal=Viruses|volume=5|issue=5|year=2013|pages=1250–1260|issn=1999-4915|doi=10.3390/v5051250}}</ref>
 **[[Cyclosporine]] levels should be targeted at 25-50 ng/ml.<ref name="urlwww.massgeneral.org">{{cite web |url=https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/mass-general-COVID-19-treatment-guidance.pdf |title=www.massgeneral.org |format= |work= |accessdate=}}</ref>
 === Surgery and Device Based Therapy ===
-Currently there are no surgical intervention required for [[COVID-19]] infection in [[Kidney transplantation|renal transplant]] patients.
+Currently there are no suurgical intervention required for [[COVID-19]] infection in [[Kidney transplantation|renal transplant]] patients.
 ==== Transplantation ====
@@ Line 459: / Line 470: @@
 * The risk of the donor to [[recipient]] transmission is unknown.
-* The chances of a [[donor]] to recipient infection might be affected by exposure of the donor, the infectivity of the donor during the incubation period, and the degree of [[viremia]] as well as the viability of virus in the specific organ system. An avid knowledge of local epidemiology is required to identify donors and recipients who may recently be exposed. One method is to have both donor and recipient practice strict social distancing i.e. 2-week home segregation prior to transplant and [[Polymerase chain reaction|PCR]] testing for both individuals, before transplant<ref name="HoChung2020">{{cite journal|last1=Ho|first1=Quan Yao|last2=Chung|first2=Shimin J.|last3=Gan|first3=Valerie H. L.|last4=Ng|first4=Lay Guat|last5=Tan|first5=Ban Hock|last6=Kee|first6=Terence Y. S.|title=High‐immunological risk living donor renal transplant during the COVID‐19 outbreak: Uncertainties and ethical dilemmas|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1949–1951|issn=1600-6135|doi=10.1111/ajt.15949}}</ref>. The reason for swabbing at the end of the segregation period is to screen asymptomatic shedders.
+* The chances of a [[donor]] to recipient infection might be affected by exposure of the donor, the infectivity of the donor during the incubation period, and the degree of [[viremia]] as well as the viability of virus in the specific organ system. An avid knowledge of local epidemiology is required to identify donors and recipients who may recently be exposed. One method is to have both donor and recipient practice strict social distancing i.e. 2-week home segregation prior to transplant and [[Polymerase chain reaction|PCR]] testing for both individuals, before transplant<ref name="HoChung2020">{{cite journal|last1=Ho|first1=Quan Yao|last2=Chung|first2=Shimin J.|last3=Gan|first3=Valerie H. L.|last4=Ng|first4=Lay Guat|last5=Tan|first5=Ban Hock|last6=Kee|first6=Terence Y. S.|title=High‐immunological risk living donor renal transplant during the COVID‐19 outbreak: Uncertainties and ethical dilemmas|journal=American Journal of Transplantation|volume=20|issue=7|year=2020|pages=1949–1951|issn=1600-6135|doi=10.1111/ajt.15949}}</ref>. The reason for swabbing at the end of the segregation period is to screen asymptomatic shedders.<ref name="MaKang2020">{{cite journal|last1=Ma|first1=Mai-Juan|last2=Kang|first2=Dian-Min|last3=Duan|first3=Li-Jun|last4=Yao|first4=Lin|last5=Wang|first5=Guo-Lin|last6=Anderson|first6=Benjamin D|last7=Yao|first7=Ming-Xiao|last8=Pang|first8=Bo|last9=Lin|first9=Can-Fang|last10=Ji|first10=Sheng-Xiang|last11=Gao|first11=Feng|last12=Hang|first12=Yang|last13=Sun|first13=Wen-Kui|last14=Kou|first14=Zeng-Qiang|last15=Lei|first15=Jie|last16=Li|first16=Cun-Bao|last17=Zhao|first17=Xiang-Na|last18=Zhang|first18=Xiao-Li|last19=Jiang|first19=Xiao-Lin|title=Transmission Potential of Asymptomatic and Paucisymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections: A 3-Family Cluster Study in China|journal=The Journal of Infectious Diseases|volume=221|issue=12|year=2020|pages=1948–1952|issn=0022-1899|doi=10.1093/infdis/jiaa206}}</ref>
 * In spite of the conceivable negative outcomes, temporary interruption of [[kidney transplantation]] might be needed in regions where the rate of [[infection]] is high.. <ref name="MichaelsLa Hoz2020">{{cite journal|last1=Michaels|first1=Marian G.|last2=La Hoz|first2=Ricardo M.|last3=Danziger-Isakov|first3=Lara|last4=Blumberg|first4=Emily A.|last5=Kumar|first5=Deepali|last6=Green|first6=Michael|last7=Pruett|first7=Timothy L.|last8=Wolfe|first8=Cameron R.|title=Coronavirus disease 2019: Implications of emerging infections for transplantation|journal=American Journal of Transplantation|year=2020|issn=1600-6135|doi=10.1111/ajt.15832}}</ref>
-* If a life-saving procedure needs to be performed, then appropriate assessment of infection in donor and recipient must be done along with appropriate informed consent.
+* If a life-saving procedure needs to be performed, then appropriate assessment of infection in donor and recipient must be done along with appropriate informed consent.<ref name="urlAn Update and Guidance on 2019 Novel Coronavirus (2019-nCov) for Transplant ID Clinicians">{{cite web |url=https://tts.org/23-tid/tid-news/657-tid-update-and-guidance-on-2019-novel-coronavirus-2019-ncov-for-transplant-id-clinicians |title=An Update and Guidance on 2019 Novel Coronavirus (2019-nCov) for Transplant ID Clinicians |format= |work= |accessdate=}}</ref>
-* ''If a transplant candidate is found to be infected with [[COVID-19]], the transplant should be delayed until the patient shows clinical improvement as well as no viral detection. Viral shedding  for an increased duration of time has been reported<ref name="ZhouYu2020">{{cite journal|last1=Zhou|first1=Fei|last2=Yu|first2=Ting|last3=Du|first3=Ronghui|last4=Fan|first4=Guohui|last5=Liu|first5=Ying|last6=Liu|first6=Zhibo|last7=Xiang|first7=Jie|last8=Wang|first8=Yeming|last9=Song|first9=Bin|last10=Gu|first10=Xiaoying|last11=Guan|first11=Lulu|last12=Wei|first12=Yuan|last13=Li|first13=Hui|last14=Wu|first14=Xudong|last15=Xu|first15=Jiuyang|last16=Tu|first16=Shengjin|last17=Zhang|first17=Yi|last18=Chen|first18=Hua|last19=Cao|first19=Bin|title=Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study|journal=The Lancet|volume=395|issue=10229|year=2020|pages=1054–1062|issn=01406736|doi=10.1016/S0140-6736(20)30566-3}}</ref>.''
+* ''If a transplant candidate is found to be infected with [[COVID-19]], the transplant should be delayed until the patient shows clinical improvement as well as no viral detection. Viral shedding  for an increased duration of time has been reported<ref name="ZhouYu2020">{{cite journal|last1=Zhou|first1=Fei|last2=Yu|first2=Ting|last3=Du|first3=Ronghui|last4=Fan|first4=Guohui|last5=Liu|first5=Ying|last6=Liu|first6=Zhibo|last7=Xiang|first7=Jie|last8=Wang|first8=Yeming|last9=Song|first9=Bin|last10=Gu|first10=Xiaoying|last11=Guan|first11=Lulu|last12=Wei|first12=Yuan|last13=Li|first13=Hui|last14=Wu|first14=Xudong|last15=Xu|first15=Jiuyang|last16=Tu|first16=Shengjin|last17=Zhang|first17=Yi|last18=Chen|first18=Hua|last19=Cao|first19=Bin|title=Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study|journal=The Lancet|volume=395|issue=10229|year=2020|pages=1054–1062|issn=01406736|doi=10.1016/S0140-6736(20)30566-3}}</ref><ref name="ZhangTong2020">{{cite journal|last1=Zhang|first1=Sheng|last2=Tong|first2=Yi Xin|last3=Xiao|first3=Ai Tang|title=Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients|journal=Clinical Infectious Diseases|year=2020|issn=1058-4838|doi=10.1093/cid/ciaa460}}</ref>.''
 ** Patients should be tested 10-14 days after symptom onset and only once all the symptoms have resolved.
-** Patients should have 2 negative PCRs at least 24hrs apart
+** Patients should have 2 negative [[Polymerase chain reaction|PCR]]<nowiki/>s at least 24hrs apart<ref>{{cite journal|doi=10.3201/eid2608.201097.}}</ref>
 === Primary Prevention ===
-*The [[Kidney transplantation|kidney transplant]] population must comply with the recommended measures of protection in the general population. Physicians can recommend the use of a mask on an individual basis, especially when the patient goes to health center or other place with agglomeration. People who show symptoms of being infected with [[SARS-CoV-2]] should wear masks to prevent the spread of the disease to others..
+*The [[Kidney transplantation|kidney transplant]] population must comply with the recommended measures of protection in the general population. Physicians can recommend the use of a mask on an individual basis, especially when the patient goes to health center or other place with agglomeration. People who show symptoms of being infected with [[SARS-CoV-2]] should wear masks to prevent the spread of the disease to others..<ref name="LópezVázquez2020">{{cite journal|last1=López|first1=Verónica|last2=Vázquez|first2=Teresa|last3=Alonso-Titos|first3=Juana|last4=Cabello|first4=Mercedes|last5=Alonso|first5=Angel|last6=Beneyto|first6=Isabel|last7=Crespo|first7=Marta|last8=Díaz-Corte|first8=Carmen|last9=Franco|first9=Antonio|last10=González-Roncero|first10=Francisco|last11=Gutiérrez|first11=Elena|last12=Guirado|first12=Luis|last13=Jiménez|first13=Carlos|last14=Jironda|first14=Cristina|last15=Lauzurica|first15=Ricardo|last16=Llorente|first16=Santiago|last17=Mazuecos|first17=Auxiliadora|last18=Paul|first18=Javier|last19=Rodríguez-Benot|first19=Alberto|last20=Ruiz|first20=Juan Carlos|last21=Sánchez-Fructuoso|first21=Ana|last22=Sola|first22=Eugenia|last23=Torregrosa|first23=Vicente|last24=Zárraga|first24=Sofía|last25=Hernández|first25=Domingo|title=Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients|journal=Nefrología (English Edition)|year=2020|issn=20132514|doi=10.1016/j.nefroe.2020.03.017}}</ref>
 *It is prudent to approve a sick leave in patients whose profession involves a high hazard for disease.<ref name="LópezVázquez2020">{{cite journal|last1=López|first1=Verónica|last2=Vázquez|first2=Teresa|last3=Alonso-Titos|first3=Juana|last4=Cabello|first4=Mercedes|last5=Alonso|first5=Angel|last6=Beneyto|first6=Isabel|last7=Crespo|first7=Marta|last8=Díaz-Corte|first8=Carmen|last9=Franco|first9=Antonio|last10=González-Roncero|first10=Francisco|last11=Gutiérrez|first11=Elena|last12=Guirado|first12=Luis|last13=Jiménez|first13=Carlos|last14=Jironda|first14=Cristina|last15=Lauzurica|first15=Ricardo|last16=Llorente|first16=Santiago|last17=Mazuecos|first17=Auxiliadora|last18=Paul|first18=Javier|last19=Rodríguez-Benot|first19=Alberto|last20=Ruiz|first20=Juan Carlos|last21=Sánchez-Fructuoso|first21=Ana|last22=Sola|first22=Eugenia|last23=Torregrosa|first23=Vicente|last24=Zárraga|first24=Sofía|last25=Hernández|first25=Domingo|title=Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients|journal=Nefrología (English Edition)|year=2020|issn=20132514|doi=10.1016/j.nefroe.2020.03.017}}</ref>
-*<nowiki/>It is recommended to screen [[Kidney transplantation|kidney transplan]]<nowiki/>t patients through teleconsultation so as to decrease the time spent in healthcare centers and decrease the risk of infection <ref name="LópezVázquez2020">{{cite journal|last1=López|first1=Verónica|last2=Vázquez|first2=Teresa|last3=Alonso-Titos|first3=Juana|last4=Cabello|first4=Mercedes|last5=Alonso|first5=Angel|last6=Beneyto|first6=Isabel|last7=Crespo|first7=Marta|last8=Díaz-Corte|first8=Carmen|last9=Franco|first9=Antonio|last10=González-Roncero|first10=Francisco|last11=Gutiérrez|first11=Elena|last12=Guirado|first12=Luis|last13=Jiménez|first13=Carlos|last14=Jironda|first14=Cristina|last15=Lauzurica|first15=Ricardo|last16=Llorente|first16=Santiago|last17=Mazuecos|first17=Auxiliadora|last18=Paul|first18=Javier|last19=Rodríguez-Benot|first19=Alberto|last20=Ruiz|first20=Juan Carlos|last21=Sánchez-Fructuoso|first21=Ana|last22=Sola|first22=Eugenia|last23=Torregrosa|first23=Vicente|last24=Zárraga|first24=Sofía|last25=Hernández|first25=Domingo|title=Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients|journal=Nefrología (English Edition)|year=2020|issn=20132514|doi=10.1016/j.nefroe.2020.03.017}}</ref>
+*It is recommended to screen [[Kidney transplantation|kidney transplan]]<nowiki/>t patients through teleconsultation so as to decrease the time spent in healthcare centers and decrease the risk of infection <ref name="LópezVázquez2020">{{cite journal|last1=López|first1=Verónica|last2=Vázquez|first2=Teresa|last3=Alonso-Titos|first3=Juana|last4=Cabello|first4=Mercedes|last5=Alonso|first5=Angel|last6=Beneyto|first6=Isabel|last7=Crespo|first7=Marta|last8=Díaz-Corte|first8=Carmen|last9=Franco|first9=Antonio|last10=González-Roncero|first10=Francisco|last11=Gutiérrez|first11=Elena|last12=Guirado|first12=Luis|last13=Jiménez|first13=Carlos|last14=Jironda|first14=Cristina|last15=Lauzurica|first15=Ricardo|last16=Llorente|first16=Santiago|last17=Mazuecos|first17=Auxiliadora|last18=Paul|first18=Javier|last19=Rodríguez-Benot|first19=Alberto|last20=Ruiz|first20=Juan Carlos|last21=Sánchez-Fructuoso|first21=Ana|last22=Sola|first22=Eugenia|last23=Torregrosa|first23=Vicente|last24=Zárraga|first24=Sofía|last25=Hernández|first25=Domingo|title=Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients|journal=Nefrología (English Edition)|year=2020|issn=20132514|doi=10.1016/j.nefroe.2020.03.017}}</ref>
-*Maintenance of general hygiene. Washing your<nowiki/> hands as often as possible with cleanser and water, or with a alcohol based hand sanitizer (60% alc), particularly: after utilizing the restroom, before eating, in the wake of blowing, coughing or sneezing and after direct contact with patient or their surroundings. Abstain from touching your eyes, nose and mouth before washing your hands.<ref name="LópezVázquez2020">{{cite journal|last1=López|first1=Verónica|last2=Vázquez|first2=Teresa|last3=Alonso-Titos|first3=Juana|last4=Cabello|first4=Mercedes|last5=Alonso|first5=Angel|last6=Beneyto|first6=Isabel|last7=Crespo|first7=Marta|last8=Díaz-Corte|first8=Carmen|last9=Franco|first9=Antonio|last10=González-Roncero|first10=Francisco|last11=Gutiérrez|first11=Elena|last12=Guirado|first12=Luis|last13=Jiménez|first13=Carlos|last14=Jironda|first14=Cristina|last15=Lauzurica|first15=Ricardo|last16=Llorente|first16=Santiago|last17=Mazuecos|first17=Auxiliadora|last18=Paul|first18=Javier|last19=Rodríguez-Benot|first19=Alberto|last20=Ruiz|first20=Juan Carlos|last21=Sánchez-Fructuoso|first21=Ana|last22=Sola|first22=Eugenia|last23=Torregrosa|first23=Vicente|last24=Zárraga|first24=Sofía|last25=Hernández|first25=Domingo|title=Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients|journal=Nefrología (English Edition)|year=2020|issn=20132514|doi=10.1016/j.nefroe.2020.03.017}}</ref>
+*Maintenance of general hygiene. Washing your hands as often as possible with cleanser and water, or with a alcohol based hand sanitizer (60% alc), particularly: after utilizing the restroom, before eating, in the wake of blowing, coughing or sneezing and after direct contact with patient or their surroundings. Abstain from touching your eyes, nose and mouth before washing your hands.<ref name="LópezVázquez2020">{{cite journal|last1=López|first1=Verónica|last2=Vázquez|first2=Teresa|last3=Alonso-Titos|first3=Juana|last4=Cabello|first4=Mercedes|last5=Alonso|first5=Angel|last6=Beneyto|first6=Isabel|last7=Crespo|first7=Marta|last8=Díaz-Corte|first8=Carmen|last9=Franco|first9=Antonio|last10=González-Roncero|first10=Francisco|last11=Gutiérrez|first11=Elena|last12=Guirado|first12=Luis|last13=Jiménez|first13=Carlos|last14=Jironda|first14=Cristina|last15=Lauzurica|first15=Ricardo|last16=Llorente|first16=Santiago|last17=Mazuecos|first17=Auxiliadora|last18=Paul|first18=Javier|last19=Rodríguez-Benot|first19=Alberto|last20=Ruiz|first20=Juan Carlos|last21=Sánchez-Fructuoso|first21=Ana|last22=Sola|first22=Eugenia|last23=Torregrosa|first23=Vicente|last24=Zárraga|first24=Sofía|last25=Hernández|first25=Domingo|title=Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients|journal=Nefrología (English Edition)|year=2020|issn=20132514|doi=10.1016/j.nefroe.2020.03.017}}</ref>
-*Regular cleaning of home with [[disinfection]] of objects and surfaces.<ref name="LópezVázquez2020">{{cite journal|last1=López|first1=Verónica|last2=Vázquez|first2=Teresa|last3=Alonso-Titos|first3=Juana|last4=Cabello|first4=Mercedes|last5=Alonso|first5=Angel|last6=Beneyto|first6=Isabel|last7=Crespo|first7=Marta|last8=Díaz-Corte|first8=Carmen|last9=Franco|first9=Antonio|last10=González-Roncero|first10=Francisco|last11=Gutiérrez|first11=Elena|last12=Guirado|first12=Luis|last13=Jiménez|first13=Carlos|last14=Jironda|first14=Cristina|last15=Lauzurica|first15=Ricardo|last16=Llorente|first16=Santiago|last17=Mazuecos|first17=Auxiliadora|last18=Paul|first18=Javier|last19=Rodríguez-Benot|first19=Alberto|last20=Ruiz|first20=Juan Carlos|last21=Sánchez-Fructuoso|first21=Ana|last22=Sola|first22=Eugenia|last23=Torregrosa|first23=Vicente|last24=Zárraga|first24=Sofía|last25=Hernández|first25=Domingo|title=Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients|journal=Nefrología (English Edition)|year=2020|issn=20132514|doi=10.1016/j.nefroe.2020.03.017}}</ref>
+*Regular cleaning of home with disinfection of objects and surfaces.<ref name="LópezVázquez2020">{{cite journal|last1=López|first1=Verónica|last2=Vázquez|first2=Teresa|last3=Alonso-Titos|first3=Juana|last4=Cabello|first4=Mercedes|last5=Alonso|first5=Angel|last6=Beneyto|first6=Isabel|last7=Crespo|first7=Marta|last8=Díaz-Corte|first8=Carmen|last9=Franco|first9=Antonio|last10=González-Roncero|first10=Francisco|last11=Gutiérrez|first11=Elena|last12=Guirado|first12=Luis|last13=Jiménez|first13=Carlos|last14=Jironda|first14=Cristina|last15=Lauzurica|first15=Ricardo|last16=Llorente|first16=Santiago|last17=Mazuecos|first17=Auxiliadora|last18=Paul|first18=Javier|last19=Rodríguez-Benot|first19=Alberto|last20=Ruiz|first20=Juan Carlos|last21=Sánchez-Fructuoso|first21=Ana|last22=Sola|first22=Eugenia|last23=Torregrosa|first23=Vicente|last24=Zárraga|first24=Sofía|last25=Hernández|first25=Domingo|title=Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients|journal=Nefrología (English Edition)|year=2020|issn=20132514|doi=10.1016/j.nefroe.2020.03.017}}</ref>
 *Keep a distance of at least two metres from people with general symptoms such as [[fever]], [[cough]], [[malaise]], [[Pharyngitis|sore throat]] or [[dyspnea]]). Abstain from sharing personal belongings.<ref name="LópezVázquez2020">{{cite journal|last1=López|first1=Verónica|last2=Vázquez|first2=Teresa|last3=Alonso-Titos|first3=Juana|last4=Cabello|first4=Mercedes|last5=Alonso|first5=Angel|last6=Beneyto|first6=Isabel|last7=Crespo|first7=Marta|last8=Díaz-Corte|first8=Carmen|last9=Franco|first9=Antonio|last10=González-Roncero|first10=Francisco|last11=Gutiérrez|first11=Elena|last12=Guirado|first12=Luis|last13=Jiménez|first13=Carlos|last14=Jironda|first14=Cristina|last15=Lauzurica|first15=Ricardo|last16=Llorente|first16=Santiago|last17=Mazuecos|first17=Auxiliadora|last18=Paul|first18=Javier|last19=Rodríguez-Benot|first19=Alberto|last20=Ruiz|first20=Juan Carlos|last21=Sánchez-Fructuoso|first21=Ana|last22=Sola|first22=Eugenia|last23=Torregrosa|first23=Vicente|last24=Zárraga|first24=Sofía|last25=Hernández|first25=Domingo|title=Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients|journal=Nefrología (English Edition)|year=2020|issn=20132514|doi=10.1016/j.nefroe.2020.03.017}}</ref>
-*During the lockdown circumstance you should stay at home aside from the specified exemptions, as indicated by the standards built up by the political and wellbeing specialists. Telephone the [[Kidney transplantation|kidney transplant]] facility at your referral community or the telephone numbers approved by the wellbeing specialists.<ref name="LópezVázquez2020">{{cite journal|last1=López|first1=Verónica|last2=Vázquez|first2=Teresa|last3=Alonso-Titos|first3=Juana|last4=Cabello|first4=Mercedes|last5=Alonso|first5=Angel|last6=Beneyto|first6=Isabel|last7=Crespo|first7=Marta|last8=Díaz-Corte|first8=Carmen|last9=Franco|first9=Antonio|last10=González-Roncero|first10=Francisco|last11=Gutiérrez|first11=Elena|last12=Guirado|first12=Luis|last13=Jiménez|first13=Carlos|last14=Jironda|first14=Cristina|last15=Lauzurica|first15=Ricardo|last16=Llorente|first16=Santiago|last17=Mazuecos|first17=Auxiliadora|last18=Paul|first18=Javier|last19=Rodríguez-Benot|first19=Alberto|last20=Ruiz|first20=Juan Carlos|last21=Sánchez-Fructuoso|first21=Ana|last22=Sola|first22=Eugenia|last23=Torregrosa|first23=Vicente|last24=Zárraga|first24=Sofía|last25=Hernández|first25=Domingo|title=Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients|journal=Nefrología (English Edition)|year=2020|issn=20132514|doi=10.1016/j.nefroe.2020.03.017}}</ref>
+*During the lockdown circumstance you should stay at home aside from the specified exemptions, as indicated by the standards built up by the political and wellbeing specialists. Telephone the kidney transplant facility at your referral community or the telephone numbers approved by the wellbeing specialists.<ref name="LópezVázquez2020">{{cite journal|last1=López|first1=Verónica|last2=Vázquez|first2=Teresa|last3=Alonso-Titos|first3=Juana|last4=Cabello|first4=Mercedes|last5=Alonso|first5=Angel|last6=Beneyto|first6=Isabel|last7=Crespo|first7=Marta|last8=Díaz-Corte|first8=Carmen|last9=Franco|first9=Antonio|last10=González-Roncero|first10=Francisco|last11=Gutiérrez|first11=Elena|last12=Guirado|first12=Luis|last13=Jiménez|first13=Carlos|last14=Jironda|first14=Cristina|last15=Lauzurica|first15=Ricardo|last16=Llorente|first16=Santiago|last17=Mazuecos|first17=Auxiliadora|last18=Paul|first18=Javier|last19=Rodríguez-Benot|first19=Alberto|last20=Ruiz|first20=Juan Carlos|last21=Sánchez-Fructuoso|first21=Ana|last22=Sola|first22=Eugenia|last23=Torregrosa|first23=Vicente|last24=Zárraga|first24=Sofía|last25=Hernández|first25=Domingo|title=Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients|journal=Nefrología (English Edition)|year=2020|issn=20132514|doi=10.1016/j.nefroe.2020.03.017}}</ref>
-*Attempt to follow a right eating routine. Abstain from smoking and liquor. These substances weaken the immune system, and increase the risk of [[Infectious disease|infectious diseases]].<ref name="LópezVázquez2020">{{cite journal|last1=López|first1=Verónica|last2=Vázquez|first2=Teresa|last3=Alonso-Titos|first3=Juana|last4=Cabello|first4=Mercedes|last5=Alonso|first5=Angel|last6=Beneyto|first6=Isabel|last7=Crespo|first7=Marta|last8=Díaz-Corte|first8=Carmen|last9=Franco|first9=Antonio|last10=González-Roncero|first10=Francisco|last11=Gutiérrez|first11=Elena|last12=Guirado|first12=Luis|last13=Jiménez|first13=Carlos|last14=Jironda|first14=Cristina|last15=Lauzurica|first15=Ricardo|last16=Llorente|first16=Santiago|last17=Mazuecos|first17=Auxiliadora|last18=Paul|first18=Javier|last19=Rodríguez-Benot|first19=Alberto|last20=Ruiz|first20=Juan Carlos|last21=Sánchez-Fructuoso|first21=Ana|last22=Sola|first22=Eugenia|last23=Torregrosa|first23=Vicente|last24=Zárraga|first24=Sofía|last25=Hernández|first25=Domingo|title=Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients|journal=Nefrología (English Edition)|year=2020|issn=20132514|doi=10.1016/j.nefroe.2020.03.017}}</ref>
+*Attempt to follow a right eating routine. Abstain from smoking and liquor. These substances weaken the immune system, and increase the risk of infectious diseases.<ref name="LópezVázquez2020">{{cite journal|last1=López|first1=Verónica|last2=Vázquez|first2=Teresa|last3=Alonso-Titos|first3=Juana|last4=Cabello|first4=Mercedes|last5=Alonso|first5=Angel|last6=Beneyto|first6=Isabel|last7=Crespo|first7=Marta|last8=Díaz-Corte|first8=Carmen|last9=Franco|first9=Antonio|last10=González-Roncero|first10=Francisco|last11=Gutiérrez|first11=Elena|last12=Guirado|first12=Luis|last13=Jiménez|first13=Carlos|last14=Jironda|first14=Cristina|last15=Lauzurica|first15=Ricardo|last16=Llorente|first16=Santiago|last17=Mazuecos|first17=Auxiliadora|last18=Paul|first18=Javier|last19=Rodríguez-Benot|first19=Alberto|last20=Ruiz|first20=Juan Carlos|last21=Sánchez-Fructuoso|first21=Ana|last22=Sola|first22=Eugenia|last23=Torregrosa|first23=Vicente|last24=Zárraga|first24=Sofía|last25=Hernández|first25=Domingo|title=Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients|journal=Nefrología (English Edition)|year=2020|issn=20132514|doi=10.1016/j.nefroe.2020.03.017}}</ref>
 === Secondary Prevention ===
@@ Line 502: / Line 513: @@
 ==References==
 {{Reflist|2}}
+[[Category:Up-To-Date]]
 [[Category:Disease]]
-<references />